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Background: Graves’ disease is an autoimmune disorder characterised by goitre, 
hyperthyroidism and Graves’ orbitopathy (GO). The hyperthyroidism is caused by 
thyroid hypertrophy and stimulation of function, resulting from anti-TSHR antibodies. 
Moreover, for pathophysiology of GO, there is compelling evidence on the role of 
antibodies to insulin-like growth factor 1 receptor (IGF-1R). However, the precise 
pathogenesis of GO remains unresolved, hampered by lack of an animal model. Our 
laboratory has previously shown that genetic immunisation leads to development of 
Graves’ disease. In addition, there were signs of orbital inflammation in some immune 
animals. 
Aims: The objective of my thesis was to modify and evaluate new regimes in the 
genetic delivery in order to develop a preclinical GO model. The new model would be 
characterised immunologically and by thyroid function studies. Furthermore, 
procedures would be developed to characterise the orbital tissue by histopathology, to 
allow better anatomical evaluation in correlation with MRI. In addition, study into the 
pathophysiology of the disease was another objective of this project.   
Results: Modifications in the immunisation scheme with hTSHR A-subunit plasmid in 
vivo electroporation were successfully established leading to induction of anti-TSHR 
response, thyroid dysfunction, and extensive remodelling of the orbital tissue. The 
orbital manifestations were characterised by infiltration of inflammatory cells including 
CD3+/CD4+ T cells, F4/80+ macrophages and mast cells, as well as hypertrophy of 
extraorbital muscles together with accumulation of glycosaminoglycan.  In addition, 
orbital heterogeneity was apparent, where some immune mice (10%) showed 
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extensive adipogenesis. Furthermore, other immune animals showed an intense CD3+ 
T cells infiltrate surrounding the optic nerve. A striking finding that underpins the 
experimental model was the in vivo MRI of mouse orbital region that provided a clear 
and quantifiable evidence of extraorbital muscle hypertrophy with orbital protrusion 
(proptosis). In addition, some animals exhibited congested eyelid manifestation of 
chemosis, which was characterised histologically as dilated orbital blood vessels and 
oedema. Immunisation with control plasmids failed to show any orbital pathology.  
High level of antibodies to hTSHR were present in sera of animals challenged with 
hTSHR A-subunit plasmid with predominantly TSH blocking antibodies, which led to 
profound hypothyroidism. Although, these findings support TSHR as the pathogenic 
antigen in GO, the enigmatic role of antibodies to IGF-1R in GO remains unclear. This 
study describes a significant response to IGF-1R in some animals immunised with 
hTSHR A-subunit plasmid. A definite way to study the nature of the anti-IGF-1R 
antibody response following challenge with a different immunogen (hTSHR A-subunit) 
is by development of monoclonal antibodies to IGF-1R induced in the model, attempts 
of which are also reported in the thesis. 
Conclusion: We successfully developed an experimental model that recapitulates 
orbital pathology in GO patients. The development of a new preclinical model for GO 
will facilitate molecular investigations into pathophysiology of the disease and 
evaluation of new therapeutic interventions. 
  
 4  
 
Claims of Originality 
 
The work described in this thesis was carried out in School of Medicine, King’s College 
London. Unless stated, the experiments were carried out by the author. 
The thesis entitled ‘Grave's orbitopathy in a new preclinical animal model’ has not 











I would like to take this opportunity to express my profound gratitude and deep 
regards to my primary supervisor, Professor J Paul Banga, who has been a tremendous 
mentor for me with almost day to day meetings throughout my study. I would also like 
to acknowledge the helpful advice of my second supervisor, Dr Michael Christie. 
I am very grateful to all member of the clinical histopathology (King’s College Hospital 
NHS Foundation Trust) for providing open access histopathological facilities. With 
special thanks to Dr Salvador Diaz-Cano (King’s College Hospital NHS Foundation Trust), 
who generously spent his precious time with me in interpreting my histological 
findings. This work would have never gone so well without him. I would also like to 
express my appreciation to Dr Michelle Ferrar (histopathology lab manager) for 
allowing me to work in the histopathology laboratories and to Dr Mohamed Khalil for 
his invaluable advice.  
I would like to express a deep sense of gratitude to Dr Po-Wah So (Preclinical Imaging 
Unit, Institute of Psychiatry, King’s College London) for her enthusiasm to establish the 
MRI protocol for orbital imaging. I would also like to thank Dr Neil Deasy (Department 
of Neuroimaging, Institute of Psychiatry, King’s College London) for his very helpful 
interpretation MRI data from preclinical imaging with clinical MRI from patients with 
orbitopathy condition.  
I am very grateful to Professor Anja Eckstein (University of Duisburg-Essen, Germany) 
for the initial suggestion of using optic nerve as a landmark in orienting orbital tissue 
for histological study.  
 6  
 
My special thanks also go to my colleagues and friends in the Rayne institute who have 
always been very nice to me for past three years, Dr Chantal Hargreaves, Dr Min Zhao, 
Helen Tang and Mei Mei Fung.  
I am indebted to Professor Farzin Farzaneh and Dr Shahram Kordasti (Department of 
haematology, King’s College London) for all their academic and more importantly 
moral support.   
 
  




I dedicate my dissertation work to my loving parents, Dr Saied Moshkelgosha and Mrs 
Zeinab Kaviani whose unlimited supports made this work happen. I also, dedicate this 
work with very special thanks to my wife, Mrs Hadiseh Khalili for being there for me 
throughout the entire doctorate program. 
  
 8  
 
Table of Contents  
ABSTRACT ................................................................................................................................. 2 
CLAIMS OF ORIGINALITY ..................................................................................................... 4 
ACKNOWLEDGMENTS ........................................................................................................... 5 
DEDICATION ............................................................................................................................. 7 
TABLE OF CONTENTS ............................................................................................................ 8 
FIGURES AND TABLES ........................................................................................................ 14 
ABBREVIATIONS .................................................................................................................. 18 
1.1 AUTOIMMUNITY ...................................................................................................... 22 
1.1 THYROID GLAND ..................................................................................................... 29 
1.1.1 Pathophysiology of thyroid gland ............................................................................................30 
1.1.2 Autoimmune thyroid diseases .................................................................................................31 
1.1.3 Hashimoto’s thyroiditis ...........................................................................................................33 
1.2 GRAVES’ DISEASE ..................................................................................................... 34 
1.2.1 Autoantigens in thyroid autoimmunity....................................................................................36 
1.2.2 TSH receptor (TSHR) ................................................................................................................37 
1.2.3 Extrathyroidal expression of TSHR ...........................................................................................40 
1.2.4 Graves’ disease and antibodies to TSHR ..................................................................................41 
1.2.5 Genetic basis for Graves' disease .............................................................................................44 
1.2.6 Environmental factors of Graves' disease ................................................................................52 
1.2.7 Autoimmune processes in Graves' disease ..............................................................................55 
1.3 GRAVES’ ORBITOPATHY (GO) ............................................................................. 56 
1.3.1 Clinical aspects of GO ..............................................................................................................59 
 9  
 
1.3.2 Determinants in the development of GO .................................................................................62 
1.3.3 The pathophysiology of GO .....................................................................................................65 
1.3.4 Roles of orbital fibroblast ........................................................................................................69 
1.3.5 Hyaluronan production from orbital fibroblasts ......................................................................71 
1.3.6 Adipogenesis ...........................................................................................................................72 
1.3.7 Insulin like growth factor 1 receptor (IGF-1R) as an autoantigen in GO ...................................74 
1.3.8 Recent findings on the role of fibrocytes in GO .......................................................................77 
1.3.9 Proposed model for pathogenesis of GO .................................................................................79 
1.3.10 Treatments for Graves’ disease and orbital conditions ............................................................80 
1.4 EXPERIMENTAL ANIMAL MODELS..................................................................... 85 
1.4.1 Graves’ disease ........................................................................................................................86 
1.4.2 Graves’ orbitopathy .................................................................................................................90 
1.5 AIMS OF PROJECT .................................................................................................... 92 
2. MATERIAL AND METHODS ................................................................................... 94 
2.1 MATERIALS ................................................................................................................ 94 
2.1.1 Medium and cell growth supplements ....................................................................................94 
2.1.2 Sterile tissue culture plastic ware ............................................................................................94 
2.1.3 Cells .........................................................................................................................................95 
2.1.4 IGF-1 and IGF-1R ......................................................................................................................96 
2.1.5 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) ..............................97 
2.1.6 Enzyme-linked immunosorbent assay (ELISA) ..........................................................................98 
2.1.7 Abs ..........................................................................................................................................98 
2.1.8 Other materials .......................................................................................................................98 
2.2 METHODS ................................................................................................................... 99 
2.2.1 Human (h) TSHR A-subunit and hIGF-1Rα plasmids .................................................................99 
 10  
 
2.2.2 Plasmid purification ............................................................................................................... 100 
2.2.3 Assay for thyroid antibodies .................................................................................................. 101 
2.2.3.1 Thyroid radiobinding assay (TRAK) ..................................................................................... 101 
2.2.3.2 Assay for thyroid stimulating antibody .............................................................................. 102 
2.2.3.3 Assay for thyroid blocking antibody ................................................................................... 106 
2.2.4 Thyroid function tests ............................................................................................................ 107 
2.2.5 Purification of IGF-1R mAbs by protein G chromatography ................................................... 108 
2.2.6 Protein detection assays ........................................................................................................ 108 
2.2.6.1 Protein assay ...................................................................................................................... 108 
2.2.6.2 SDS-PAGE ............................................................................................................................ 109 
2.2.6.3 Western blotting ................................................................................................................ 110 
2.2.7 Flow cytometry...................................................................................................................... 111 
2.2.7.1 Evaluation of IGF-1R expression in NWTB3 cells by flow cytometry .................................. 111 
2.2.7.2 Evaluation of TSHR expression in GPI9-5 cells by flow cytometry ..................................... 112 
2.2.8 Establishment of assays for IGF-1R Abs ................................................................................. 113 
2.2.8.1 ELISA ................................................................................................................................... 113 
2.2.8.2 Competitive binding assay.................................................................................................. 113 
2.2.9 Development of mAbs ........................................................................................................... 115 
2.2.10 Histology ............................................................................................................................... 117 
2.2.10.1 Mouse thyroid histology..................................................................................................... 118 
2.2.10.2 Establishment of histology technique for orbital tissue ..................................................... 119 
2.2.11 Quantification ....................................................................................................................... 123 
3. DEVELOPMENT AND CHARACTERISATION OF A PRECLINICAL MOUSE 
MODEL OF GO ...................................................................................................................... 125 
3.1 INTRODUCTION ...................................................................................................... 125 
3.2 AIMS ........................................................................................................................... 128 
3.3 RESULTS.................................................................................................................... 129 
3.3.1 Evaluation of experimental GO model after modification of immunisation ........................... 130 
3.3.1.1 Changes in weight of immune animals during course of immunisation ............................ 131 
3.3.1.2 Histological study of thyroid gland ..................................................................................... 132 
3.3.1.3 Studies into retrobulbar histopathology ............................................................................ 134 
3.3.1.4 Histopathological studies by immunohistochemistry into retrobulbar tissue ................... 139 
3.3.1.5 Histopathological studies of chemosis ............................................................................... 144 
3.3.1.6 Evaluation of thyroid function ............................................................................................ 146 
3.3.1.7 Evaluation of thyrotropin binding inhibition immunoglobulins activity (TBII) ................... 148 
 11  
 
3.3.1.8 Determination of TSHR stimulating and blocking Abs ........................................................ 149 
3.3.2 Longitudinal studies on TSHR antibodies during the course of disease .................................. 151 
3.3.2.1 Histological study of thyroid gland ..................................................................................... 152 
3.3.2.2 Studies into retrobulbar histopathology ............................................................................ 154 
3.3.2.3 Histopathological studies of chemosis ............................................................................... 155 
3.3.2.4 Evaluation of thyroid function ............................................................................................ 156 
3.3.2.5 Longitudinal studies into TSHR Abs .................................................................................... 157 
3.3.3 Characterisation of long-term immunity to hTSHR ................................................................ 160 
3.3.3.1 Studies into retrobulbar histopathology ............................................................................ 160 
3.3.3.2 Evaluation of thyroid function ............................................................................................ 161 
3.4 DISCUSSION ............................................................................................................. 163 
3.5 SUMMARY ................................................................................................................. 167 
4. NEURORADIOLOGICAL ANALYSIS IN EXPERIMENTAL GO MODEL ....... 169 
4.1 INTRODUCTION ...................................................................................................... 169 
4.1.1 Clinical neuroradiological methods ........................................................................................ 170 
4.1.1.1 Magnetic resonance imaging ............................................................................................. 170 
4.1.1.2 Computed tomography ...................................................................................................... 173 
4.1.1.3 Orbital ultrasound and octreotide scanning ...................................................................... 174 
4.1.2 Preclinical imaging studies ..................................................................................................... 175 
4.1.3 Anatomy of mouse orbit and differences with human orbital structure ................................ 176 
4.1.4 Preclinical MRI in experimental GO model ............................................................................ 177 
4.2 AIMS ........................................................................................................................... 179 
4.3 RESULTS.................................................................................................................... 180 
4.3.1 Coronal view, to identify proptosis of the eye in the GO model ............................................ 180 
4.3.2 Quantification of extraorbital muscle hypertrophy ............................................................... 184 
4.3.3 Alignment of MRI results with histological studies ................................................................ 185 
4.4 DISCUSSION ............................................................................................................. 190 
4.5 SUMMARY ................................................................................................................. 194 
 12  
 
5. THE ENIGMA OF ANTIBODIES INDUCED TO IGF-1R FOLLOWING 
IMMUNISATION WITH TSHR A-SUBUNIT PLASMID .............................................. 196 
5.1 INTRODUCTION ...................................................................................................... 196 
5.1.1 IGF-1R and Abs to IGF-1R ....................................................................................................... 198 
5.2 AIMS ........................................................................................................................... 207 
5.3 RESULTS.................................................................................................................... 208 
5.3.1 Development and validation of assays for IGF-1R Abs ........................................................... 208 
5.3.1.1 Flow cytometry ................................................................................................................... 209 
5.3.1.2 Evaluation for constitutive expression of TSHR in NWTB3 cells ......................................... 214 
5.3.1.3 Cell based competitive binding assay ................................................................................. 216 
5.3.1.4 ELISA ................................................................................................................................... 220 
5.3.2 Evaluation of IGF-1R Abs in mice immunised with TSHR A-subunit using modified protocol . 223 
5.3.2.1 Studies into induction of IGF-1R Abs in Group 1 immunisation ......................................... 223 
5.3.2.2 Longitudinal studies into induction of IGF-1R Abs in the Group 2 immunisation .............. 226 
5.3.3 Development of mAbs to IGF-1R ........................................................................................... 228 
5.3.3.1 First attempt on generation of hybridoma for mAbs to IGF-1R ......................................... 228 
5.3.3.2 Second attempt on generation of hybridoma for mAbs to IGF-1R .................................... 230 
5.4 Discussion .............................................................................................................................. 232 
6. GENERAL DISCUSSION AND FUTURE EXPERIMENTS ................................ 239 
6.1 GENERAL DISCUSSION ......................................................................................... 239 
6.2 LIMITATIONS .......................................................................................................... 248 
6.3 PROPOSED FUTURE STUDIES ............................................................................ 250 
BIBLIOGRAPHY .................................................................................................................. 255 
APPENDICES ........................................................................................................................ 294 
Appendix 1 Summary of individual immune mice in 4 groups of immunisations ................................ 294 
Appendix 2 Flow cytometry intra-assay and inter-assay CV ............................................................... 296 
Appendix 3 Calculations for competition assay; displacement of LUMI-IGF-1 with unlabelled IGF-1 .. 297 
 13  
 
Appendix 4 Calculations for comparison of competition assay in this study with Weightman et al,1993
 298 
Appendix 5 ELISA intra-assay and inter-assay CV ............................................................................... 299 
Appendix 6 Cutting Edge publication accompanied with “News and Views” ...................................... 300 
Appendix 7 Abstract of oral presentation at 37
th
 ETA conference 2013, Lieden, The Netherlands ...... 302 
Appendix 8 Young Investigator Award certificate, 37
th
 ETA conference 2013, Lieden, The Netherlands
 303 
 
 14  
 
Figures and Tables  
 
Fig 1.1 Overlap of the TH17, iTreg, and TH1 cells axes of differentiation 
Fig 1.2 Putative model for balance regulation between Treg and Th17 cells  
Fig 1.3 Thyroid gland and thyroid follicular cells 
Fig 1.4 Schematic of negative feedback mechanism of thyroid hormone 
Fig 1.5 Schematic view of TSHR gene and protein  
Fig 1.6 TSHR and its stimulating and blocking mAbs binding sites 
Fig 1.7 Susceptible genes for Graves’ disease and Hashimoto’s thyroiditis 
Fig 1.8 Rundle curve of activity and severity of GO 
Fig 1.9 Schematic view of heterogeneity of orbital fibroblast 
Fig 1.10 Schematic view of IGF-1R 
Fig 1.11 Proposed model for pathogenesis of GO 
Fig 2.1 pTriEx™-1.1 Neo plasmid map 
Fig 2.2 A series of contiguous coronal T2w MRI 
Fig 2.3 A series of contiguous T2w MRI with axial slices guide 
Fig 2.4 A series of contiguous axial T2w MRI 
Fig 3.1 Gel electrophoresis of TSHR A-subunit plasmid  
Fig 3.2 Schematic view of inserted TSHR A-subunit gene  
Fig 3.3 Gel electrophoresis of IGF-1Rα plasmid  
Fig 3.4 Schematic view of inserted IGF-1Rα gene  
Fig 3.5 Immune mice weight monitoring 
Fig 3.6 Thyroid histological studies in immune mice of Group 1 
Fig 3.7 Thyroid histological studies in control mice of Group 1 
Fig 3.8 Histology of orbital tissue from a normal mouse 
Fig 3.9 H&E stained section of retrobulbar tissue from immune mice of Group 1 
Fig 3.10 H&E and IHC studies in orbital tissue from mice 60/0 and 60/L 
Fig 3.11 H&E and IHC studies in orbital tissue from mice 59/0 and 59/L 
Fig 3.12 Quantification of number of infiltrated CD3+ T cells into extraorbital muscles 
Fig 3.13 Appearance of head region of immune mouse (59/2) with chemosis 
Fig 3.14 H&E stained section of eye lid tissue with chemosis 
 15  
 
Fig 3.15 Evaluation of thyroid function by ELISA in mice sera of Group 1 
Fig 3.16 TRAK assay in immune mice sera of Group 1 
Fig 3.17 The bovine TSH dose response in cAMP bioassay 
Fig 3.18 Measurement of TSBAbs in immune mice sera of Group 1 
Fig 3.19 Measurement of TSAbs in immune mice sera of Group 1 
Fig 3.20 Thyroid histological studies in immune mice of Group 2 
Fig 3.21 H&E stained section of retrobulbar tissue from immune mice of Group 2 
Fig 3.22 Appearance of head region of two immune mice with chemosis 
Fig 3.23 H&E stained section of eyelid with chemosis 
Fig 3.24 Evaluation of thyroid function by ELISA in immune mice sera of Group 2 
Fig 3.25 Longitudinal analysis of TSBAbs  
Fig 3.26 Longitudinal analysis of TSAbs  
Fig 3.27 Evaluation of TRAK assay in immune mice sera of Group 2 
Fig 3.28 Thyroid histological studies in immune mice of Group 3 
Fig 3.29 Thyroid histological studies in control mice of Group 3 
Fig 3.30 H&E and IHC examination in retrobulbar tissue of mice (57/0, 57/L and 58/0)  
Fig 3.31 H&E and IHC examination in retrobulbar tissue of mice (57/R and 58/R) 
Fig 3.32 Masson’s Trichrome staining in mice from Group 3  
Fig 3.33 Evaluation of thyroid function by ELISA in mice sera from Group 3 
Fig 3.34 TRAK assay in immune mice sera of Group 3 
Fig 3.35 Measurement of TSBAbs and TSAbs in immune mice sera of Group 3 
Fig 4.1 Axial T1w MRI of a GO patient 
Fig 4.2 Basic concepts of MR imaging 
Fig 4.3 The differences between T1w and T2w in MRI of orbital tissue 
Fig 4.4 The standard protocol of MRI for GO patients 
Fig 4.5 The CT scan of orbital region from a patient with GO 
Fig 4.6 Contiguous coronal view T2w MRI of mouse 64/R with orbital protrusion 
Fig 4.7 Contiguous coronal view T2w MRI of mouse 64/L with orbital protrusion 
Fig 4.8 Contiguous coronal view T2w MRI of control mice 
Fig 4.9 Diameter of orbital globe in immune and control mice 
Fig 4.10 The MRI of extraorbital muscles 
Fig 4.11 Contiguous axial view T2w MRI of mouse 63/2 
 16  
 
Fig 4.12 Contiguous axial view T2w MRI of mouse 64/0 
Fig 4.13 Contiguous axial view T2w MRI of mouse 64/L 
Fig 4.14 Contiguous axial view T2w MRI of mouse 64/R 
Fig 4.15 Contiguous axial view T2w MRI of mouse 64/2 
Fig 4.16 Contiguous axial view T2w MRI of control mouse AM1 
Fig 4.17 Contiguous axial view T2w MRI of control mouse AM2 
Fig 4.18 Contiguous axial view T2w MRI of control mouse AM3 
Fig 4.19 Quantification of MRI showing hypertrophy in the extraorbital muscles  
Fig 4.20 Alignment of MR images with histology of extraorbital muscles in mice 
undergoing GO.  
Fig 4.21 Alignment of MRI with histology of extraorbital muscles in control mice 
Fig 4.22 Quantification of hypertrophy in the extraorbital muscles by histology 
Fig 5.1 Displacement of labelled IGF-1 by purified IgG from GO patients. Adapted from 
Weightman et al. 1993 
Fig 5.2 Displacement of labelled IGF-1. Adapted from Pritchard et al., 2003 
Fig 5.3 Flow cytometry in NWTB3 cells with 1H7 mAb 
Fig 5.4 Flow cytometry in NWTB3 cells with different anti-IGF-1R mAbs  
Fig 5.5 Evaluation of TSHR expression in NWTB3 cells by flow cytometry  
Fig 5.6 Flow cytometry in GPI5-9 cells by anti-TSHR mAb  
Fig 5.7 Binding of Lumi-IGF-1 NWTB3 cells in dose dependent manner  
Fig 5.8 Competition curve of different concentrations of Lumi-IGF-1  
Fig 5.9 Displacement of Lumi-IGF-1 in NWTB3 cells with anti-IGF-1R mAbs 
Fig 5.10 Determination of sensitivity of ELISA using different concentrations of 1H7 
mAb  
Fig 5.11 Re-examination of IGF-1R Abs by ELISA assay in serum samples in immune 
mice from study by Zhao and colleagues   
Fig 5.12 Re-examination of IGF-1R Abs by flow cytometrey in serum samples in 
immune mice from study by Zhao and colleagues 
Fig 5.13 Evaluation of IGF-1R Abs by ELISA in mice immunised with hTSHR A-subunit 
plasmid of Group 1  
Fig 5.14 Determination of IGF-1R Abs by flow cytometry in mice immunised with 
hTSHR A-subunit plasmid of Group 1 
 17  
 
Fig 5.15 Longitudinal analysis of anti-IGF-1R antibodies by ELISA in immune mice of 
Group 2 
Fig 5.16 Assessment of antibodies to IGF-1R by ELISA in immune mice of Group 3 
Fig 5.17 Analysis of anti-IGF-1R antibodies in immune mice of Group 4 
Fig 5.18 Immunohistochemistry analysis of frozen orbital tissue from a mouse 
immunised with TSHR A-subunit in Group 4 
 
Table 2.1 Reagents for separating and stacking gels 
Table 2.2 Mice identification codes for immunisation 
Table 2.3 The list of components in HBSS 
Table 2.4 Preparation of working sample for cAMP bioassay  
Table 2.5 List of T4 standards 
Table 2.6 Preparation of samples for SDS gel 
Table 3.1 DNA yield from plasmid purification using Giga prep kit 
Table 3.2 Double-blinded examination of orbital histology  
Table 4.1 Summary of in vivo MRI analysis of 5 immune mice  
Table 5.1 Specification of anti-IGF-1R mAbs received from Professor Siddle’s laboratory 
Table 5.2 Results of first attempt to generate IGF-1R mAbs 
Table 5.3 Results of second attempt to generate IGF-1R mAbs 
  




AITD   Autoimmune thyroid disease  
APC                                 Antigen presenting cell    
BSA   Bovine serum albumin 
bTSH                               Bovine TSH 
cAMP                             Cyclic adenosine monophosphate 
CTLA4                            Cytotoxic T lymphocyte antigen 4 
ELISA   Enzyme-linked immunosorbent assay 
EOM                               Extraorbital muscles  
ER                                   Endoplasmic reticulum  
EUGOGO              European group on Graves’ orbitopathy 
FCS                                 Foetal calf serum 
Foxp3                             Forkhead box P3 
FOV                                Field of view  
FSE                                  Fast-spin-echo 
GAGs   Glycosaminoglycans 
GO                                   Grave’s orbitopathy      
GWAS                             Genome-wide association studies 
H2O2    Hydrogen peroxide 
HBSS                               Hanks’ buffered saline solution 
HLA                                 Human leukocyte antigen 
hTSHR                             Human thyroid-stimulating hormone receptor 
 19  
 
IBMX                              3-isobutyl-1-methylxanthine 
IFN-γ                               Interferon gamma  
IGF-1   Insulin-like growth factor-1     
IGF-1R   Insulin-like growth factor-1 receptor    
Ig   Immunoglobulin  
IgG   Immunoglobulin G 
IHC                                  Immunohistochemistry  
IL-1                                  Interleukin1 
IL-6                                  Interleukin6 
KO                                    knockout  
LATS                                Long-acting thyroid stimulator  
Lumi-IGF-1               Chemiluminescent labelled IGF-1  
mAb                Monoclonal Antibody 
MFI                                Mean fluorescence intensity   
MHC                               Major histocompatibility complex 
mIGF-1R                       mouse IFG-1R 
MTC                               Masson’s trichrome  
mTECs                           Medullary thymic epithelial cells 
NIS                                 Sodium-iodide symporter   
PBS               Phosphate buffer solution 
PPAR-γ                          Peroxisome proliferator-activated receptor γ  
PRR                                Pattern recognition receptor  
 20  
 
PTPN22                         Protein tyrosine phosphatase  
RAI              Radioactive iodine      
rhIGF-1             Recombinant human insulin-like growth factor-1  
RORγ                             RAR-related orphan receptor gamma 
SDS-PAGE            Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
STAT4                           Signal transducer and activator of transcription 4  
T3              Triiodothyronine     
T4              Thyroxine  
TCRs                              T cell receptors  
TE                                  Echo time 
Tfh                                 T follicular helper  
Tg   Thyroglobulin  
TGF-β                              Transforming growth factor beta 
TNF                                  Tumour necrosis factor     
TPO    Thyroid peroxidise 
TR                                    Repetition time  
Tregs                               Regulatory T cells  
TSAbs                              Thyroid stimulation antibodies 
TSBAbs                           Thyroid stimulation blocking antibodies 
TSH   Thyroid-stimulating hormone     
TSHR   Thyroid-stimulating hormone receptor 
  











The most important aspect of the immune response is to distinguish between self/host 
tissues and infection. However, in some cases, the immune system is inappropriately 
targeted to host tissues; i.e. causes autoimmunity. Generally, autoimmunity results 
from a failure of self-tolerance, which may lead to an imbalance between lymphocyte 
activation and regulation. However, it is very unlikely that self-reactive lymphocytes 
that have escaped central and peripheral tolerance mechanisms are able to cause 
autoimmunity unless activated APCs present autoantigens to those lymphocytes 
(Abbas et al., 2012). Two main players have been implicated in autoimmune diseases: 
CD4+ T cells and MHC molecules. In the last few years, many studies have shed light on 
the emerging role of different CD4+ T subsets in autoimmunity, including Tregs, Th17 
cells and Th22 cells.  
As mentioned earlier, regulatory T cells play a fundamental role in the suppression of 
self-reactive lymphocytes in the periphery. Tregs are also responsible for the 
regulation of the inflammatory process to prevent extensive tissue injury. There are 
two suppression mechanisms proposed for the action of Tregs, inhibitory cytokine 
release and a contact-mediated effect on APCs (Caridade et al., 2013). Regulatory T 
cells inhibit the ability of APCs to stimulate T cells. Tregs mediate this mechanism 
through the inhibition of binding of T cells and APCs by CTLA-4 (Romo-Tena et al., 
2013). CTLA-4 of Tregs bind to B7 molecules which reduces the availability of B7 and 
prevents adequate co-stimulation required for the immune response. 
In addition, regulatory T cells produce IL-10 and TGF-β, both of which inhibit immune 
responses (Zhou et al., 2011). TGF-β regulates the differentiation of functionally 
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distinct subsets of T cells. As described before, the development of peripheral FoxP3+ 
regulatory T cells depends on TGF-β. However, in combination with IL-1 and IL-6, TGF-β 
promotes the development of the Th17 subset of CD4+ T cells by virtue of its ability to 
induce the transcription factor RORγt. 
TH17 cells are activated to eliminate extracellular bacteria and fungi (Zelante et al., 
2007). Moreover, Th17 cells have been implicated in the development of autoimmune 
diseases [reviewed in (Miossec et al., 2009, Wilke et al., 2011, Maddur et al., 2012)]. 
Th17 cells are characterised by the secretion of major cytokines such as IL-17A, IL-17F, 
and IL-22 (Liang et al., 2006). In addition to those major cytokines, Th17 cells also 
produce other effector cytokines, including IL-6, IL-9, IL-23, IL-26, and TNFα. Evidence 
suggests that Th17 cells are closely related to TH1 cells, as they may express T-bet in 
addition to RORγt. Th17 also induce IFN-γ in the presence of IL-12 (Basu et al., 2013) 
(Fig1.1).  
 Tregs and Th17 cells are two important CD4+ T cell subsets, which have important 
roles in peripheral immune responses, so that an imbalance in their relative activities 
can lead to the development of tissue inflammation and autoimmune diseases (Li et 
al., 2007).  An imbalance between Th17 cells and nTregs in rheumatoid arthritis has 
been described (Niu et al., 2010). However, skewed balance toward Th17 is not 
necessarily a fundamental part of autoimmune disease, particularly in MS (Haas et al., 
2005, Feger et al., 2007, Saresella et al., 2008, Jadidi-Niaragh and Mirshafiey, 2011). 
Recently, other studies have focused on an unusual potency of Th17 cells, and of 
plasticity of Tregs. Th17 cells, in contrast to Th1 and Th2 cells, possess a tendency for 
developmental flexibility or plasticity (Lee et al., 2009, Murphy and Stockinger, 2010). 
Moreover, there is evidence in support of an early developmental overlap in Th17 and 
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iTregs, as both require a common developmental factor, TGF-β (Bettelli et al., 2006, 
Weaver et al., 2006, Mangan et al., 2006). Similarly, iTregs, but not thymically derived 
natural Tregs, also retain substantial developmental plasticity (Fig1.1).  
 
Fig 1.1 Overlap of the Th17, iTreg, and TH1 cells axes of differentiation 
Developmentally, the Th17 lineage overlaps the iTreg pathway early and Th1 
pathway late. Adapted from Basu et al., 2013, revised and re-drawn by 
applicant.  
 
Therefore, in a new immunological perspective, Tregs and Th17 cells may be 
considered to orchestrate the pathogenesis of autoimmunity. While Tregs suppress 
the autoreactive responses in various autoimmune diseases, Th17 cells exacerbate 
these diseases through induction of various pro-inflammatory mediators. So the 
regulation of the relative activity of these cells may assign the fate of autoimmune 
diseases (Wright et al., 2011).  More recently, it was postulated that TGF-β, retinoic 
acid and lipid mediators are potential mediators in establishing the balance between 
Tregs and Th17 cells (Haak et al., 2009, Maddur et al., 2012) (Fig 1.2). 
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Fig 1.2 Putative model for balance regulation between Treg and Th17 cells 
This model suggests that balance between Treg and Th17 cells orchestrated by 
TGF-β. Adapted from Jadidi-Niaragh, 2012, revised and re-drawn by applicant. 
 
The aetiology and pathogenesis of autoimmune diseases remain largely unknown. The 
major factors that contribute to the development of autoimmunity are genetic 
susceptibility and environmental triggers. The higher concordance of autoimmune 
diseases in monozygotic twins, compared to dizygotic or sibling pairs, supports a role 
for genetic susceptibility. For instance, type 1 diabetes shows a concordance of close 
to 50% in monozygotic twins and 5% to 6% in dizygotic twins (Lo et al., 1991, Bach, 
2002). There are similar observations in systemic lupus erythematosus (Block et al., 
1975) and autoimmune thyroid disease (Brix et al., 1998, Brix et al., 2001, Brix and 
Hegedus, 2011, Brix et al., 2011) (it will be discussed on more detail in this chapter). 
However, there are differences in type 1 diabetes incidence among genetically similar 
groups that live in dissimilar environmental conditions, with the incidence often 
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following local incidence trends (Bach, 2002). Thus, autoimmune diseases are 
characterised as complex or multifactorial disease (Selmi et al., 2012).  
Most autoimmune diseases are complex polygenic traits, in which affected individuals 
inherit multiple genetic polymorphisms that contribute to disease susceptibility 
(Stankov et al., 2013). Some of these polymorphisms are genes representing the 
susceptibility alleles shared amongst different, clinically unrelated autoimmune 
diseases, such as MHC (Tsai and Santamaria, 2013), STAT4 (Glas et al., 2010, Ji et al., 
2010) and IL-12A receptor (Bossini-Castillo et al., 2012, Zhang et al., 2012). Other loci 
are associated with particular diseases, suggesting that they may affect organ damage. 
The technique of genome-wide association studies has greatly extended the analysis of 
the genetic basis of complex diseases, and we now know of many genes that are 
associated with autoimmune diseases (Barrett et al., 2009). Among the genes that are 
associated with autoimmunity, the strongest associations are with MHC genes. In fact, 
in many autoimmune diseases, the MHC locus alone contributes half or more of the 
genetic susceptibility. However, the mechanisms underlying the association of 
particular MHC alleles with various autoimmune diseases are still not clear. Amongst 
the non-MHC genes associated with autoimmunity, the protein tyrosine phosphatase 
PTPN22 is associated with several autoimmune diseases such as rheumatoid arthritis, 
type 1 diabetes, autoimmune thyroiditis, and systemic lupus erythematosus (Fousteri 
et al., 2013). 
Evidence continues to accumulate supporting a role for the environment in 
autoimmunity   (Hemminki et al., 2010, Selmi et al., 2012, Miller et al., 2012). Among 
environmental factors implicated, the most important factor is infection (Root-
Bernstein and Fairweather, 2014). A number of theories have been proposed to 
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explain how infections could cause autoimmune diseases. These include exposure of 
the immune system to a cryptic antigen, epitope spread, molecular mimicry and 
bystander effect (Rose, 2012, Getts et al., 2013, Mangalam et al., 2013, Rigante et al., 
2014). The theory of cryptic antigen is one of the oldest theories explaining the role of 
infection in autoimmunity. It is based on the idea that self reactive antigens are 
“cryptic” the checkpoints of central and peripheral tolerance. Thus, infection triggers 
to release the cryptic antigens. Epitope spreading is an alternative to the cryptic 
antigen theory. The epitope spread theory originated following observations of 
changes in the major epitopes recognised during progression of autoimmune disease 
(Lehmann et al., 1992). Epitope spread occurs as part of the normal immune response 
to infections. Initially, in encountering to infection, the immune system reacts to a 
dominant epitope, but when it later re-encounters the same pathogen, it produces an 
immune response against different epitopes of the pathogen, so that the immune 
system improves its ability to clear the pathogen.  
The idea that molecular mimicry could drive autoimmunity originated after the 
observation of close sequence homology between microbial and human proteins 
(Fujinami et al., 1983). Over the last three decades, experimental evidence 
demonstrated cross-reactivity between pathogens and self antigens (Cunningham, 
2012, Christen et al., 2012, Smyk et al., 2012) . However, a mechanism involving 
molecular mimicry in the induction of autoimmunity has recently been challenged 
(Tandon et al., 2013, Root-Bernstein and Fairweather, 2014). Another popular theory 
to explain role of infection in autoimmune diseases is the “bystander effect”, which 
proposes that proinflammatory cytokines are released by innate immune cells in 
response to infections, which can then activate autoreactive T lymphocytes (Owens 
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and Bennett, 2012). It has been suggested that the bystander effect is crucial for the 
induction of autoimmunity (Mangalam et al., 2013). This would explain the need for 
adjuvants in animal models of autoimmune disease. 
An underlying assumption of most of these theories is that autoimmunity is the 
consequence of a defect in the immune response (Mills, 2011, Blander et al., 2012, 
Cusick et al., 2012). However, recent studies hypothesise that self-reactivity is part of 
normal regeneration and healing processes (Galli et al., 2012). A major problem in 
defining the connection between infection and autoimmunity is that the detection of 
infectious microorganisms in the individual at the time when autoimmunity develops is 
not easy to achieve. The lesions that result in autoimmunity are probably not due to 
the infectious agent itself but result from host immune responses that may be 
triggered or dysregulated by the microbe. 
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1.1 Thyroid gland 
 
The thyroid gland is the largest endocrine gland in humans. The main function of 
thyroid gland is the synthesis and secretion of thyroid hormones, thyroxine (T4) and 
triiodothyronine (T3). Thyroid hormones regulate a wide range of normal physiological 
processes including metabolism, growth, development and reproduction. The gland is 
composed of closely packed spherical units, which are called follicles. On cross-section, 
follicles consisting of single layer of thyroid cells surrounding a lumen (Fig 1.3 A). On 
the apical side of thyroid follicular cells, there are numerous microvilli extended into 
the colloid where secretion of hormone occurs (Fig 1.3 B).  
 
 
Fig 1.3 Thyroid gland and thyroid follicular cells 
(A) Cross-section of thyroid gland from a normal mouse thyroid, 100X.  
(B) Schematic presentation of thyroid follicular cells and hormone synthesis.  
 
 
Thyroid follicular cells synthesise thyroglobulin (Tg) and thyroid peroxidase (TPO). 
While Tg is transported to the colloid by exocytosis, TPO is anchored to the apical cell 
membrane. At this membrane, oxidation of iodide occurs by iodination of tyrosyl 
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residues in the large Tg molecule to monoiodotyrosine and diiodotyrosine. Iodination 
takes place in the colloid in the presence of TPO and hydrogen peroxide (H2O2). One 
molecule of T4 is made by coupling two diiodotyrosines in the Tg molecule. In the 
same way T3 is made from monoiodotyrosine and diiodotyrosine. At the thyroid 
follicular cell apical membrane, colloid is taken up into vesicles by pinocytosis and 
absorbed into the cell. Lysosomes containing proteolytic enzymes then fuse with the 
colloid vesicle. This releases T4 and T3, as well as inactive iodotyrosines. Although T4 is 
the major hormone secreted by the thyroid gland, it is not biologically active. T4 is 
converted to the active T3 in peripheral tissues by iodothyronine deiodinases.  
Iodine, which is acquired from the diet, is an indispensable component of thyroid 
hormones. Iodine is reduced to iodide and taken up throughout the small intestine via 
the mucous membrane to the blood. It is then concentrated into the thyroid follicular 
cell by a specialised symporter, the sodium-iodide symporter (NIS). Thyroid stimulating 
hormone (TSH) regulates both the synthesis and the function of NIS. Intact NIS in the 
basal cell membrane is a necessary for accumulation of iodine in the thyroid. Once 
iodide is transported across the basal membrane by NIS, it passes via passive diffusion 
in the cytoplasm to the apical membrane. In the apical membrane pendrin, the anion 
transporter, transfers iodide across the apical membrane by exchanging chloride ions 
for iodide to the lumen where thyroid hormone synthesis takes place.  
 
1.1.1 Pathophysiology of thyroid gland 
 
Thyroiditis is a common name for several inflammatory conditions in the thyroid. 
Thyroid autoimmune diseases and multi-nodular goitre are the most common 
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conditions affecting the thyroid gland. The goitre is the thyroid condition in which 
iodine deficiency, in most cases, leads to enlargement of the thyroid. Apart from iodine 
deficiency, the main cause of goitre is multi-nodular nontoxic benign goitre. 
Pathogenesis of goitre occurs because of focal follicle cell hyperplasia at one or more 
sites in the thyroid gland. Multi-nodular goitre can develop to a toxic phase from a 
nontoxic multi-nodular goitre. In this case, the growing goitre can be toxic with 
increasing synthesis and release of hormone. Although thyroid nodules are common, 
thyroid cancer is a relatively rare condition. A thyroid tumour is normally derived from 
thyroid follicle cells and in rare cases from C cells, which lie between follicle cells in the 
connective tissue. The most common thyroid tumours are classified into follicular 
adenoma, follicular cancer, papillary cancer and medullary thyroid cancer. 
 
1.1.2 Autoimmune thyroid diseases  
 
Intriguingly, thyroid autoimmunity consists of two opposing clinical syndromes, 
Hashimoto’s (destructive) thyroiditis and Graves’ (hyperthyroidism) disease. In this 
section, a brief description of thyroid autoimmunity in general is provided and more 
detail of each condition will be   discussed in subsequent sections. 
Autoimmune thyroid disease (AITD) is the most common organ-specific autoimmune 
disorder affecting Caucasians in the Western world, with an incidence 1–2% of the 
population (Jacobson et al., 1997, Hollowell et al., 2002). The disease incidence rate is 
up to 10 times higher in women than men (Gessl et al., 2012). It is also postulated that 
there is an association between pregnancy in women and AITD. During pregnancy, the 
serum concentrations of thyroid Abs decrease due to generation of maternal Tregs 
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that maintain tolerance to the foetus (Weetman, 2010, Weetman, 2012). After 
delivery, there is a rebound with a transient rise in thyroid Abs. The postpartum period 
carries a risk of onset of Graves’ disease; although, the risk might have been 
overestimated (Rotondi et al., 2008). Furthermore, evidence from different studies 
confirmed that skewed X-chromosome inactivation is associated with an increased risk 
of developing AITD in women (Brix et al., 2005, Simmonds et al., 2014). AITD is also an 
age-related condition and mostly occurs at ages between 35 and 60; although, there 
are cases of younger age (Hollowell et al., 2002, Gastaldi et al., 2014, Diana et al., 
2014, Levy-Shraga et al., 2014).   
Infiltration of the thyroid gland by lymphocytes and production of thyroid 
autoantibodies are the main characteristics of autoimmune thyroid diseases. In 
Hashimoto’s thyroiditis, the immunological process is dominated by lymphocyte-
mediated cell-damaging processes, leading to destruction of follicular cells. However, 
in Graves’ disease, immune reactivity is dominated by synthesis and release of Abs.  
AITD is a multifactorial disease where both genetic and environmental factors 
contribute to pathogenesis of the disease and its severity.  
Genetic factors and environmental factors associated with AITD are reviewed in 
(Tomer, 2010) and (Menconi et al., 2011) respectively. Twin studies confirmed that 
AITD has a major genetic contribution (Brix et al., 1998, Brix et al., 2001, Brix and 
Hegedus, 2011, Brix et al., 2011).  Thus, different groups attempted to find an 
association between disease incidence and susceptible genes. According to recent 
reviews, three gene loci are most associated with autoimmune thyroid disease; (i) 
MHC region, (ii) CTLA4 and (iii) PTPN22 (Weetman, 2009, Brand and Gough, 2010). In 
addition, for hyperthyroid AITD patients, there is one thyroid specific susceptibility 
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locus which is TSHR (Dechairo et al., 2005, Brand et al., 2009) (these genes will be 
discussed in more detail in section 1.3.7). Moreover, SNP in the Kozak sequence of 
CD40 is associated with Graves’ disease in Caucasians and Koreans, but not in 
Taiwanese (Jacobson and Tomer, 2007, Hsiao et al., 2008). The genetic and epigenetic 
factors that may increase the risk of AITD are still not fully defined (Tomer, 2014). 
Although, twin studies have convincingly demonstrated that genetic factors contribute 
about 70% to the development of AITD (Brix and Hegedus, 2012),  the interaction of 
environmental factors with genetic susceptibility is required for breakdown of self-
tolerance leading to AITD (Effraimidis and Wiersinga, 2014).  
1.1.3 Hashimoto’s thyroiditis 
 
Hashimoto’s thyroiditis is the most common thyroid autoimmune condition in man. 
The condition was first reported by Hakaru Hashimoto in 1912. Similar to many other 
autoimmune diseases, Hashimoto's disease is more common in females and is age-
related; usually occurring after the age of 30. Hashimoto’s thyroiditis is characterised 
by destruction of the thyroid tissues due to autoimmune reactivity.  The hallmark of 
Hashimoto’s disease is the presence of Abs against Tg and TPO in patients’ sera. 
However, destruction of thyroid follicular cells is mostly associated with cellular rather 
than humoral immunity (Quaratino et al., 2004). At disease onset, secretion of thyroid 
hormone may be increased due to release of stored hormone from the lumen into the 
periphery. Subsequently, as a result of damage to thyrocytes, thyroid hormone 
production decreases, which leads to hypothyroidism. 
As mentioned earlier, both genetic and environmental factors are considered to be 
involved in Hashimoto’s thyroiditis. The relative contribution of each is not clearly 
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defined and may vary from patient to patient. High intake of iodine is demonstrated to 
play an important role as an environmental factor (Laurberg et al., 2010). Evidence 
shows that the destruction of thyroid follicles occurs by the apoptotic mechanisms 
(Wang et al., 2004).  
1.2 Graves’ disease 
 
Clinical features of Graves' disease were described in late 1700s by Caleb Parry. 
However, Robert James Graves, an Irish physician, published in 1835 case reports of 
patients with goitre and palpitation with one case of exophthalmos. At the same time, 
Karl von Basedow also well documented case reports and suggested mineral water 
containing iodide as a treatment. Different aetiologies were described for Graves’ 
disease until the early 19th century including cardiac, neurological and hyper-secretion 
from ductless glands. After the identification of TSH in the 1930s, it was suggested that 
an excess of TSH caused Graves’ disease. However, it was demonstrated that TSH 
levels remain constant in Graves’ patients and may be lower than in controls. 
Subsequently, in 1962, long-acting thyroid stimulator (LATS) was described. With the 
activity found in the gamma-globulin fraction of  patients’ sera (McKenzie, 1962).  
Finally, in 1964, the autoimmune basis of Graves’ disease was established by 
describing the immunoglobulin nature of LATS (Kriss et al., 1964).  
In contrast to Hashimoto’s thyroiditis, patients with Graves’ disease mostly show 
hyperthyroidism. Excessive circulating thyroid hormone leads to an increase in 
metabolic rate and cell proliferation. The most common symptoms of hyperthyroidism 
are weight loss, nervousness and heat intolerance. Hyperthyroidism results from 
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activating Abs to TSHR on thyroid follicular cells, which are able to emulate the actions 
of TSH. Stimulation of TSHR by Abs makes the negative feedback regulation 
inoperative, as the stimulating Abs are persistently activating the thyroid gland. In 
addition to hyperthyroidism and thyroid enlargement, which are the classical 
symptoms, the well-known complication of Graves’ disease  is Graves’ orbitopathy 
(GO). There are also other rare extrathyroidal signs on Graves’ patients including 
pretibial myxoedema, skin changes (thyroid dermopathy) and, more rarely, fingertip 
and nail abnormalities (thyroid acropachy) (Fatourechi, 2012). 
Graves’ disease is the most common cause of hyperthyroidism in areas with sufficient 
iodine intake, with a prevalence of about 0.5% (Brent, 2008) and incidences around 21 
per 100,000 per year (Nystrom et al., 2013). Individuals of any age can be affected, but 
women aged 40–60 years have the highest risk of developing the disease (Weetman, 
2000). Genetic factors account for up to 80% of the risk of developing Graves’ disease 
(Brix et al., 2001, Brand and Gough, 2010); the other 20% represent environmental risk 
factors, such as cigarette smoking, sex hormones, pregnancy, stress, infections and 
adequate iodine intake (Brand and Gough, 2010, Morshed et al., 2012, Effraimidis and 
Wiersinga, 2014). These factors contribute to the onset of Graves’ disease in 
genetically predisposed individuals. In different population studies, smoking is 
negatively associated with both progressing and de novo development of thyroid 
autoantibodies (Strieder et al., 2003, Asvold et al., 2007, Pedersen et al., 2008). 
Furthermore, a prospective study reported a transient increase in the risk of 
autoimmune thyroid disease after cessation of smoking (Effraimidis et al., 2009).  
Unlike Hashimoto’s thyroiditis, in Graves’ disease, immune reactivity is dominated by 
synthesis and release of antibodies [reviewed in (Prabhakar et al., 2003, Weetman, 
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2003)]. The antibodies consist of two opposite types in terms of pathophysiological 
activities, thyroid stimulating antibodies and thyroid blocking antibodies, which will be 
described in more detail later. Although infiltration and inflammation occur in the 
thyroid in the disease, it is rare to see destruction of thyroid tissue in Graves’ patients.  
1.2.1 Autoantigens in thyroid autoimmunity 
 
Although, the aetiology of autoimmune thyroid diseases remains unclear, auto-
antigens and their roles in pathogenesis of the disease are well studied. TPO, Tg, and 
TSHR are three well-known antigens that are targeted in autoimmune thyroid disease 
(details of each antigen will be discussed in next sub-sections). In addition, there is 
contradictory evidence of autoantibodies against other receptors such as sodium-
iodide symporter (NIS) and pendrin. Since 1996, when NIS was successfully cloned (Dai 
et al., 1996), a possible role for NIS as an autoantigen was postulated (Ajjan et al., 
1998a, Ajjan et al., 1998b). NIS has only a small ectodomain attached to 13 membrane-
spanning segments. Early studies detected autoantibodies in serum from patients with 
thyroid autoimmune disease that bound to NIS and inhibited its iodide transport 
function (Raspe et al., 1995, Ajjan et al., 2000). In contrast, other data did not provide 
support for NIS as a major autoantigen (Seissler et al., 2000, Heufelder et al., 2001). 
Furthermore, a potential role of pendrin, another thyroidal iodide transporter, in AITD 
pathogenesis has been suggested (Czarnocka, 2011), but a recent study has excluded 
pendrin from being a major thyroid autoantigen (Kemp et al., 2013). A recent twin 
study shows that, although pendrin and NIS antibodies are absent in healthy 
individuals, autoantibodies are rare in diseased twin pairs too (Brix et al., 2014).  
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1.2.2 TSH receptor (TSHR) 
 
The TSHR is a member of G protein–coupled receptor family with 7–transmembrane 
domains. TSHR gene (Fig 1.5 A) was cloned and sequenced completely for the first 
time at 1989 and 1990 by three independent groups (Libert et al., 1989, Misrahi et al., 
1990, Frazier et al., 1990).  This 764-aa protein is coded by a single gene on 
chromosome 14 (14q3). TSHR is comprised of three main parts, starting with residues 
1 to 21, which form the signal peptide of TSHR. There is a large glycosylated 
ectodomain with 394-aminoacid encoded by 9 exons. The last is the 7–transmembrane 
domain and cytoplasmic tail of 350 amino acids which is encoded by one single exon. 
The transmembrane region is comprised of 281 amino acids with the cytoplasmic 
region 69 residues. The highly glycosylated ectodomain consists of two smaller 
domains of ten leucine rich regions (LRR, amino acids 22 - 316) and the “cleavage” or 
the “hinge” region (amino acids 316 to 366). The LRR interacts with the ligand TSH and 
with antibodies to TSHR. Glycosylation is important for binding to cell surface mannose 
receptors on APCs and their subsequent internalisation (Stahl and Gordon, 1982), a 
process that markedly enhances the efficacy of T-cell responses (Engering et al., 1997).  
Intramolecular cleavage within the hinge region represented by residues 316-366 
(Tanaka et al., 1999b) divides TSHR into two distinct subunits. The secretory region is 
known as the A-subunit, whilst the B-subunit consists of the rest of the protein 
including the hinge region, a short membrane-anchored region and the intracellular 
portion (Fig 1.5 B) (Kajita et al., 1985, Loosfelt et al., 1992, Misrahi et al., 1994). 
Evidence from thyrocyte culture shows that the A-subunit is shed into the medium 
(Couet et al., 1996b, Tanaka et al., 1999a). The mechanism of A-subunit shedding is still 
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uncertain. Dissociation disulﬁde bonds by protein disulﬁde isomerase (PDI) (Couet et 
al., 1996a) is one of the most accepted concepts. Importantly, it was demonstrated 
that TSHR antibodies interact with TSHR A-subunit more strongly than to holoreceptor 
expressed on the cell surface (Chazenbalk et al., 2002, Nagayama et al., 2002)  
TSH binding to the TSHR induces proliferation in thyrocytes through a cAMP-
dependent signalling pathway. However, in the absence of ligand, TSHR is still able to 
generate a signal (Van Sande et al., 1995). This phenomenon is called constitutive 
activity. Studies showed increased constitutive activity following removal of the entire 
TSHR ECD (Zhang et al., 2000). Consequently the TSHR ectodomain can be regarded as 
a tethered, inverse agonist (Vlaeminck-Guillem et al., 2002). Binding of TSH to the 
ectodomain converts it to surrogate ligand (Vlaeminck-Guillem et al., 2002). So, it is 
the ectodomain, not TSH, which directly interacts with the transmembrane domain. 
Development of a mAb (CS17) that can block TSHR constitutive activity has been 
reported (Chen et al., 2007). The recent findings of G protein–coupled receptor 
structure after successful crystallography has provided insight into critical aspects of 
binding of endogenous ligands leading to activation of the receptor (Audet and 
Bouvier, 2012). It is suggested the important role of particular sites of transmembrane 
domains in receptor signalling. Site directed mutagenesis revealed that constitutive 
signalling activity can be silenced by mutation in the allosteric ligand binding site (Haas 
et al., 2011). These allosteric binding sites are independent of TSH binding and, 









Fig 1.5 Schematic view TSHR gene and protein  
(A) Structure of the TSHR gene and coding sequence (CDS). Boxes represent 
exons numbered 1 to 10 and proportional to length, red representing the 
coding sequence, grey representing untranslated regions (UTR); the horizontal 
line joining exons represents introns. Positions below the CDS are numbered 
relative to the transcription start. Three vertical arrows in Intron 1 represent 
common SNPs (rs179247, rs12101255, and rs12101261) susceptible for 
developing Graves’ disease. Adapted from NCBI website, drawn by applicant.    
(B) Schematic of TSHR protein showing A-subunit, B-subunit, hinge region 
(cleavage region), leucine rich domains (LRRs) are indicated.  Adapted from 
Morshed et al. 2012 with permission from Prof T.F. Davies. 
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The TSHR is the master regulator of the thyroid gland and controls cell differentiation 
and hormone secretion. As TSHR affects different functions of the thyroid, it has been 
implicated in a wide range of thyroid diseases. Certain TSHR mutations lead to 
hyperthyroidism by over-activity of thyroid cells; in contrast, other deficiencies have 
resulted in receptor inactivation, which may lead to hypothyroidism. The TSHR is the 
major target auto antigen in Graves’ disease, but, interestingly, thyrocytes are not the 
only cells that express TSHR.  
 
1.2.3 Extrathyroidal expression of TSHR 
 
In the late 1970s, different investigators showed functional expression of TSHR in fat 
cells (Mullin et al., 1976) and retrobulbar adipose tissue (Davies, 1978). It is also shown 
that, in the pretibial skin of patients with thyroid exophthalmos, the level of TSHR is 
elevated (Daumerie et al., 2002). A low abundance of TSHR in other tissues has also 
been reported, including skin, adrenal gland, kidney, and thymus (Endo et al., 1993, 
Feliciello et al., 1993, Paschke et al., 1994, Dutton et al., 1997). However, it seems that 
TSHR is detectable only at the transcriptional level (Paschke et al., 1994). The presence 
of the TSHR protein in extrathyroidal tissue, where functional receptor expression is 
more abundant, appears to be the cause of pathology in extrathyroidal tissue in 
Graves’ disease. This idea is supported by findings that orbital tissue from patients 
suffering from an orbital condition of Graves’ disease have more abundant expression 
of TSHR in comparison with normal orbital tissue (Bahn et al., 1998, Starkey et al., 
2003).  
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1.2.4 Graves’ disease and antibodies to TSHR  
 
The interaction of TSHR with its ligands is very complex. For instance, TSH is considered 
to have more than 52 amino acids interacting with the receptor: 33 from the TSH A-
subunit and 19 residues from the TSH B-subunit. Each of those binding sites 
contributes differently to binding affinity (Nunez Miguel et al., 2009). 
The antibodies to TSHR comprise three different subtypes, thyroid stimulating 
antibodies (TSAbs), thyroid blocking antibodies (TSBAbs) and neutral antibodies (Rees 
Smith et al., 1988). TSAbs mimic the actions of TSH and initiate the TSHR signalling 
cascade leading to hyperthyroidism. In contrast, TSBAbs inhibit TSHR stimulation by 
TSH leading to a decrease of thyroid hormone secretion (Rees Smith et al., 1988, 
Jaume et al., 1997). The binding site for stimulating antibodies is represented by all 10 
LRRs. TSH is not able to bind to a receptor that is already occupied by TSAbs (Jeffreys 
et al., 2002).  The binding site for TSHR blocking antibodies is different to that of 
stimulating Abs (Oda et al., 2000); TSBAbs also inhibit the binding of TSH to receptor 
but are not able to induce cAMP production (Fig 1.6 A,B). On the other hand, neutral 
TSHR antibodies neither block TSH binding nor stimulate the receptor and they do not 
induce cAMP generation (Morshed et al., 2010).  
The study of the interaction between the TSHR and antibodies in disease is difficult 
because of the very low serum concentration in patients (de Forteza et al., 1994, 
Jaume et al., 1997). However, in last decade, two major approaches have advanced 
our understanding of TSHR Abs and their roles in Graves’ disease. These are (i) 
isolation of monoclonal antibodies (mAbs) to TSHR and (ii) development of animal 
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models. The isolation of TSHR mAb helped to characterise Graves’ disease. The first 
real success was achieved in 2002 when hamster and mouse monoclonal antibodies to 
the TSHR were produced (Ando et al., 2002, Sanders et al., 2002, Costagliola et al., 
2002). One year later, a human thyroid stimulating mAb, M22, was generated from 
Graves’ patient samples (Sanders et al., 2003).  Human blocking mAbs (5C9) have also 
been isolated (Sanders et al., 2005). There is also evidence that patient sera contain a 
mixture of stimulating and blocking type TSHR autoantibodies (Rees Smith et al., 1988, 
Watanabe et al., 1997). More recently, the isolation of a blocking type TSHR mAb (K1-
70) and a stimulating type TSHR mAb (K1-18) from a single patient has been reported 
(Evans et al., 2010). The crystal structure of the A-subunit of TSHR with the Fab 
fragment of the human thyroid stimulating mAb M22 has been determined at 2.55Å 
resolution (Sanders et al., 2007) and the crystal structure of the A-subunit of TSHR with 
the Fab human thyroid blocking mAb, K1-70 at 1.9Å resolution (Sanders et al., 2011). 
Both M22 and K1-70 bind to the concave surface of the TSHR LRR; however the 
interactions of the K1-70 involve regions located more towards the N-terminus of the 
LRR than the M22. In particular, K1-70 interacts with TSHR leucine rich repeats 1 to 8, 
while M22 binds to entire 10 LRR (Sanders et al., 2007, Nunez Miguel et al., 2009, 
Sanders et al., 2011) (Fig 1.6 A,B). 
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Fig 1.6 TSHR and its stimulating and blocking mAbs binding sites  
Schematic view of differences in binding sites of TSAbs, TSBAbs and neutral Abs in 
TSHR structure. Adapted from Morshed et al. 2012 with permission from Prof T.F. 
Davies.  
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1.2.5 Genetic basis for Graves' disease 
 
As already mentioned there is a strong evidence for genetic basis of autoimmune 
thyroid diseases based on the finding that 50% of patients have family members with 
Graves’ disease and that siblings from Graves’ patients have a risk of 33% to develop 
an autoimmune thyroid disorder themselves (Simmonds and Gough, 2004, Tomer, 
2010). Moreover, concordance rates for Graves’ disease are 35% in monozygotic twins, 
while this is only 3% in dizygotic twins (Brix et al., 2001, Brix and Hegedus, 2012). 
Statistical modelling estimates that 79% of the predisposition to Graves’ disease is 
determined by genetic factors, while environmental factors account for the other 21% 
(Brix and Hegedus, 2012).  
Moreover, current advances in genomics, including the identification of more than a 
million common SNPs ,the creation of accurate linkage disequilibrium maps of these 
SNPs and more recently genome wide association study (GWAS) approach have 
revealed a novel set of susceptible genes for AITD as well as other autoimmune 
diseases (Cho and Gregersen, 2011, Simmonds, 2013). Genetic studies, however, 
before existence of such advance methods have been performed using candidate gene 
case–control studies involving screening variants SNPs within genes of interest. These 
studies led to three susceptible loci; HLA class II region, CTLA-4 and PTPN22 (Simmonds 
and Gough, 2011). In early years of 21st century, newly developed fluorescence-based 
genotyping uncovered association of CD25 and HLA class I region in AITD, and TSHR in 
Graves’ disease specifically (Simmonds and Gough, 2011). Afterwards, GWAS study in 
large cohorts (more than 1000 patients and 1000 controls) has been used to identify 
new susceptible loci (Simmonds, 2013). The first AITD GWAS was performed in 2011 in 
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a Chinese cohort and confirmed association of several known Graves’ disease 
susceptibility loci including the HLA region, TSHR and CTLA4, along with two novel 
susceptibility loci at chromosome positions 6q27 and 4p14 (Chu et al., 2011). Another 
GWAS was undertaken in primarily European ancestry and supported association 
between PTPN22, the HLA class I region, CTLA4 and hypothyroidism (Eriksson et al., 
2012). More recently, strong association for seven additional loci was also found, 
including MMEL1, TRIB2, LPP, BACH2, chromosome 11q21, PRICKLE1 and ITGAM by 
Immunochip project in the UK (Cooper et al., 2012). 
Intriguingly, there are several susceptible genes in common between both AITDs, while 
some genes are unique for each of these pathologically distinct syndromes (Fig 1.7) 
(Tomer, 2014). Generally, the genes associated with AITDs and particularly with 
Graves’ disease are divided into two different groups; immune response related genes 
and thyroid function associated genes. Here we briefly discuss the role of well-studied 
genes in pathology of the disease while the novel identified loci need further 
investigations.  
 
 46  
 
 
Fig 1.7 Susceptible genes for Graves’ disease and Hashimoto’s thyroiditis. 
Adapted from Tomer, 2014, revised and re-drawn by applicant. 
  
MHC 
 Early studies showed an association between MHC regions and the development of 
Graves’ disease (Jacobson et al., 2008). MHC regions encode for the human leukocyte 
antigen proteins which are essential for peptide presentation to immune cells. Initially 
it was thought that a HLA class I molecule, HLA-B8, accounted for the association 
between HLA and the development of Graves’ disease  in Caucasians (Bech et al., 
1977), but later studies revealed that this association is due to a HLA class II molecule, 
HLA-DR3 (Boehm et al., 1992). Recently, it is shown that HLADRβ1-Arg74 is critical for 
the development of AITD (Ban et al., 2004, Menconi et al., 2008). An arginine at 
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position 74 has similar effect on development of type 1 diabetes (Menconi et al., 
2010). Interestingly, replacement of arginine by glutamine at that position plays a 
protective role (Menconi et al., 2008). Further studies confirmed the previous 
associations and also showed positive associations between Graves’ disease and HLA-
DRB1, HLA-DQA1 and HLA-DQB1 (Tomer, 2010, Chu et al., 2011). In contrast, some HLA 
molecules, such as HLA-DR5, have a protective effect on the development of Graves’ 
disease (Uno et al., 1981). 
CTLA4 
The CTLA4 gene encodes the cytotoxic T-lymphocyte-associated serine esterase-4 
protein that suppresses T-cell activation and subsequent T-cell driven immune 
responses. The CTLA-4 protein is not expressed by resting, naive T cells, but is 
expressed upon T-cell receptor - HLA interaction (Teft et al., 2006). The CTLA4 gene is a 
highly polymorphic gene and specific polymorphisms have been associated with 
various autoimmune diseases, such as type I diabetes mellitus, autoimmune 
hypothyroidism, celiac disease, primary biliary sclerosis, systemic lupus erythematosus, 
multiple sclerosis and rheumatoid arthritis (Gough et al., 2005). Four different 
polymorphisms have been consistently linked to the development of Graves’ disease 
across different ethnic groups (Allahabadia et al., 2001, Kavvoura et al., 2007). 
Together with the HLA genes, polymorphisms in CTLA4 have been predicted to account 
for 50% of the genetic predisposition for Graves’ disease (Jacobson and Tomer, 2007, 
Tomer, 2010). 
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CD40 
CD40 plays a key role in the cross talk between APCs and T cells. Importantly, on B 
cells, CD40 provides a crucial signal for proliferating, differentiating, and switching to 
the production of immunoglobulin G (Jacobson and Tomer, 2007). Therefore, CD40 is 
among the susceptible genes for number of autoimmune diseases (Peters et al., 2009) 
including Graves’ disease (Jacobson et al., 2007). A C/T polymorphism was detected in 
the Kozak sequence of the CD40 gene of which the CC genotype is strongly associated 
with Graves’ disease (Ban et al., 2006, Kavvoura et al., 2007, Jacobson et al., 2007), 
although there is contradictory evidence in different ethnicity (Hsiao et al., 2008). The 
C-allele of this polymorphism is associated with increased CD40 expression on B cells 
and antigen presenting cells, which may result in higher activity of auto-reactive B 
cells. In addition, increased CD40 expression on thyroid cells enhances thyroid 
proinflammatory functions, thereby perpetuating the inflammatory process (Jacobson 
et al., 2005, Jacobson et al., 2007, Tomer, 2014). More recently by using a Graves’ 
mouse model, it is shown that upregulation of CD40 accelerates disease by activating 
IL-6 (Huber et al., 2012).  
PTPN22 
The PTPN22 gene encodes the lymphoid tyrosine phosphatase (LYP) protein. This 
protein regulate the T cell receptor signalling pathway which is like CTLA4 has a 
powerful inhibitory effect (Burn et al., 2011). There is an evidence that replacement of 
arginine by tryptophan at amino acid 620 of LYP (R620W) due to a SNP at position 
1858 in PTPN22 is associated with Graves’ disease (Velaga et al., 2004). It is 
hypothesised that the LypR620W variant loses its function and influence on immune 
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responses, which increases the risk for autoimmune disease (Davies et al., 2012). 
However, it is shown that LypR620W allele is a gain-of function variant that suppresses 
T cell receptor signalling. It is unclear how such suppression predisposes to 
autoimmunity, but some have suggested that it allows escape from central tolerance 
in the thymus (Vang et al., 2007). Interestingly, this association seems specific for 
Caucasians and was not found in the Japanese GD population (Jacobson and Tomer, 
2007). 
CD25  
As already mentioned in section 1.1.1, Tregs are divided into nTregs and iTregs. Natural 
Tregs is formed in the thymus and is characterised by the expression of the FoxP3, high 
expression of CD25 and low CD127 expression. They migrate peripherally and affect 
the immune system through the production of anti-inflammatory cytokines and direct 
cell-to-cell interactions, performing suppressive and protective functions. However, 
iTregs are formed peripherally out of CD4+ CD25- stimulated by TGFβ, transforming 
into the phenotype CD4+CD25+CTLA4+ and FoxP3 (Ohkura and Sakaguchi, 2010). The 
role of Tregs in the pathogenesis and development of different autoimmune disorders 
are well studied (Chavele and Ehrenstein, 2011, Szypowska et al., 2012). However, only 
few studies have been conducted on the role of Tregs in AITD and Graves’ disease 
(Fountoulakis et al., 2008, Pan et al., 2009, Bossowski et al., 2013). One of the recent 
study by analysis of Tregs in newly diagnosed patients with Graves’ disease revealed a 
reduction in the CD4+ FoxP3 and CD4+ CD25high  lymphocytes compared to the control 
group (Bossowski et al., 2013). Moreover, an earlier study showed that in AITD it is not 
the number of Tregs but the incomplete suppressive function of Tregs in peripheral 
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blood that may lead to autoimmune process (Marazuela et al., 2006). Furthermore, it 
is confirmed that polymorphism in CD25 gene is associated with Graves’ disease 
(Brand et al., 2007). More recently, similar study has shown the association between 
FoxP3 polymorphism and Graves’ disease in Chinese Han population (Zheng et al., 
2015).   
In addition to genes encoding proteins associated with immunological functions that 
have been mentioned above (Cooper et al., 2012), polymorphisms in genes encoding 
cytokines such as interleukin 1 receptor antagonist, tumour necrosis factor (TNF)-α, 
interferon (IFN)-γ, IL-4 as well as the vitamin D receptor gene have shown to be 
associated with Graves’ disease (Hunt et al., 2000), but need to be validated in other 
and larger patient cohorts. 
Thyroid-specific genes 
Of the three thyroid main autoantigens which were explained in earlier sections, Tg 
and TSHR have been shown to be associated to Graves’ disease. However, a very 
recent GWAS meta-analysis provided some evidence that TPO gene is also associated 
at least with the production of TPO Abs (Medici et al., 2014). TSHR gene association 
and its possible mechanisms will be discussed in detailed in this section. 
TSHR 
Prior to the completion of the human genome project and the availability of detailed 
SNP maps, three common germline SNPs of the TSHR have been examined for 
association with Graves’ disease (Tonacchera and Pinchera, 2000). The first two SNPs 
are located in the extracellular domain at positions 36 and 52, an aspartic acid to 
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histidine substitution (D36H), and a proline to threonine substitution (P52T). The third 
SNP is a substitution of glutamic acid for aspartic acid (D727E) within the intracellular 
domain of the receptor. However, for a long time there was no consistent evidence 
between Graves’ disease and above polymorphisms by studying in different ethnical 
populations (Tomer and Davies, 2003).  More recent evidence suggested association 
between Graves’ disease and non-coding (intronic) SNPs, most consistently with an 
intron 1 SNP (Fig 1.5 A) (Hiratani et al., 2005, Yin et al., 2008, Tomer and Huber, 2009, 
Ploski et al., 2010, Tomer et al., 2013). 
 In last few years, there have been different attempts to explain the mechanisms by 
which SNPs in intron 1 TSHR predisposes to Graves’ disease (Colobran et al., 2011, 
Stefan et al., 2014). Two explanatory mechanisms have being postulated;  
i) It is shown that the intronic TSHR polymorphisms could influence the splicing of 
exons coding the extracellular domain of the protein (Hiratani et al., 2005). There is 
also evidence indicating that the risk alleles of TSHR SNPs (rs179247 and rs12101255) 
were associated with production of the soluble A-subunit (Brand et al., 2009). As 
already mentioned in Section 1.3.4, the production of soluble form of TSHR would 
favour the generation of an autoimmune response to the receptor.  
ii) An evidence on association between the risk alleles and a lower TSHR expression in 
the thymus (Colobran et al., 2011) proposed that the escape of more TSHR reactive T 
cells might related to induction of Graves’ disease. Recent study supported this 
mechanism by demonstrating that IFNα interacts through chromatin remodelling with 
an SNP in intron 1 of the TSHR gene (rs12101261) to reduce thymic TSHR expression 
(Stefan et al., 2014). If TSHR expression in the thymus were reduced by the intron 1 
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variants, that would enable autoreactive T cells that target the TSHR to escape deletion 
in the thymus and thereby trigger disease later in life (Colobran et al., 2011, Tomer, 
2014, Stefan et al., 2014, Gimenez-Barcons et al., 2015, Pujol-Borrell et al., 2015).  
1.2.6 Environmental factors of Graves' disease 
 
Besides genetic factors, environmental factors have also been implicated in the 
development of Graves’ disease and are estimated to account for 21 % of the 
predisposition for Graves’ disease (Brix et al., 2001).  
Smoking  
Smoking is considered as highly associated socio-environmental risk factor to Graves’ 
disease development (Vestergaard et al., 2002). There is also evidence to show 
smoking increase the chance of relapse as well as its negative effects on the remission 
of disease following treatments (Glinoer et al., 2001, Kimball et al., 2002). A dose 
dependent association exists between smoking and the risk to develop Graves’ 
disease, but effect of smoking is mostly studied in GO (Tanda et al., 2009, Hemminki et 
al., 2010, Miller et al., 2012, Wiersinga, 2013) which will be discussed in more detail 
later. 
Iodine 
Iodine is required for the synthesis of thyroid hormones and a clear relationship exists 
between the amount of iodine intake and the occurrence of thyroid hormone 
disorders (Brent, 2010). Hyperthyroidism is more common in geographical areas with 
sufficient iodine intake, in contrast to hypothyroidism which is more prevalent in 
iodine-deficient areas (Laurberg et al., 2000, Laurberg et al., 2010). Increased iodine 
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intake normally leads to a reduction of thyroid hormone production (the Wolff-
Chaikoff effect). However, in patients having areas of autonomous thyroid hormone 
production in their thyroid, this may lead to increased thyroid hormone production 
(the Jod-Basedow effect). Usually these effects resolve within a few days, but when 
persisting, they may lead to thyroid damage and autoimmune activation (Zimmermann 
and Boelaert, 2015). Apart from this, iodine can also influence thyroid autoimmunity 
via direct activating effects on immune cells or by highly iodinated and therefore 
immunogenic Tg (Papanastasiou et al., 2007).  
Selenium 
Selenium is an important trace mineral which is an essential nutrient for 
selenocysteine synthesis that influences thyroid hormone production (Duntas, 2010). 
Selenium deficiency has been associated with an increased thyroid gland volume and 
echogenicity. Oxidative stress plays a role in GD and selenium also functions as an anti-
oxidant. Besides this, selenium exerts other immunomodulatory effects, such as the 
reduction of macrophage migration and a decreased T-cell proliferation (Duntas, 
2010). Selenium supplementation results in a decrease of TPO antibody levels in 
hypothyroid patients and improves the clinical signs of moderate-to-severe GO 
(Marcocci et al., 2011). 
Infections 
Differences in the occurrence of GD between seasons and geographic locations, 
together with serological evidence for recently encountered infections in Graves’ 
patients, support the association between specific infections and Graves’ disease 
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(Tanda et al., 2009, Hemminki et al., 2010). For instance Borrelia burgdorferi and 
especially Yersinia enterocolitica infections have been associated with Graves’ disease. 
The association between Graves’ disease and B. burgdorferi is merely based on shared 
genetic homologies between B. burgdorferi and thyroid antigens, but experimental 
evidence is limited to a case study (Benvenga et al., 2006). The association between Y. 
enterocolitica infections and Graves’ disease is supported by the increased frequency 
of Y. enterocolitica specific antibodies in Graves’ patients (Corapcioglu et al., 2002). 
Moreover, our laboratory recently provided evidence on cross-reactivity of Y. 
enterocolitica outer membrane porin with TSHR using strong stimulating TSHR mAb 
(Hargreaves et al., 2013). Molecular mimicry between certain Y. enterocolitica peptides 
and TSHR epitopes has been shown to play a role herein. More recently, Prof Pujol-
Borrell and colleagues suggested that continuous stimulation of thymocytes by low 
affinity antibacterial Abs such as Y. enterocolitica, that cross-react with TSHR 
eventually leading to high affinity TSAbs (Gimenez-Barcons et al., 2015). Despite these 
data, a prospective studies showed that Y. enterocolitica antibodies are independent 
from the occurrence of Graves’ disease and that no causal or pathogenic role exists for 
Y. enterocolitica in Graves’ disease (Effraimidis et al., 2011). 
Viral infections (especially hepatitis C infections) have also been associated with 
Graves’ disease. Increased frequencies of thyroid disorders or thyroid autoantibodies 
were found in patients infected with the hepatitis C virus, but conflicting data exist and 
the exact mechanism by which hepatitis C infections contribute to Graves’ disease 
development is still unknown (Menconi et al., 2011). 
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1.2.7 Autoimmune processes in Graves' disease 
 
Genetic, environmental and endogenous factors contribute to a break-down of self 
tolerance and the formation of autoantibodies against the TSHR. A complex interplay 
between dendritic cells, Treg, T cells, B cells and thyrocytes plays a role in the 
development of Graves’ disease (Mao et al., 2011). DCs have been found elevated in 
the thyroid and peripheral blood from Graves’ patients (Quadbeck et al., 2002). DCs 
within the thyroid initially display an immature phenotype and are predominantly 
found in close contact with thyroid follicular cells (Quadbeck et al., 2002). Following 
the uptake of thyroid antigens, the DCs mature and obtain a phenotype that is well-
equipped for antigen presentation. Thyroid antigen presentation to lymphocytes may 
take place in the thyroid and the draining lymph nodes which leads to selective 
activation of T cells that express a T cell receptor recognising thyroid antigens 
(Quadbeck et al., 2002). T cells that infiltrate the thyroid gland of Graves’ patients are 
predominantly CD4+ T cells and, together with B cells, they form germinal centre-like 
structures (Ben-Skowronek et al., 2009). In contrast to Hashimoto's thyroiditis, Graves’ 
disease is characterised by a mild lymphocytic infiltration and only little glandular 
destruction, indicating that destructive T cell mediated reactions are hardly involved in 
Graves’ disease (Ben-Skowronek et al., 2009). Therefore, although T cells in Graves’ 
patients recognise multiple epitopes of TSHR receptor and may target the TSHR 
directly (Ben-Skowronek et al., 2009), it is more likely that the DC activated T cells are 
involved in providing the essential co-stimulatory signals to B cells for the initiation of 
efficient autoantibody responses (i.e. B-cell maturation, antibody class switching) to 
thyroid antigens. 
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High expression of Fas and Fas ligand molecules on thyrocytes, DCs, and activated T 
cells may also contribute to Treg apoptosis. Tregs are potent suppressors of 
autoreactive T cell proliferation, antibody production by B cells and DC maturation 
(Nakamura et al., 2004). The decreased numbers of Treg in Graves’ patients may lead 
to high numbers of naive and autoreactive T cells in the thyroid gland (Mao et al., 
2011). The importance of Treg in the development of Graves’ disease is further 
illustrated by studies showing that Treg depletion by anti-CD25 exacerbates disease 
onset in animal model in BALB/c and C57BL/6 mice (Saitoh et al., 2007, Nagayama et 
al., 2007).  
Activated T cells, B cells and DC produce various inflammatory cytokines, which amplify 
the inflammatory process. The thyroidal inflammatory environment of Graves’ disease 
is dominated by Th2 related cytokines, including IL-4, IL-5, IL-10 and IL-13 (Gianoukakis 
et al., 2008). Thyrocytes play a central role in the maintenance and perpetuation of the 
autoimmune inflammatory process in the thyroid gland. This is reflected by their 
increased expression of adhesion molecules, such as ICAM-1, and production of 
cytokines/chemokines including IL-6, IL-8, CCL5, IL-16 and CXCL10 (Gianoukakis et al., 
2008).  
1.3 Graves’ orbitopathy (GO) 
 
Various terms have been used to describe the eye complications associated with 
thyroid disease including “Graves’ eye disease” or “Graves’ ophthalmopathy”, because 
it commonly presents in Graves’ disease, however it has also been referred to as 
“thyroid associated eye disease” or “thyroid associated ophthalmopathy” because it 
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may also present in other thyroid diseases such as Hashimoto’s thyroiditis (Bahn, 
2010).  The term “Graves’ orbitopathy” will be used in this thesis in accordance with 
the recommendation of European group on Graves’ orbitopathy (EUGOGO), a 
multidisciplinary consortium of clinicians who have special clinical and research 
interests in Graves’ orbitopathy.  The ,annual incidence of GO is approximately 16 per 
100,000  and 3 per 100,000 for women and men, respectively (Garrity and Bahn, 
2006). 
Graves’ orbitopathy is a common chronic extrathyroidal manifestation of Graves’ 
disease. GO is characterised by an increase in orbital adipose tissue and an 
accumulation of glycosaminoglycans (GAGs); in other cases there is also expansion of  
extraorbital muscles causing increased volumes of orbital tissue (Weetman, 2003). 
Proptosis, periorbital swelling and extraocular muscle dysfunction are clinical 
symptoms of GO that can be explained by volume expansion in the bony orbital 
structure. CT scans show enlargement of both the orbital connective tissue and the 
extraorbital muscles in GO cases, but others appear to have involvement of only one 
eye (Garrity and Bahn, 2006). Some Graves’ patients experience mild ocular discomfort 
and only 5% have severe orbitopathy; however almost all patients with Graves’ disease 
have subclinical signs of orbitopathy (Piantanida et al., 2013, Tanda et al., 2013). The 
severity of proptosis is governed more by the expansion of orbital adipose and 
connective tissue volume than to increased muscle volume (Peyster et al., 1986). 
Common GO symptoms include ocular discomfort from dry eyes, excessive 
lacrimation, diplopia and photophobia. Patients with overt Graves’ orbitopathy 
frequently present with upper eyelid retraction, proptosis and oedema and erythema 
of the periorbital tissues and conjunctivae (Bahn, 2010). In most cases, the onset of GO 
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is concomitant with the onset of hyperthyroidism, but orbital complication may 
present prior to, or following, the presentation of hyperthyroidism (Wiersinga and 
Bartalena, 2002).  
To find the connection between thyroid and orbital tissue in Graves’ orbitopathy, 
different theories have been proposed. A contribution of immunity was suggested a 
few years after the discovery of the autoimmune nature of Graves’ disease (Kriss et al., 
1964, Kriss et al., 1967).  The detection of antibodies to striated muscle cells in sera of 
Graves’ patients in the 1970s led to the proposal that muscle proteins express a 
candidate autoantigen for the disease; however antibodies to striated muscle cells 
have been found in many other conditions in which muscle cells are destroyed. These 
antibodies are now considered as a consequence, rather than cause, of inflammatory 
reaction in extra orbital muscles (Mizokami et al., 2004).  Studies into the expression of 
functional TSHR on fibroblasts led to the concept of  Abs to TSHR as the link between 
thyroidal and extrathyroidal tissue (Rotella et al., 1987). Meanwhile, evidence was 
emerging for a second potential autoantigen in Graves’ orbitopathy. Weightman et al. 
showed that IGF-1R as a potential target for the “ophthalmopathy inducing antibodies” 
(Weightman et al., 1993). A few years later, studies demonstrated heterogeneity of 
orbital fibroblast which were led to understand the special role of orbital fibroblast in 
GO, reviewed in (Smith et al., 2002). In the last decade, investigators have attempted 
to understand in more detail the pathogenesis of the disease, including attempts to 
develop animal models (Weetman, 2000, Garrity and Bahn, 2006, Bahn, 2010, Bahn, 
2013).  
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1.3.1 Clinical aspects of GO 
 
An increase in orbital connective and/or muscle tissue within the relatively fixed space 
constraint of the bony orbit leads to protrusion of the eye and subsequent ocular 
symptoms such as upper eyelid retraction, oedema, erythema of the periorbital tissues 
and conjunctivae, proptosis and strabismus (Bahn, 2010). The expansion of orbital 
connective and muscle tissue is the result of a pathophysiological process to which 
several cell types and mediators contribute. The pathophysiology of GO includes at 
least one of the process below; 
i) Inflammation: infiltration of inflammatory cells into retrobulbar tissue 
ii) Excessive extracellular matrix, mostly GAGs, deposition by orbital 
fibroblasts 
iii) Expansion of the adipose tissue within the connective tissue of orbits. 
Based on clinical features and imaging, GO patients can be classified as type I, which is 
associated with predominantly fat compartment enlargement, or type II, which is 
associated with predominantly extraorbital muscles enlargement (El-Kaissi et al., 2004, 
Kuriyan et al., 2013). In most GO patients however, a variable mixture of muscle 
enlargement (due to inflammation and deposition of extracellular matrix) and adipose 
expansion can be observed (Orgiazzi and Ludgate, 2010). There is evidence to show 
that the type of orbital pathology is age-dependant as expansion of adipose tissue has 
been more described in patients below 40 years of age and older individuals with GO 
predominantly show enlargement of extraorbital muscles (Eckstein et al., 2009). In 
case of extraorbital muscle enlargement, the most affected muscles are inferior rectus 
and medial rectus while the other muscles often not being involved (Kvetny et al., 
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2006). It is also clear from orbital region imaging in GO patients that only the belly part 
of the muscles is affected, and the tendons remain unchanged, which differentiates 
GO from extraocular myositis (Orgiazzi and Ludgate, 2010). The orbital muscle 
enlargement is not associated with direct damage to the muscle cells, but is caused by 
infiltration of orbital fibroblasts and massive accumulation of ECM components 
between the muscle fibres (Eckstein et al., 2009).  
The diagnosis of GO is usually made clinically. The signs and symptoms of active GO 
include lid retraction, proptosis, chemosis, diplopia, and corneal ulceration (Naik et al., 
2010). In the chronic fibrotic phase, lid retraction, proptosis and restrictive strabismus 
are the most common findings. Patients with GO pose few diagnostic difficulties when 
these characteristic ocular findings occur concomitantly with the thyroid disease. 
However, when unilateral or inconclusive ocular features occur in the absence of 
objective evidence of thyroid dysfunction, GO can be difficult to diagnose (Feldon, 
1990). Although the diagnosis of GO is based primarily on clinical signs and  laboratory 
test results of thyroid dysfunction and autoimmunity, imaging studies, such as 
computed tomography (CT), magnetic resonance imaging (MRI), ultrasonography (US) 
and colour Doppler imaging (CDI), can also be extremely important in both the 
diagnosis and clinical or surgical and drug treatment follow-up (Kirsch et al., 2010). 
Imaging studies can verify possible extraocular muscle involvement as part of the 
diagnostic workup and may help distinguish the early acute inflammatory stage from 
the fibrotic, inactive stage of the disease (Kirsch et al., 2009). Finally, imaging studies of 
patients prone to develop dysthyroid optic neuropathy make the timely diagnosis and 
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treatment of the condition possible, avoiding permanent visual loss (Goncalves et al., 
2012). More detail of imaging modalities will be discussed in Chapter 4. 
The typical clinical course of GO in patients not receiving any treatment for their 
orbital complaints was first described and depicted by Rundle in 1957 (Fig 1.8) (Rundle, 
1957). Generally, patients suffer an initial phase of progressive disease, the 'active' 
phase which is characterised by active inflammation, orbital infiltration of immune 
cells, ECM production and oedema. This may last several months and then the activity 
subsides and progresses to a phase of slow spontaneous recovery. This chronic 
'inactive' phase may take months to years and is associated with fibrotic changes in the 
orbital tissue. The fibrosis is largely responsible for residual disease features such as 
adipose tissue expansion, proptosis and chronic eye movement dysfunction and 
determines the 'severity' of the disease (Perros and Kendall-Taylor, 1998). Assessment 
of the natural course of non-treated patients with mild-to-moderate GO revealed that 
22% of patients showed definite improvement,  43% showed minor improvement 21% 
had no improvement and 14% got worse (Perros and Kendall-Taylor, 1998). Although 
GO is predominantly a mono-phasic disease; around 5% of GO patients experience a 
new flare up (Selva et al., 2004) 
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Fig 1.8 Rundle curve of activity and severity of GO.   
The graph for showing the activity (line) and severity (dotted line) of orbital 
manifestation in GO patients known as Rundle curve. Adapted from Rundle 1957 and 
Cawood et al. 2004, revised and re-drawn by applicant.   
 
 
1.3.2 Determinants in the development of GO 
 
Comparable to other autoimmune diseases, women have a higher risk to develop GO. 
Male patients do however tend to develop a more severe phenotype. Furthermore, 
the prevalence increases from Asian to Caucasian to African populations (Stan and 
Bahn, 2010). Although this difference may be genetically determined, culture and life-
style variations likely also contribute, as both endogenous (genetic factors, higher age, 
male sex) and exogenous (smoking, hypo/hyperthyroidism, iodine treatment) factors 
contribute to the development and the severity of GO (Stan and Bahn, 2010). The 
presence of such risk factors is important for the development of GO, as the presence 
of GD is necessary, but not required for the development of GO. 
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Genetics 
Genetic predisposition for GO development largely parallels that of Graves’ disease (as 
already discussed in section 1.3.7). The most important genes in which specific 
variations predispose for GO are those encoding CTLA4, PTPN22, CD40, TSHR (Eckstein 
et al., 2009, Stan and Bahn, 2010). In addition, HLA-DR3 is also associated with pre-
disposition for GO. Several studies using relatively small patient cohorts also revealed 
associations between GO and polymorphisms in genes encoding Toll –like receptor-9 
(Liao et al., 2010), CD86 (Liao et al., 2011) , transforming growth factor β (TGF-β), IL-4, 
IL-10 , IL-1α, IL-1 Ra , IL-12, IFN-γ, TNF-α (Khalilzadeh et al., 2009, Khalilzadeh et al., 
2010, Anvari et al., 2010), intercellular adhesion molecule (ICAM)-1 (Kretowski et al., 
2003), IL-23R (Huber et al., 2008) and IL-23 (Jia et al., 2015). The reported associations 
however vary considerably between different populations and the majority of these 
studies lack numbers and power to detect associations with the occurrence and 
severity of GO. Thus, although variations in genes, especially those encoding 
immunological factors, have been associated with GO, large and well-controlled 
studies are awaited before the exact contribution of specific gene variations can be 
determined. However, considering the clinical heterogeneity of GO, the relatively high 
number of genetic candidates possibly involved, and especially the low relative risks of 
these genetic factors, environmental factors are likely as important determinants as  
gene polymorphisms in GO development and its severity. 
Smoking 
Smoking is the best-known and strongest risk factor for the development and 
deterioration of GO. A dose-dependent relation exists between the number of pack 
years and the development of GO, with current smokers having a higher risk than past 
 64  
 
smokers (Hegedius et al., 2004, Wiersinga, 2013). Smoking also increases the likelihood 
of GO progression after radioiodine therapy and delays or decreases the 
responsiveness to treatment with steroids or orbital irradiation (Eckstein et al., 2003). 
The detrimental effect of smoking on GO is considered to be due to induction of 
hypoxia (Cawood et al., 2007, Regensburg et al., 2011). Hypoxia modulates cytokine 
networks and enhances HLA-DR expression on fibroblasts (Cawood et al., 2007). 
Moreover, in vitro models have shown that cigarette smoke extract enhances 
adipogenesis and glycosaminoglycan production by orbital fibroblasts (Regensburg et 
al., 2011, Chng et al., 2014). 
Mechanical factors 
Swelling of tissues within the inextensible bony orbital cavity leads to an increase in 
intra orbital pressure by 3-8 folds in severe cases (Riemann et al., 1999b, Berthout et 
al., 2010) of normal orbital pressure, 4mmHg (Riemann et al., 1999a). This has 
mechanical consequences which account for most of the signs and symptoms of GO 
(Orgiazzi and Ludgate, 2010). Orbital tissue expansion impairs the venous and 
lymphatic outflow of the orbit, which subsequently leads to chemosis, periorbital 
oedema and inflammation. The importance of mechanical factors in the course of GO 
is further illustrated by the rapid alleviation of clinical symptoms after decompressive 
surgery (Eckstein et al., 2009). Recent in vitro study provided an evidence on the 
molecular mechanism of mechanical factors on progression of GO (Li et al., 2014). It 
was already shown that tissue tension modulates stem cell to differentiate particularly 
into adipocytes (McBeath et al., 2004).  Dr Ezra and colleagues developed a novel in 
vitro 3D culture model as a platform for testing contractile effect on orbital fibroblasts. 
By using this 3D model environment, they also showed that orbital fibroblast from GO 
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patients, but not controls, can undergo adipogenesis without chemical stimulation (Li 
et al., 2014).     
Thyroid hormone levels 
Thyroid hormone level fluctuations, predominantly those associated with the 
occurrence of hypothyroidism after treatment of hyperthyroidism, is another 
important risk factor for the development of GO. Clearly, early and adequate 
stabilisation of thyroid hormone levels decreases the risk and severity of orbitopathy in 
GO patients (Kung et al., 1994). In addition, TSHR stimulating antibody levels correlate 
positively with the clinical activity and severity of GO and also decrease and stabilise 
upon adequate treatment of the hyperthyroidism (Ponto et al., 2011). This may be 
related to the stimulatory effects that TSHR stimulating antibodies exert on orbital 
fibroblasts. 
 
1.3.3 The pathophysiology of GO 
 
The pathophysiology of GO comprises various cells that interact with each other and as 
such contribute to orbital inflammation and tissue expansion, either via direct cell -cell 
contact or via secreted factors. The immune cells involved in GO include at least T cells, 
B cells, monocytes, macrophages and mast cells (Weetman et al., 1989, Kahaly et al., 
1994, Pappa et al., 2000, Eckstein et al., 2004, Boschi et al., 2005, Morshed et al., 
2012). Furthermore, orbital fibroblast is considered to fulfil a central role in GO (will be 
discussed in next section).  
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T cells 
Infiltration of T cells into thyroid tissue (Davies et al., 1991, Davies et al., 1992) and 
their reactivity to TSHR antigen (Dayan et al., 1991, Martin et al., 1997) has been well 
described. As already mentioned above, there is also strong evidence on infiltration of 
T cells into orbital tissue of GO patients (Weetman et al., 1989, Kahaly et al., 1994, 
Pappa et al., 2000, Eckstein et al., 2004, Boschi et al., 2005). Studying retrobulbar 
tissue sample from GO patients revealed the cytokine and chemokine profile   
including very late antigen (VLA)-4, lymphocyte function associated protein (LFA-1), 
ICAM-I, vascular cell adhesion molecule (VCAM-1), and CD44 that play a key role in 
tissue inflammation (Heufelder and Bahn, 1992, Heufelder and Bahn, 1993a, Heufelder 
and Bahn, 1993b, Heufelder, 2000).  
The TCR repertoire is restricted in early GO orbital tissue, suggesting orbit-antigen 
specific recruitment and expansion. T cells in orbital tissue from later stages of GO 
exhibit a much broader TCR repertoire (Heufelder et al., 1995a, Heufelder et al., 
1995b, Heufelder et al., 1996b, Heufelder et al., 1996a). The infiltrated T cells 
communicate with target cells such as orbital fibroblasts via the secretion of soluble 
mediators (cytokines) or via direct cell-cell contact. In early GO, T cells predominantly 
produce Th1 cytokines (e.g. IL-2, IFN-γ, TNF-α), which shifts towards the production of 
Th2 cytokines (e.g. IL-4, IL-5, IL-10) in late GO (Aniszewski et al., 2000, Hiromatsu et al., 
2000, Wakelkamp et al., 2003). A predominance of Th2 cytokines is linked to tissue 
remodelling and fibrosis (Barron and Wynn, 2011), which typically occurs during the 
later stages of GO.  
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T cells from GO patients specifically recognise autologous orbital fibroblasts (Grubeck-
Loebenstein et al., 1994, Otto et al., 1996), a process in which TCR interaction with 
certain TSHR epitopes expressed on orbital fibroblasts can be involved (Arnold et al., 
1994). In addition, cellular interaction between CD154 (also called CD40-Ligand) 
expressed by T cells and CD40 expressed by orbital fibroblasts also leads to production 
of various inflammatory mediators by orbital fibroblasts (Hwang et al., 2009, Zhao et 
al., 2010). This data suggests that orbital fibroblasts are prime targets of the T cell 
response in GO (Feldon et al., 2005, Feldon et al., 2006). Besides the effects of T cells 
on orbital fibroblasts, the CD40-CD154 co-stimulatory signal together with HLA class II - 
TCR interactions between B and T cells are essential to elicit a proper humoral immune 
response by B cells, which is evidently involved in Graves’ disease and GO (Lehmann et 
al., 2008).  
B cells 
Only few B cells are present in orbital tissue from GO patients (Pappa et al., 2000, 
Kahaly et al., 1994). Despite this, the concomitant occurrence of GO and Graves’ 
hyperthyroidism suggests that TSHR stimulating antibodies play an important role in 
the development of GO. This is further supported by the positive correlation of the 
clinical activity of GO with TSHR autoantibody levels and the elevated expression of 
TSHR in GO orbital tissues (Boschi et al., 2005, Khoo and Bahn, 2007). 
Mast cells 
The presence of mast cells in orbital tissues from GO patients has already been noticed 
for a long time (Wegelius et al., 1957). The importance of mast cells in GO is 
underscored by the improvement of tearing, itching and dryness of the eyes in a small 
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cohort of GO patients treated with the mast cell stabilising drugs montelukast and 
cetirizine  (Lauer et al., 2008). Despite this, the exact role that mast cells fulfil in the 
pathophysiology of GO is largely unknown. In GO orbital tissue mast cells are mostly 
located in close proximity to adipocytes or fibroblasts and show features of 
degranulation (Boschi et al., 2005). This suggests that they might regulate orbital 
fibroblast and adipocyte activity. So far, however, only a limited number of in vitro 
studies explored the effect of mast cells on orbital fibroblast behaviour. These studies 
revealed that mast cells stimulate the production of hyaluronan and prostaglandin E2 
(PGE2) by orbital fibroblasts (Guo et al., 2010, Smith and Parikh, 1999), processes in 
which mast cell-derived prostaglandin D2 (PGD2) (Guo et al., 2010), and CD40 - CD154 
ligation between orbital fibroblasts and mast cells are involved (Zhao et al., 2010) 
The reason of the increased mast cell numbers in GO orbital tissue is unknown, but 
stem cell factor (SCF, a growth factor for mast cells) is increased in serum from GD 
patients and may facilitate mast cell accumulation (Yamada et al., 1998). Serum levels 
of IgE can be increased in GD patients and correlations between elevated serum IgE 
levels and the presence of GO have been described (Molnar et al., 1996, Sato et al., 
1999). In addition to this, immunohistochemical studies revealed the presence of IgE in 
GO orbital tissue (Raikow et al., 1990). IgE binds FcRE on mast cells and upon 
interaction with antigen, FcRE cross-linking causes degranulation of mast cells 
(Theoharides et al., 2007). Some investigators found IgE molecules that specifically 
recognised TSHR in GO patients (Metcalfe et al., 2002) which may possibly be involved 
in regulating mast cell recruitment and degranulation in GO. Although these data 
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indicate an important role for mast cells in GO, further studies are required to 
delineate the exact contribution of mast cells to the pathophysiology of GO. 
 
1.3.4 Roles of orbital fibroblast 
 
Studies on patients who suffer from Graves’ orbitopathy have suggested that the 
extraorbital muscles remain intact early in the disease (Garrity and Bahn, 2006). But 
intense infiltration of T lymphocytes, mast cells and more abundant macrophages in 
connective/preadipocyte tissue indicate that they might be the primary target tissue 
(Bahn, 2003).  Orbital fibroblast presence in orbital connective tissue as well as 
surrounding the extraorbital muscles (Garrity and Bahn, 2006). It has been 
demonstrated that orbital fibroblast express TSH receptor at both the mRNA and 
protein level (Feliciello et al., 1993, Heufelder et al., 1993, Mengistu et al., 1994, 
Hiromatsu et al., 1996, Valyasevi et al., 1999) and more abundant so in GO patients 
than in controls (Bahn et al., 1998, Starkey et al., 2003, Kumar et al., 2004). 
Investigators also showed expression of IGF-1 receptor in orbital fibroblasts 
(Weightman et al., 1993). Moreover, orbital fibroblasts seem to be very special for the 
synthesis and regulation of hydrophilic glycosaminoglycan (Smith et al., 1991, Smith et 
al., 1995b) and show particularly strong responses to proinflammatory cytokines 
(Young et al., 1998).  
Importantly, orbital fibroblasts differ from other anatomic regions in that they have 
high proportions of CD90- (Thy-1 negative) cells, up to 35%, in comparison to other 
fibroblasts (Smith et al., 1995a, Koumas et al., 2002). CD90 is well-known as a classical 
T cell marker (Rege and Hagood, 2006). Heterogeneity of orbital fibroblasts in terms of 
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CD90, make them specific in response to different cytokine stimulators. CD90- orbital 
fibroblasts differentiate into mature adipocytes (adipogenesis) when treated with 
peroxisome proliferator-activated receptor γ (PPAR-γ) agonists (Smith et al., 2002) as 
well as with cAMP-enhancing agents (Valyasevi et al., 1999, Crisp et al., 2000).  
On the other hand, CD90+ orbital fibroblasts, which are more abundant in extraorbital 
muscles, are particularly capable of producing IL-6 and prostaglandin E2 (Koumas et al., 
2002). Those cells that express CD90 are not able to differentiate to adipocytes; 
although, they express PPAR-γ in common with CD90- fibroblasts (Smith et al., 2002). 
CD90+ orbital fibroblasts are able to differentiate to myofibroblasts instead of 
adipocytes (Koumas et al., 2003). The heterogeneic nature of orbital fibroblast is 
summarised in (Fig 1.9). Both subsets of orbital fibroblasts produce IL-6 after 
stimulation with IL-1 through the CD40 pathway. CD90+ orbital fibroblasts produce 
higher levels of prostanoids and display higher CD40 levels than CD90-, whereas CD90- 








Fig 1.9 Schematic view of heterogeneity of orbital fibroblast 
Orbital fibroblast expressing CD90 (Thy-1) differentiate to myofibroblasts after 
stimulation with TSAbs (left panel), while CD90- orbital fibroblasts undergo 
adipogenesis (right panel). 
   
 
1.3.5 Hyaluronan production from orbital fibroblasts  
 
Evidence shows that orbital fibroblasts are able to synthesise hydrophilic 
glycosaminoglycans (GAGs), particularly hyaluronan (Smith et al., 1991, Smith et al., 
1995b). Hyaluronan is an abundant non-sulphated GAG and is an important 
component of the extracellular matrix in orbital tissue. Production of hyaluronan from 
orbital fibroblast occurs regardless of CD90 expression. The accumulation of 
 72  
 
hyaluronan secreted from CD90- orbital fibroblastss within the adipose tissue may 
cause a greater expansion of the fat compartment. Likewise, in the perimysial 
connective tissues within the extraorbital muscles, hyaluronan secretion from CD90+ 
cells causes an increase in the size of muscle bundles. Hyaluronan accumulation in 
both tissues results in the enlargement of the orbital compartment and subsequently 
proptosis.  
Orbital fibroblasts derived from patients with GO, in contrast to orbital fibroblasts 
from healthy donors, respond to cytokines such as IL-1β and CD40 ligand (CD154) by 
increasing production of hyaluronan (Pritchard et al., 2003). Hyaluronan production is 
also inducible by GD-IgG in differentiated orbital fibroblast from patients who suffer 
GO (Smith and Hoa, 2004, van Zeijl et al., 2011), but not in non-differentiated orbital 
fibroblasts from GO patients (van Zeijl et al., 2010). Although, it has been proposed in 
some studies that hyaluronan secretion is mediated through the cAMP pathway (Imai 
et al., 1994, Zhang et al., 2009), evidence from a more recent study indicates that 
TSHR-mediated cAMP signalling is not a major pathway for hyaluronan synthesis (van 
Zeijl et al., 2011). In addition to TSHR-mediated signalling pathway, different groups 
showed that an IGF-1R blocking mAb can inhibit hyaluronan secretion from orbital 
fibroblast derived from GO patients (Smith and Hoa, 2004, Kumar et al., 2012). 
1.3.6 Adipogenesis 
 
Increased levels of adipogenic markers such as leptin, adiponectin and PPAR-y found in 
GO orbital tissue, which indicates the accumulation of adipose tissue in GO (Kumar et 
al., 2004, Kumar et al., 2005). Orbital fibroblasts have the capacity to differentiate into 
adipocytes and increase adipogenesis of orbital fibroblasts is a characteristic of GO. 
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Orbital fibroblasts that undergo adipogenic differentiation accumulate lipid vacuoles, 
and increase their TSHR expression and cytokine production (Valyasevi et al., 1999, 
Koumas et al., 2002). Especially Thy-1- orbital fibroblasts differentiate in mature 
adipocytes when cultured under serum-free conditions in the presence of  
dexamethasone and isobutylmethylxanthine (IBMX) (Valyasevi et al., 1999, Koumas et 
al., 2002). Possibly, differences in the size of the Thy-1- orbital fibroblast pool may be 
related to differences in adipose tissue expansion between GO patients (Khoo and 
Bahn, 2007).  
Various factors stimulate adipogenic differentiation of orbital fibroblasts including IL-
1β (Cawood et al., 2007), IL-6 (Jyonouchi et al., 2001), PGD2 (Guo et al., 2010) , TSH 
(Kumar et al., 2011) and TSHR stimulating antibodies (Kumar et al., 2010). Also the 
physical interaction between orbital fibroblasts and autologous T cells (Feldon et al., 
2006) and cigarette smoke constituents (Cawood et al., 2007, Cawood et al., 2006) 
promote adipogenesis by orbital fibroblasts. Remarkably, Th1 cytokines such as TNF-α 
and IFNγ inhibit adipogenesis by orbital fibroblasts. (Valyasevi et al., 2001, Cawood et 
al., 2006). This fits in their role in early inflammation rather than in the later tissue 
expanding processes, although the Th2 related factor TGF-β also inhibits the 
adipogenesis by orbital fibroblasts (Valyasevi et al., 2001). 
PPAR-γ is a nuclear transcription factor that is involved in cellular metabolism. 
Activation of PPAR-γ with thiazolidinediones such as pioglitazone or rosiglitazone is 
used as a treatment for type 2 diabetes as it increases lipid metabolism (Lehmann et 
al., 2008). GO patients who were treated with these drugs for type 2 diabetes 
sometimes encounter orbital deterioration due to PPAR-γ activation (Valyasevi et al., 
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2002, Smith et al., 2002, Starkey et al., 2003). Besides their stimulating effect on 
adipogenesis, PPAR-γ agonists may also inhibit orbital inflammation and remodelling 
(Guo et al., 2011). Therefore, PPAR-y may be an important regulatory factor in GO and 
a well balanced PPAR-y activity may be beneficial in GO (Lehmann et al., 2008). 
1.3.7 Insulin like growth factor 1 receptor (IGF-1R) as an 
autoantigen in GO 
 
Insulin like growth factor receptor type 1 (IGF-1R) consists of 1368 amino acids and 
belongs to a family of relatively large transmembrane tyrosine kinase receptors. IGF-1R 
and insulin receptor (IR) have considerable similarities in their structure.  IGF-1R is 
synthesised from a single mRNA and the translated protein is cleaved at residues 708 
and 710 by furin enzyme. Two polypeptide subunits, α and β, are generated as a result 
of this cleavage.  The α-subunit includes the extracellular domain and the β-subunit 
consists of a transmembrane domain, a tyrosine kinase domain and the C terminus. 
The α-subunit is subdivided into six protein domains as shown in (Fig 1.10 A). IGF-1Rα 
and IGF-1Rβ are linked together by disulfide bonds (Fig 1.10 B). The structure of the 
first three domains was revealed in 2001 (Ward et al., 2001) and subsequently, in 
2009, the crystal structure of ECD has been resolved (Whitten et al., 2009). 
The pathogenic role of IGF-1R in GO has been proposed after the following 
observations. A case study in 1986 demonstrated that IGF-1 expression was 
significantly increased in a retrobulbar  biopsy specimen of GO patients in comparison 
to controls and also other tissues from the same GO patients (Hansson et al., 1986). 
They also reported the specificity of the increase in IGF-1, but not of other closely 
related family members such as insulin and IGF-II (Hansson, 1989). The same results 
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were also shown in thyroid tissue, but not specifically in Graves’ disease (Minuto et al., 
1989).  In 1986, Kohn and colleagues showed that antibodies from Graves’ patients are 
able to immunoprecipitate the tyrosine kinase domain of IGF-1R (Kohn et al., 1986). 
The results from these studies, in addition to evidence that showed an effect of IgG 
from GO patients in orbital fibroblast (Rotella et al., 1986) and extraorbital muscles 





               
Fig 1.10 Schematic view of IGF-1R 
(A) Homodimeric structure of IGF-1Rα and IGF-1Rβ subunits (including tyrosine 
kinase) (B) Six domains of IGF-1R α subunit (numbered) and IGF-1R cleavage 
site to yield IGF-1R α-subunit. 
 
 
The key to early in vitro findings on association between IGF-1R and TSHR was the 
realisation that rat clonal thyroid epithelial cell line, FRTL-5, respond higher to TSH 
 76  
 
stimulation in the presence of IGF-1 (Tramontano et al., 1986, Tramontano et al., 1987, 
Tramontano et al., 1988a, Tramontano et al., 1988b). Briefly, Ingbar’s group reported 
that stimulation by not only TSH but also IGF-1 is able to increase cell proliferation and 
DNA synthesis in FRTL-5 cells (Tramontano et al., 1986, Tramontano et al., 1987). 
However, the results of their studies indicated that stimulation by IGF-1 does not 
activate cAMP signalling pathway (Tramontano et al., 1988a, Tramontano et al., 
1988b). 
In 1993,  for the first time it was shown that immunoglobulin from  Graves’ patients, 
but not controls, can displace radiolabeled IGF-1 from orbital fibroblasts (Weightman 
et al., 1993). A decade later, Professor Smith’s laboratory demonstrated that GD-IgG 
from Graves’ patients can induce IL-16 and RANTES (Pritchard et al., 2003) and 
hyaluronan (Smith and Hoa, 2004) in orbital fibroblast. More importantly, this 
induction of cytokines and hyaluronan can be inhibited by a blocking IGF-1R mAb (1H7 
mAb). In addition, the same group showed that TSHR and IGF-1R were co-localised on 
orbital fibroblast plasma membranes, forming a functional complex by both receptors 
(Tsui et al., 2008). More recently, functional studies in orbital fibroblasts have shown 
the close inter-relationship at the functional level between TSHR and IGF-1R (van Zeijl 
et al., 2010, van Zeijl et al., 2011). M22, the powerful stimulatory TSHR mAb, is able to 
enhance phosphorylation of Akt, but this is inhibited by the 1H7 mAb (Kumar et al., 
2010, Kumar et al., 2012).  
In other intriguing studies, IGF-1R expression has been shown in T cells and B cells 
derived from the peripheral blood of Graves’ disease patients, whereas expression is 
absent in healthy controls (Douglas et al., 2007).  In the T cell population, the up-
regulation of IGF-1R was specifically present in the CD45RO subpopulation of memory 
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T cells. It was postulated that this may be related to inhibition of Fas-mediated 
apoptosis of T cells. On the contrary, up-regulation of IGF-1 expression by B cells in 
peripheral blood, orbit, and bone marrow is probably related to the increased 
expansion of B cells in Graves’ patients (Douglas et al., 2008). IGF-1R expression by T 
and B cells is well documented, showing that there is no correlation of IGF-1R 
expression by lymphocytes and genetic determinants by twin studies (Douglas et al., 
2009). The expression of IGF-1R on T and B cells will likely aggravate immune reactions 
directed against orbital fibroblast. The role of IGF-1R Abs in the pathogenesis of GO 
was reviewed in (Smith et al., 2012, Smith, 2013, Wang and Smith, 2014, Shan and 
Douglas, 2014) and will be discussed in more detail in Chapter 5 of this thesis. 
 
1.3.8 Recent findings on the role of fibrocytes in GO   
 
Although, much progress has been made over the past few years in understanding the 
dysregulation of the immune response in autoimmunity and the role of the target 
autoantigens (Kuchroo et al., 2012), the relationship between the thyroid and the 
extrathyroidal manifestations in GO is still not clear. Recent studies suggested the 
potential role for fibrocytes in  GO  (Smith, 2010b, Douglas et al., 2010, Gillespie et al., 
2012). It is already known that fibrocytes are monocyte lineage derived from the bone 
marrow that have been implicated in many aspects of wound healing, tissue 
remodelling, and immune function (Chesney et al., 1997, Chesney et al., 1998). It is 
shown that fibrocytes express CXCR4, which is the receptor for CXCL12, in addition to 
expressing collagen-I and CD34 (Barth and Westhoff, 2007, Quan et al., 2004). The 
 78  
 
CD34+ population of fibrocytes are able to differentiate into adipocytes when treated 
with PPAR-γ and into myofibroblasts in response to TGF-β (Hong et al., 2007).  
  Fibrocytes are extremely rare (less than 1% of mononuclear cells) in the circulation of 
healthy individuals. However, in certain condition such as extensive tissue injury the 
abundance of fibrocytes increases dramatically (Moeller et al., 2009). Similarly, the 
laboratory of Prof Smith showed that CD34+ fibrocytes are far more frequent 
component of PBMCs in Graves’ patients compared to healthy controls (Douglas et al., 
2010, Smith, 2015). In addition, numerous fibrocytes accumulate in the orbital 
connective tissue of patients with GO, an observation not seen in controls. 
Interestingly, they showed that infiltrated fibrocytes into orbital tissue of GO patients 
express high levels of both TSHR and IGF-1R (Douglas et al., 2010, Fernando et al., 
2012). The level of surface expression of the TSHR seem to be equivalent on fibrocytes 
and thyroid epithelial cells and are substantially higher than those found on orbital 
fibroblasts (Smith, 2015). In addition, they were able to confirm functionality of 
expressing TSHR in fibrocytes by releasing proinflammatory cytokines in response to 
TSH or M22 (Gillespie et al., 2012). Besides TSHR, other thyroid-specific protein, such 
as Tg (Fernando et al., 2012) NIS and TPO (Fernando et al., 2014) are also expressed by 
cultured fibrocytes.  
These data confirm that fibrocytes resemble orbital fibroblast function in Graves’ 
patients (Koumas et al., 2002, Smith et al., 2002, Smith, 2010b, Douglas et al., 2010). 
Prof Smith and his colleges suggested a potential mechanism for involvement of 
fibrocytes in the pathogenesis of GO which is infiltration of fibrocytes with high level 
expression of TSHR and IGF-1R into orbital tissue and inducing cytokine secretion in 
response to TSHR Abs.   . Subsequently, inflammation and fibrosis process occurs. The 
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suggested mechanism clearly needs improvement as it does not cover how fibrocytes 
infiltrate into orbital tissue in the first place. Moreover, although the first paper in the 
potential role of fibrocytes on GO by this laboratory was published in 2010 (Douglas et 
al., 2010) and followed by number  of publications (Fernando et al., 2012, Gillespie et 
al., 2012, Chen et al., 2014, Fernando et al., 2014, Smith, 2015), it is remained to be 
verified by an independent group.  
1.3.9 Proposed model for pathogenesis of GO 
 
Orbital fibroblasts begin to differentiate into adipocytes when activated by TSHR Abs, 
which results in increased expression of TSHR (Sorisky et al., 1996, Smith et al., 2002). 
Similarly, stimulation of IGF-1R results in the secretion of hyaluronan as well as 
chemokines including IL-16 and RANTES. These chemokines enhance the recruitment 
of activated T cells and other mononuclear immune cells into the orbit (Fig 1.11). 
Consequently, stimulation of orbital fibroblasts with cytokines, including interferon-γ 
and TNF, leads to increased hyaluronan secretion (Valyasevi et al., 1999, Starkey et al., 
2003). Accumulation of hyaluronan between intact extraocular muscle fibres and 
within the orbital adipose tissues, results in enlargement of the orbital tissues.  The 
expression of CD40 in orbital fibroblasts, and CD40 ligand (CD40L or CD154) in T cells, 
allows the direct interaction between orbital fibroblasts and T cells. Adipocytes and 
fibroblasts produce IL-6, which increases B cell maturation and increases the 
production of local TSHR Abs by plasma cells within the orbit (Weetman, 2000, 
Weetman, 2001, Weetman, 2003, Garrity and Bahn, 2006, Bahn, 2010, Iyer and Bahn, 
2012, Smith et al., 2012, Smith, 2013).  
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Fig 1.11 Proposed model for pathogenesis of GO 
Abs to TSHR results in activation of orbital fibroblast to differentiate to adipocytes. 
Stimulation of the IGF-1R results in the secretion of IL-16 and RANTES which 
enhances recruitment of activated T cells and other mononuclear immune cells 
into the orbit. Figure is drawn by applicant.  
 
1.3.10 Treatments for Graves’ disease and orbital 
conditions 
 
The ideal treatment for Graves’ disease should restore normal thyroid function, 
prevent hypothyroidism and any recurrence of hyperthyroidism (Bartalena, 2013). 
Although various pharmacological therapies that aim to target the disease process are 
currently under investigation (Bahn, 2012b), management of Graves’ disease still relies 
on three classical therapeutic methods which have been used for several decades 
(Hegedus, 2009): pharmacological treatment with antithyroid drugs, 131I-radiotherapy 
and thyroidectomy (Bahn et al., 2011, Bartalena, 2013). 
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The approved antithyroid drugs are usually derived from thionamide components 
including methimazole, carbimazole and propylthiouracil. The main mode of action of 
this set of drugs is to decrease excess thyroid hormone synthesis by inhibiting TPO, 
thereby reducing the production of T3 and T4. In addition, these drugs can have 
immunosuppressive effects directly or through normalisation of thyroid status 
(Weetman, 1992, Cooper, 2005). Antithyroid drug therapy is suggested to be the first 
line of treatment for Graves’ patients in European countries. The major drawback of 
antithyroid drug therapy is the high rate of recurrence, between 30% and 70% (Vitti et 
al., 1997, Allahabadia et al., 2000).  
The 131I therapy causes gradual necrosis of thyroid cells and can be effectively used for 
treatment of Graves’ disease (Ross, 2011). The loss of functional thyroid tissue 
eventually results in hypothyroidism in most patients who receive 131I-radiotherapy 
(Vaidya et al., 2008). There are two main concerns in 131I-radiotherapy, apart from 
lifelong hypothyroidism: 1) radiation exposure and 2) possible progression or de novo 
occurrence of GO. Different studies show progression in pre-existing mild GO or even 
de novo occurrence as a result of 131I-radiotherapy (Tallstedt et al., 1992, Bartalena et 
al., 1998, Traisk et al., 2009). The 131I-radiotherapy can cause or progress orbitopathy 
in up to 20% of patients (Acharya et al., 2008), particularly in smokers (Traisk et al., 
2009).  
Surgery is a valid and definitive treatment for Graves’ disease (Annerbo et al., 2012, Al-
Adhami et al., 2012, Genovese et al., 2013) but is used less often than 131I-
radiotherapy. Patient preferences have a major role in the choice of surgery or 131I-
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radiotherapy. Thyroidectomy is clearly indicated in patients with relapse of 
hyperthyroidism after antithyroid drug treatment and in those with large goitres.  
Similar to management of Graves’ disease, the treatment for the orbital condition has 
also not changed for several decades (Stiebel-Kalish et al., 2009). Basically, the 
treatment of GO is limited to three options including local, oral or intravenous 
glucocorticoids, orbital radiotherapy and orbital decompression surgery. The available 
treatment options for GO are dependent on the severity of disease, based on the 
consensus statement of EUGOGO (Bartalena et al., 2008).   
Glucocorticoid therapy, in comparison with other treatments, shows a favourable 
response in about 33–63% of patients, based on the open trials or randomised studies 
(Marcocci et al., 2001, Kahaly et al., 2005). Local (retrobulbar or subconjuctival) 
application of glucocorticoids therapy is less effective than oral form (Marcocci et al., 
1987). The evidence also shows that i.v. glucocorticoids therapy is more effective than 
oral administration (Marcocci et al., 2001, Perros and Dickinson, 2005, Kahaly et al., 
2005, Ng et al., 2005). However, i.v. glucocorticoids increase the risk of acute liver 
damage in association with very high cumulative doses (Weissel and Hauff, 2000, 
Marino et al., 2004). Glucocorticoids are the first line of treatment in patients with 
moderate to severe GO with active condition (Bartalena et al., 2008).    
Orbital radiotherapy is shown to be effective in about 60% of GO patients by open 
trials (Prummel et al., 1989). It is also demonstrated that a combination of orbital 
radiotherapy with glucocorticoids (either orally or locally) is more effective than either 
treatment alone (Bartalena et al., 1983, Marcocci et al., 1991). Although, the main 
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concern about orbital radiotherapy is radiation exposure, studies on long-term safety 
are reassuring (Marquez et al., 2001, Marcocci et al., 2003, Wakelkamp et al., 2004). 
Since anti-inflammatory treatment and orbital radiotherapy of GO rarely results in a 
complete resolution of symptoms, surgical treatment is very important for patients 
well-being. So the aims of surgical treatment in Graves' orbitopathy are improvement 
of function and appearance. Rehabilitative surgery includes orbital decompression, 
squint correction, lid lengthening and blepharoplasty (Eckstein et al., 2012). Surgery is 
usually performed in the inactive stage of disease with a minimum of 6 months of 
stable inactive orbitopathy (Rosen and Ben Simon, 2010). Additionally, sight-
threatening GO is an indication for emergency surgery. Sight-threatening GO refers to 
either compressive optic neuropathy, which has to be treated immediately if there is 
no improvement after 2 weeks of i.v. steroid application (Bartalena et al., 2008).  
A novel approach for optimal treatment of Graves’ disease and its extrathyroidal 
complications has focused on both systemic dampening of the immune response 
dysregulation and antagonising excessive TSHR signalling (Bahn, 2012a). The studies on 
both the strategies are carried out via targeted biological agents including mAbs and 
small molecular ligands (SMLs). The rationale behind the targeted biological therapy is 
that antibody to TSHR is the key player in pathogenesis of Graves’ disease (Iyer and 
Bahn, 2012). So, the disease can be managed by blocking or reducing the generation of 
pathogenic antibodies (Bahn, 2012b).  
Studies showing a beneficial effect of B-cell depletion in other autoimmune diseases 
has led to the suggestion that B lymphocyte depletion may also be effective in patients 
with Graves’ disease (El Fassi et al., 2006, Salvi et al., 2006). Rituximab (RTX), a 
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humanised chimeric mAb that targets CD20 on B cells, is one of the well-studied 
biological agents in Graves’ disease (El Fassi et al., 2007, Salvi et al., 2007, Heemstra et 
al., 2008, El Fassi et al., 2009, Salvi et al., 2013). RTX inhibits the activation and 
differentiation of B lymphocytes by lysing these cells. More importantly, RTX also 
inhibits the ability of B cells to act as antigen-presenting cells and impairs T cell 
activation, thereby decreasing levels of both T and B cell derived cytokines. Despite the 
significant effect in the activity and severity of GO (Salvi et al., 2013), the high rate of 
side effects and poor cost-effectiveness (Hegedus et al., 2011) prohibit RTX as a 
standard therapeutic tool in GO. More recently, two randomised control trials of the 
RTX effects on GO patients have been performed, one in the USA and one in Europe. 
Although, two trials were designed comparable in terms of number and condition of 
recruited patients and RTX dosage, surprisingly the reported results completely 
contradict each other. The laboratory of Prof Bahn reported no additional benefit from 
RTX over placebo for their GO patients (Stan et al., 2015). On the other hand, Dr Salvi 
and his colleagues found RTX an effective disease-modifying treatment for moderate 
to severe GO patients (Salvi et al., 2015). The latter group mentioned slight differences 
in the baseline parameters of recruited patients may account for the discrepant 
outcome of the two studies (Salvi et al., 2015). 
Furthermore, the idea of neutralising inflammation in autoimmune diseases either by 
blocking proinflammatory cytokines (Cho and Feldman, 2015) including anti-TNF 
agents (Feldmann, 2002), anti-IL-1 receptor agents (Dinarello, 2000),  anti-IL-6 receptor 
agents  (Nishimoto and Kishimoto, 2006) and anti-IL-12/ IL-23 (Teng et al., 2015) or 
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cellular immunity interaction (Keymeulen et al., 2005) has emerged a potential therapy 
in GO (Tan et al., 1996, Durrani et al., 2005, Paridaens et al., 2005).    
As mentioned earlier, another potential therapy, apart from systemic dampening of 
the immune response, is antagonising excessive TSHR signalling. Although, the strong 
blocking TSHR mAbs (e.g. 5C9 mAb and 1-70 mAb) are available to compete with TSAbs 
for receptor binding (Sanders et al., 2008, Sanders et al., 2011), limitations to mAbs 
therapy include the risk of toxicity and unexpected immune reactions that have 
prevented their application in GO patients. Recently, the generation of small molecule 
ligands (SMLs) that antagonise TSHR signalling by two different laboratories tackled 
the limitations of mAb therapy (Neumann et al., 2011, van Zeijl et al., 2012). These 
high affinity and high potency molecules act as allosteric modulators of TSHR signalling 
without competing for extracellular ligand-binding sites (van Koppen et al., 2012). The 
in vitro studies in primary thyroid follicular cells and GO orbital fibroblasts confirmed 
the inhibition of TSHR signalling (van Zeijl et al., 2012, Turcu et al., 2013). In addition, 
an in vivo study in an animal model showed reduction in thyroid hormone by applying 
TSHR antagonist SMLs (Neumann et al., 2014), despite the criticisms of the animal 
model (Davies et al., 2014). Moreover, an in vitro study by another laboratory into PI3K 
inhibition in orbital fibroblast showed reduction of hyaluronan accumulation and 
adipogenesis (Zhang et al., 2014). 
1.4 Experimental animal models 
 
There are two types of animal models of autoimmunity used for in vivo studies on 
disease, induced models and spontaneous models. For example, non-obese diabetes 
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(NOD) mouse model, which develop type 1 diabetes, is very well known for 
spontaneous model. NOD mice that survive the onset of type 1 diabetes develop 
autoimmune thyroid disease characterised by thyroiditis later in life. Without 
immunisation, thyroiditis develops spontaneously in Biobreeding rats (Allen et al., 
1986), NOD mice (Bernard et al., 1992) and NOD.H2h4 mice, only if given iodine in 
their drinking water. Unlike the occurrence of thyroiditis in nonhuman species, neither 
TSHR antibodies nor Graves’ hyperthyroidism develop spontaneously in animals. 
Recent investigations into whether species more closely related to humans, i.e. the 
great apes, develop Graves’ like syndromes have also proved negative (McLachlan et 
al., 2011, Aliesky et al., 2013). However, in last decade, a number of induced 
experimental models have been developed for Graves’ disease, details of which are 
outlined below.   
1.4.1 Graves’ disease 
 
As already explained, like other autoimmune diseases, one of the main approaches to 
define the pathogenesis of Graves’ disease and Graves’ orbitopathy is the 
development of animal models. In spite of difficulties to develop an animal model for 
Graves’ disease, and specifically for extrathyroidal conditions, four successful animal 
models developed so far which will be outlined below. A number of reviews on animal 
models for Graves’ disease have been published in the last few years (Ludgate, 2000, 
McLachlan et al., 2005, Nagayama, 2005, Dağdelen et al., 2009, Wiesweg et al., 2013).  
Although there were many attempts to develop animal models for Graves’ disease 
(Volpe et al., 1993, Soliman et al., 1995), there were no significant successes in terms 
of development of reproducible animals model with high level of TSAbs until 1996 
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(Shimojo et al., 1996). After cloning of the human TSHR (Libert et al., 1989, Misrahi et 
al., 1990, Frazier et al., 1990), immunisation of mice with recombinant TSHR led to 
induction of TSHR antibody activity in different studies, but none demonstrated 
hyperthyroidism activity because of a lack of stimulating Abs  (Marion et al., 1994, 
Wagle et al., 1994, Carayanniotis et al., 1995, Costagliola et al., 1995, Wang et al., 
1998). Only one reported study, using a soluble, secreted ECD of human TSHR in 
female BALB/c mice, reported induction of stimulating antibodies and hyperthyroidism 
(Kaithamana et al., 1999), but this has not been reproduced in any other laboratory, 
including that of Professor Banga (Wang et al., 1998). 
The first successful animal model for Graves’ disease is known as Shimojo model 
(Shimojo et al., 1996). The rationale behind this model was based on the study in 1983 
that showed induction of MHC II-expressing thyrocytes led to autoimmunity (Bottazzo 
et al., 1983). Thus, Shimojo and colleagues used transfected fibroblast cell lines (L-
cells) that expressing both human TSHR and MHC class II antigens for injection to 
animals (Shimojo et al., 1996). The model relied on multiple injections of AKR/N mice 
because these mice have the same class I and a homologous class II to transfected 
fibroblasts. Disease incidence in this model was 10-15%. The following studies by same 
laboratory revealed more details of the model (Yamaguchi et al., 1997, Kikuoka et al., 
1998). The Shimojo model was reproduced by other groups with some improvement 
when adjuvant is incorporated in the injection (Kita et al., 1999, McLachlan and 
Rapoport, 2004). Due to limitations of the model including nonspecific immune 
reactivity, low rate of disease incidence and lack of TSAbs (Rao et al., 2003, McLachlan 
and Rapoport, 2004), further studies on the model have not been reported.  
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Because of difficulties associated with immunisation of cells, most attention has been 
paid to genetic immunisation. Outbred mice were injected with plasmid vector coding 
the human TSHR and this led to autoimmune hyperthyroidism, but the disease 
incidence continued to be very low at around 15% (Costagliola et al., 1998), and not 
very different from that seen in the Shimojo model. Furthermore, success seemed to 
be restricted to outbred mice and inbred strains were resistant (Costagliola et al., 
2000). Nevertheless, this model has led to the generation of monoclonal stimulating 
Abs against TSHR (Sanders et al., 2002, Costagliola et al., 2004). Despite of the 
simplicity of this model, it continues to be difficult to reproduce (Pichurin et al., 2001, 
Pichurin et al., 2002, Rao et al., 2003).  
Nevertheless, the model was improved by immunisation of transgenic HLA-DR3 mice, 
lacking endogenous MHC class II, in conjunction with cytokines (IL-4 or GM-CSF) 
resulting in an increase in disease incidence to 30%. The increased in disease incidence 
was accompanied by focal lymphocytic infiltrates in the thyroid glands of some 
immune mice (Flynn et al., 2004).  
By changing in delivery method of TSHR gene from plasmid to recombinant adenovirus 
in inbred mice (BALB/c), a significant improvement was achieved in terms of disease 
incidence (55%) and presence of TSAbs (Nagayama et al., 2002). Modification of the 
immunogen to a cDNA representing the TSHR A-subunit instead of full length TSHR 
caused an increase in the hyperthyroidism to 70% to 80%, as well as high levels of 
TSAbs (Chen et al., 2003). This method was also reproduced by other groups (Gilbert et 
al., 2006, Land et al., 2006, Mizutori et al., 2006, Wu et al., 2011, Ye et al., 2012). The 
major drawback of viral  immunisation is that the virus has immunogenic elements 
that cause the immune response to be directed to nonspecific viral proteins (Veron et 
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al., 2012). Furthermore, the TSHR antibody declines rapidly after the last 
immunisation, hence long-term immunity is difficult to maintain in this model 
(McLachlan et al., 2012).   
 The next step toward development of an animal model for Graves’ disease is based on 
the immunisation with plasmid vector containing TSHR A-subunit cDNA in conjunction 
with delivery by electroporation (Kaneda et al., 2007). Using electroporation to 
transfer TSHR A-subunit gene into the leg muscles of BALB/c mice caused induction of 
hyperthyroidism in 70-80% of the immune mice. Most importantly, long-term 
immunity to the receptor was maintained for at least 8 months after the last injection 
(Kaneda et al., 2007).  Therefore, this model is useful also to study pathology of 
Graves’ disease and more importantly GO. This model has been recently reproduced in 
our laboratory and the persistence of long term immunity to the TSHR confirmed (Zhao 
et al., 2011). 
More recently, a new model has been developed based upon mouse TSHR 
immunisations (rather than human TSHR immunisations in all the models described 
above) and hence represents a true, bonafide model for autoimmune Graves’ disease.  
The model involves the transfer of TSHR autoimmunity from TSHR knockout (KO) mice 
to nude mice (Nakahara et al., 2012). Briefly, wild type mice are tolerant to mouse 
TSHR, which is impossible to ‘break’ by immunisation but, TSHR knockout mice do not 
develop tolerance to the receptor and hence amenable to induction of an immune 
response to the mouse receptor.  However, no hyperthyroidism is expected because 
these mice lack the endogenous TSHR. By adoptive transfer of splenocytes from TSHR 
KO mice into nude mice, 50% of recipient mice were found to have TSHR Abs which 
persisted for 24 weeks. However, the majority of Abs were blocking antibodies and, by 
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week 24, those in whom stimulating antibodies had previously been detected had a 
dominant blocking antibody response. Nevertheless, two novel findings were reported 
in this model, long lasting immunity and a small degree of orbital inflammation was 
reported. The model is very recent and awaits confirmation by other groups, but the 
fact that orbital changes were reported makes it exciting model.  
1.4.2 Graves’ orbitopathy  
 
In attempts to develop GO in experimental animal model, first successful study 
involved the transfer of TSHR-primed splenic T cells from mice immunised with TSHR 
fusion proteins to naive BALB/c mice (Many et al., 1999). The orbital tissue showed 
dissociation of orbital muscle bundles by oedema, accompanied by accumulation of 
glycosaminoglycans and adipose tissue together with an inflammatory infiltrate of T 
and B cells and macrophages, similar to GO in man (Many et al., 1999). In a separate 
study by the same group, but using genetic immunisation to induce hyperthyroidism in 
outbred mice, scattered mast cells were also reported in the orbital muscle tissues 
(Costagliola et al., 2000). Importantly, the reported findings have been difficult to 
substantiate (Baker et al., 2005). In another study, accumulation of mast cells in orbital 
tissue was also reported after genetic immunisation of outbred mice with TSHR cDNA 
and G2s cDNA (Yamada et al., 2002). More recently, improvements in the plasmid 
delivery with in vivo muscle electroporation (Kaneda et al., 2007) has resulted in 
increasing transfection efficiency and induction of a strong antibody response to TSHR. 
Importantly, this model generates long lasting immunity (Kaneda et al., 2007, Zhao et 
al., 2011), which may be critical for the development of tissue pathology. In the earlier 
study using plasmid immunisation with electroporation technique, fibrosis in orbital 
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tissue were reported by histology  (Zhao et al., 2011). More recently, induction of mild 
orbital inflammation was also reported in the new experimental model which was 
based on the transferring TSHR autoimmunity from knockout (KO) mice to nude mice 
(Nakahara et al., 2012). A common feature in two recent animal models of Graves’ 
disease was that both the models show long-term persistence of induced immunity to 
the TSHR. Thus this may be a critical feature for development of complications of 
Graves’ disease, such as orbital pathology (Zhao et al, 2011; Nakahara et al, 2012). 
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1.5 Aims of Project 
 
Scientific advancement for understanding the pathophysiology of GO has been 
hampered by the lack of an animal model. The objective of my project was to tackle 
this issue. Our laboratory has previously shown that genetic immunisation of female 
BALB/c mice with hTSHR A-subunit plasmid in combination with in vivo muscle 
electroporation leads to development of Graves’ disease. However, this animal model 
has not led to extensive remodelling in orbital tissue. Thus, we hypothesised that the 
modification of the genetic delivery of hTSHR A-subunit plasmid immunisation scheme 
will lead to orbital manifestation. We aim to develop an animal model that 
recapitulate orbital pathology of orbital muscle inflammation and adipogenesis to that 
present in GO patients.  
Thus, characterisation of orbital pathology in the preclinical GO model was the main 
aim. The development of preclinical animal model and the histopathological 
procedures to characterise the orbital tissue for better anatomical evaluation of orbital 
muscle, adipose tissue and inflammation are described in Chapter 3. Furthermore, 
small animal MRI of the orbital regions to demonstrate proptosis and the assessment 
of orbital tissue hypertrophy are described in Chapter 4. The final results Chapter deals 
with studies on the IGF-1R antibodies induced in the model following immunisation 
with hTSHR A-subunit plasmid in vivo electroporation. 
 
  








Material and Methods  
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2.1.1 Medium and cell growth supplements 
 
All medium and cell growth supplements were purchased from PAA, unless otherwise 
stated. 
 Ham’s F12  
 RPMI1640 with L-Glutamine 
 DMEM low glucose (1g/L) with L-Glutamine 
 Sterile Dulbecco's phosphate buffered saline without calcium and magnesium 
 Geneticin (G418) sulphate solution (50 mg/ml) 
 Foetal calf serum (FCS) were purchased from Invitrogen, UK, and stored at -20oC 
freezer. FCS prior to use was treated at 56oC for 30 minutes to inactivate 
complement in all experiments. 
 HEPES buffer solution (1M) ( Invitrogen, UK) 
 Sodium pyruvate (100mM) ( Invitrogen, UK) 
 Cell dissociation solution (non-enzymatic) (Sigma-Aldrich, UK). 
 Doma Drive Hybridoma feeder supplements (Immune systems, UK). 
 
 
2.1.2 Sterile tissue culture plastic ware 
 
Cells were cultured in sterile tissue culture flasks (25, 75 and 175 ml) and 24, 48 and 
96-well plates (CELLSTAR, Greiner Bio-One, Germany) as described below. 





Transfected cell line expressing TSHR A-subunit (GPI9-5) 
 
Chinese hamster ovary (CHO) cells expressing the TSHR A-subunit anchored by a 
glycosylphosphatidylinositol (GPI) moiety, and expressing the TSHR A-subunit at an 
approximate density of 500,000 receptors/cell (Metcalfe et al., 2002) were donated by 
Dr Phillip Watson, University of Sheffield, and called GPI9-5cells. Cells were cultured in 
Ham's F12 medium containing 10% FCS and 0.01% PSF. Geneticin G418 added to cell 
culture to a final concentration of 200 μg/ml. 
 
Transfected cell line expressing TSHR (JP09) 
 
CHO cells express the full-length TSHR at an approximate density of 90,000 TSHR/cell 
and called JP09 cells, were donated by Professor G Vassart, Brussels (Perret et al., 
1990). The JP09 cells were used for cAMP stimulating bioassays and the GPI9-5 cells 
were used in flow cytometry assays. Cells were cultured in Ham's F12 medium 
containing 10% FCS and 0.01% PSF. The cells in culture were supplemented with 
Geneticin G418 added to cell culture to a final concentration of 200 μg/ml. 
 
Non-secretor Myeloma (X63-Ag8653) cells 
 
Non-secretor Myeloma X63-Ag86S3 (X63) cells (Kohler and Milstein, 1975) were 
available in the laboratory (Ewins et al., 1992) and used for fusion with murine 
splenocytes to generate hybridomas. The cells were cultured in suspension in RPMI 
medium, supplemented with 10% FCS and 0.0 1% PSF.  
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Transfected cell line expressing IGF-1R (NWTB3) 
 
The NWTB3 cells, mouse fibroblast cell line stably transfected to express hIGF-1R were 
kindly provided by Professor LeRoith (Mount Sinai hospital, New York, NY). The 
transfected cells were reported to express 410,000 receptors per cell (Blakesley et al., 
1995). Cells were cultured in DMEM medium containing 10% FCS and 0.01% PSF. 
Geneticin G418 added to cell culture to a final concentration of 750 μg/ml. 
 
2.1.4 IGF-1 and IGF-1R  
 
Recombinant hIGF-1R (rhIGF-1R) is commercially available from R&D Systems 
(catalogue number: 391-GR). It is a recombinant protein comprising the ectodomain (α 
subunit) of the receptor, which has been expressed in transfected mouse myeloma cell 
line and then purified from tissue culture supernatants by biochemical procedures. As 
specified, 50 µg of freeze-dried, purified rhIGF-1R was reconstituted in 500 µl of sterile 
phosphate buffer solution (PBS) to achieve a concentration of 100 µg/ml. rhIGF-1R was 
then made into aliquots and stored at -80°C. 
 
Chemiluminescent labelled IGF-1 (Lumi-IGF-1)  
Lumi-IGF-1 was a gift from Professor Lutz Schomburg and Dr Waldemar Minich (Minich 
et al., 2013), (Institute for Experimental Endocrinology, Charité Campus Virchow-
Klinikum, Berlin, Germany). The Charité group labelled IGF-1 with acridinium ester, 
which was then purified by gel filtration. Lumi-IGF-1 at a concentration of 108 RLU/µl in 
PBS/1% bovine serum albumin (BSA) was made into aliquots and stored at -80°C. 
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IGF-1  
The ligand, IGF-1, was a gift from Ipsen Pharma (Slough, UK) kindly arranged through 
Dr Charles Buchanan (Consultant paediatric endocrinologist). Increlex, also known as 
Mecasermin, is a therapeutic preparation of recombinant human IGF-1 which is used 
to treat primary IGF-1 deficiency in children or adolescents presenting with short 
stature and growth failure (BNF, 2010). It was supplied in a vial as a 4 ml (10 mg/ml) 
sterile solution. For experimentation, Increlex was diluted in sterile PBS to achieve a 
concentration of 1mg/ml, made into aliquots and stored at -80°C. 
 
2.1.5 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
 
Reagent Separating gel (12%) Stacking gel (6%) 
Polyacrylamide (30%) 
Tris 
10% ammonium persulphate (APS) 
10% sodium dodecyl sulphate (SDS) 
Distilled water (dH20) 
Tetramethylethylenediamine (TEMED) 
6.4 ml 












Table 2.1: Reagents for separating and stacking gels 
 
 Precision Plus Protein Dual Colour Standards, commercially available from Bio-Rad 
 Bromophenol blue  
 Coomassie Brilliant Blue  
 20% methanol/10% acetic acid  
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2.1.6 Enzyme-linked immunosorbent assay (ELISA) 
 
 Nunc MaxiSorp 96-well plates which have high protein-binding capacity 
 Anti-mouse IgG–alkaline phosphatase( Sigma-Aldrich) 
 Alkaline phosphatase yellow (pNPP) from ( Sigma-Aldrich) 
 3M NaOH 




 CD3, rat anti-mouse monoclonal (CD3-12), AbD Serotec, UK 
 CD4, rat anti-mouse monoclonal (GK1.5),TONBO biosciences, USA 
 CD8α, rat anti-mouse monoclonal (53-6.7),TONBO biosciences, USA 
 F4/80, rat anti-mouse monoclonal (CI:A3-1), AbD Serotec, UK 
 B220, rat anti-mouse monoclonal,( RA3-3A1/6.1), Ancell Corp, USA 
 CD221 (IGF-1R), anti-human monoclonal (1H7 mAb), BioLegend, UK 
 
2.1.8 Other materials 
 
Ammonium molybdate, ampicillin, bovine serum albumin (BSA), CaCI2.2H20, 
chloramphenicol, CaCI2.6H20, Coomassie blue R250, CuS04, dimethyl sulphoxide 
(DMSO), DNase I, ethidium bromide, FeS04, glucose, H202, imidazole, KCI, MgCI2, 
molecular biology water, Trypsin, EDTA, Triton-X-100, Tween-20, ZnS04, HEPES, 
isopropanol, KH2P04, MgS04.7H20, NaAc, NaCI, NaHC03, Na2HP04, NaOH, NH4CI, 
(NH4)2S208, SDS, sucrose, Tris base. 
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2.2 Methods 
2.2.1 Human (h) TSHR A-subunit and hIGF-1Rα plasmids 
 
Human TSHR A-subunit cDNA and IGF-1Rα cDNA were cloned pTriEx1.1 Neo vector by 
my predecessor, Dr Susan Zhao as described in their published report (Zhao et al., 
2011). The pTriEx™-1.1 Neo is a commercial vector supplied by Novagen (Fig 2.1). In 
addition, pTriEx1.1 Neo β-Gal (Novagen, Merk, Germany) was used as a control 
plasmid for immunisation. 
 
Fig 2.1 pTriEx™-1.1 Neo plasmid map.  
The schematic map of the plasmid shows the size, expressing genes and restriction 
sites. 
 
Procedure of cloning and primer details is briefly outlined below. Human TSHR A-
subunit (amino acid residues 1–289) and human IGF1Rα subunit (741 amino acids) 
cDNA was cloned into BamH1 and Not1 restriction sites in pTriEx-1.1 Neo by 
ampliﬁcation from pcDNA3.1-human TSHR plasmid using forward primer 5’-
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CGCGGATCCATGAGGCGATTTCGGAGG-3’ and reverse primer 5’-ATAAGAA 
TGCGGCCGCTTACTGATTCTTAAAAGCACAGC-3’. The cDNA was fully sequenced and 
then excised and subcloned into BamH1 and Not1- digested pTriEx-1.1 Neo vector.  
IGF1Rα (741 amino acids) cloned into the pTriEx-1.1 Neo by using the region of 2223 
bp (including the stop codon) forward primer with BamHI site: 5’-
CGCGGATCCATGAAGTCTGGCTCCGG-3’ and reverse primer with NotI site: 5’-
ATAAGAATGCGGCCGCTTATCTCCGCTTCCTTT CAGG-3’. The cDNA was fully sequenced 
and then excised and subcloned into BamH1 and Not1- digested pTriEx-1.1 Neo vector. 
All plasmids were grown in E. coli XL-1 Blue cells in LB medium in 2.5 litres cultures and 
were puriﬁed using the QIAﬁlter Plasmid Giga Kit (Qiagen, UK).  
 
2.2.2 Plasmid purification  
 
Plasmids were purified in milligram quantities for immunisation of mice. For 
purification, a single small colony from a freshly streaked selective plate was picked 
and incubated a starter culture in 10 ml LB medium containing the 10 µl ampicillin. 
After 8 hours incubation at 37°C in shaking incubator (for good aeration in the culture) 
at 250 revolutions  per minute (rpm), each 2 ml of starter medium was diluted to 500 
ml fresh medium. The 500 ml culture was incubated at the same condition overnight. 
Next day, the wet bacterial pellet was harvested and was weighed (the optimum 
weight range is approximately 3 g/l). The bacterial pellet was resuspended in provided 
reagents by Giga Kit to lyse the bacterial cells. To isolate plasmids from bacterial 
contents, two steps of filtration was applied with the prepared cartridges and tips. 
Puriﬁed plasmid concentrations were measured using a Nanodrop spectrophotometer, 
resuspended in sterile water, and stored at -80˚C. Purity of DNA was assessed by 
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agarose gel electrophoresis. Plasmids were treated either with one of the restriction 
enzymes, BamH1 and Not1, or both. In addition, in order to future confirmation of 
inserted DNA to plasmid, bands on the right size were purified from agarose gel and 
were treated with restriction enzymes. To examine TSHR A-subunit, the isolated cDNA 
from agarose gel treated with HindIII that provided two bands of 220bp and 732bp. In 
the same concept, IGF1Rα cDNA treated with Xho1 which cut the inserted cDNA at 
277bp.   
 
2.2.3 Assay for thyroid antibodies  
 
2.2.3.1 Thyroid radiobinding assay (TRAK) 
 
To study the presence of TSHR antibodies in immune mice sera, displacement 
radiolabelled 125I-TSH from binding immobilised TSHR is assayed using commercial kits, 
Brahms TRAK Human RIA (Thermo Fisher Scientific, Germany). This kit is based upon 
capturing of recombinant human TSHR by immobilised mAb on tubes and 125I-TSH 
(Costagliola et al., 1999). Results are presented as % inhibition of 125I-TSH binding 
where values up to 15% (grey zone) scored as negative and greater value scored as 
positive. The brief technical protocol is described below. 
 50 μL of mice sera were diluted 1:1 in normal human serum for saving valuable mice 
sera, as the kits are optimised for 100 μL of sera. All samples were diluted in normal 
human serum (that did not interfere with the assay) from the same donor (SM or JPB). 
For mAb screening, medium or purified mAbs was diluted 1:2 in normal human sera. 
The experiment was performed on a single basis with an appropriate number of 
positive and negative controls. 200 μL of Buffer 0 was added to TSHR-coated tubes, 
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except the first two tubes.  100 μL of each of standards was added to the appropriate 
tubes. Test samples were prepared by adding 50 μL mice sera to 50 μL normal human 
serum. 100 μL of this was added to the appropriate tube. The tubes were incubated for 
2 h with shaking at room temperature. After washing twice with 2 mL wash buffer, 200 
μL of 125I-TSH was added to each tube and incubated for 1 h with shaking at room 
temperature. The tubes were washed three times with wash buffer and counted in a 
gamma counter for 1min (DSLaboratories). Generally, the maximum count of 200μL of 
tracer (125I-TSH) was about 10000 cpm while the maximum binding by standard 0 (B0) 
was about 10% which is around 1000 cpm. The inhibition of binding of mice sera was 
expressed as percentage inhibition of 125I-TSH binding to TSHR. Percentage inhibition 
of 125I-TSH binding to TSHR was calculated by dividing radioactivity of each sample by 
B0 times 100. Dose response of KSAB1 has been performed for each new lot number of 
kits. The maximum coefficient variation (CV) of intra-assay and inter-assay precision of 
the kit were 9.3% and 14.1% respectively. Moreover, it was mentioned by company 
that the functional assay sensitivity is 1.0 ± 0.2 IU/L.  
 
2.2.3.2 Assay for thyroid stimulating antibody 
 
The JP09 cells, CHO (Chinese Hamster Ovary) cell line stably transfected to express full 
length human TSHR were kindly provided by Professor G Vassart (Belgium) (Perret et 
al., 1990). This cell line provides a powerful response by TSAbs. The concentration of 
TSHR stimulating antibodies is directly correlated to production of cAMP.  Thus, TSAbs 
are specifically detectable by measuring of cAMP produced from JP09 cells. This assay 
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was well validated in our laboratory (Gilbert et al., 2006, Padoa et al., 2010, Rao et al., 
2003) 
JP09 cells (30,000 cells per well) were added to 96 flat well plates and left to grow for 
18-20 hrs grown in F12 complete medium (37o 5% CO2). The medium was removed and 
cells were gently washed with PBS, taking care not to disrupt the monolayer of cells, 
before adding samples and controls. Forskolin and different doses of bovine TSH and 
KSAB1 were used as a positive control. Mice sera samples and controls were diluted in 
complete Hank’s buffer salt free solution (HBSS). The components of HBSS, which is a 
fairly complex solution, are listed in Table 2.3.  Complete HBSS was made by adding 50 
μl IBMX (50 ml IBMX + 450 μl DMSO) and 0.75g BSA to 50 ml HBSS. Mice sera samples 
and controls were diluted in complete HBSS as summarised in Table 2.4. 150 μl of 
prepared samples was added to each well and was incubated for 4 hours at 37oC, 5% 
CO2. After incubation time, supernatant was collected and stored in -80
oC to test the 
concentration of cAMP by cAMP ELISA kit (Enzo Life Sciences). 
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Component Formula M.W. Molarity (mM) Conc  (g/L) 
Calcium 
chloride 
CaCl2.2H2O 147.0 1.26 0.185 
Potassium 
chloride 




KH2PO4 136.0 0.44 0.060 
Magnesium 
chloride 
MgCl2 95.2 0.50 0.048 
Magnesium 
sulphate 
MgSO4.7H20 246.0 0.41 0.101 
Sodium 
bicarbonate 




Na2HPO4 142.0 0.30 0.043 
Glucose  180.0 5.6 1.008 
HEPES  238.3 20.00 4.766 
Sucrose  342.3 222.0 75.991 
 
Table 2.3 List of the chemical components in HBSS.  
 
Briefly, 100 µL of Standards (#1 through #5) and samples were transferred to the 
bottom of the appropriate wells. 50 µL of the blue conjugate was added into each well 
except the TA and Blank wells. Afterwards, 50 µL of the provided antibody was added 
into each well except the Blank, TA, and NSB wells. Plate wasIncubated for 2 hours on 
a plate shaker (500 rpm) at room temperature before washing 3 times with 400 µL of 
wash buffer. 5µL of the blue conjugate was added to the TA wells. Subsequently, 200 
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µL of the substrate solution was added into each well and incubated for 1 hour at 
room temperature without shaking.  In the last step, 50 µL stop solution was added 
into each well and read optical density (OD) at 405 nm. 
 
 Samples Sample volume HBSS 
1 Forskolin 15 μl 135 μl 
2 bTSH (1.6, 0.8, 0.4, 
0.2, 0.1, 0.01 mU/ml) 
54 μl 96 μl 
3 KSAb1 mAb 
(100ng/ml) 
54 μl 96 μl 
4 KSAb1 mAb (10ng/ml) 54 μl 96 μl 
5 IgG2b (100ng/ml) 54 μl 96 μl 
6 IgG2b (10ng/ml) 54 μl 96 μl 
7 Mice sera 3 μl 147 μl 
   
Table 2.4 Preparation of working sample for cAMP bioassay. 
The volume of sera samples and controls need to be added in each well of 96 
well plate of JP09 cell.   
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2.2.3.3 Assay for thyroid blocking antibody 
 
The blocking assay designed to evaluate TSBAbs in the test serum sample by measuring 
inhibition of cAMP production induced by sub-saturating concentration of bovine TSH. 
This assay is similar to the above assay to measure thyroid stimulating antibody. The 
only difference between these two assays is that, JP09 cells were incubated by 
prepared mice sera samples (as explained in 2.2.4.2) for 2 hours to inhibit induction of 
cAMP (in case of TSBAbs present) from bovine TSH which has been added later and 
incubate for another 2 hours.  
Briefly, JP09 cells were cultured in 96 flat well plates for 18-20hrs in F12 complete 
medium (37o 5% CO2). The medium was removed and cells were gently washed with 
PBS. The suboptimal dose of bovine TSH was already examined from the prior assay. A 
patient serum (named as Patritia) kindly provided by Dr Philip Watson (University of 
Sheffield) that considered possessing blocking activity used as a positive control. Mice 
sera samples and controls were diluted in complete HBSS as summarised in Table 2.4.  
150 μl of prepared samples was added to each well and was incubated for 2 hours at 
37oC, 5% CO2. After 2 hours incubation, 150 μl of 0.2 mU/ml bTSH was added to all 
wells and incubated for 2 hours at 37oC, 5% CO2. After incubation time, supernatant 
was collected and stored in -80oC to measure concentration of cAMP, as explained 
earlier in 2.2.4.2. The acquired raw data was then calculated by dividing level of cAMP 
from each well by the suboptimal value of 0.2 mU/ml bTSH. Results were express as 





 107  
 
2.2.4 Thyroid function tests 
 
The hyperthyroid states of immunised mice were assessed by measuring total serum 
T4 concentrations using a commercial kit that uses the smallest volume of serum, Ratio 
Diagnostics, (Germany). In order to outset the assay, 25 μL of mice sera and standards 
(Table 2.5), was added to each well. It was followed by adding 200 μL of working 
conjugate solution to each well. The plate was incubated for 30 min at 37o C on a 
thermoshaker 500rpm followed by washing 5 times with 300 μL with provided washing 
solution. Subsequently, 100 μL of TMB was added to each well and incubated for 15 
min at room temperature in the dark. In the last step 150 μL stopping reagent was 
added and gently mixed for 10 seconds. Optical density was measured on the micro-
plate reader at 450 nm. Total T4 of mice sera was calculated based on the absolute OD 
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2.2.5 Purification of IGF-1R mAbs by protein G chromatography 
 
Professor Kenneth Siddle(University of Cambridge, UK) kindly provided four anti-IGF-
1R mAbs with different specificity, called 24-31mAb, 24-60mAb, 17-69mAb and 24-
57mAb as freeze-dried ascites (Soos et al., 1992). To purify freeze-dried ascites, initially 
each mAb vial was resuspended in 1 ml of sterile distilled water. Salt reconstitution 
was not necessary because mAbs had been freeze-dried from mouse ascitic fluid. 
Resuspended mAbs were passed through the column containing protein G Sepharose 
gel and the columns were washed with 10  x 1 ml of 100 mM Tris (pH 8.0) and then 
with 10 x 1ml of 10 mM Tris (pH 8.0). The mAbs were eluted from protein G with 5 x 1 
ml fractions of eluting buffer (50 mM glycine, pH 3.0). The eluted fractions (0.5 ml) 
were collected in individual microcentrifuge tubes containing 50 µl of 1M Tris buffer to 
neutralise acidity. In addition, the starting sample (SS), flow through (FT), column wash 
(CW) samples were already collected in the separate tubes.  The samples were 
individually dialysed overnight in sterile PBS at pH 7.4 at 4°C.  
 
2.2.6 Protein detection assays  
 
2.2.6.1 Protein assay 
 
To analyse the mAbs concentration which were purified by column chromatography 
micro-scale protein assay using BCA Protein Assay Kit (Novagen). Initially, the BCA 
working reagent was prepared in a microcentrifuge tube; each well required 200 µl of 
BCA solution and 4 µl of 4% cupric sulfate. 25 µl of each standard and protein sample 
(elute 1–5) was added into single wells of a standard 96-well microtitre plate and then 
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200 µl of BCA working reagent was added to the wells. The plate was covered with 
adhesive plate sealing film and placed on a plate shaker for 30 seconds to enable 
mixing. There were 2 options for incubation; the standard assay and the enhanced 
assay. This experiment followed the standard assay with incubation at 37°C for 30 
minutes. After incubation, plate was remained for few minutes to cool down to the 
room temperature. The absorbance was measured at 630 nm using a microplate 
reader. 
 
2.2.6.2 SDS-PAGE  
 
The separating and stacking gels were prepared with the reagents in Table 2.1. TEMED 
is required to polymerise the gels and should be added just before pouring the gels 
into the gel cassette. The separating gel was first poured into the gel cassette up to 
about 1 cm below the position of the comb and isopropanol was then added to 
remove air bubbles. The gel was left to set for 10–15minutes before washing the gel 
cassette with distilled water. The stacking gel was then poured to fill the gel cassette 
and the comb was inserted into stacking gel. Again, isopropanol was added before 
allowing the gel to set for 10–15 minutes. The gel cassette was removed from the gel 
caster and placed into the electrophoresis tank which was then filled with SDS running 
buffer. 5 µl of the protein ladder was first added to the gel, followed by samples 
prepared with bromophenol blue (refer to Table 2.6). The gels ran at 70V until the 












5 µl of SS + 5 µl of bromophenol blue 
5 µl of FT + 5 µl of bromophenol blue 









15 µl of E1 + 15 µl of bromophenol blue 
15 µl of E2 + 15 µl of bromophenol blue 
15 µl of E3 + 15 µl of bromophenol blue 
15 µl of E4 + 15 µl of bromophenol blue 







Table 2.6 Preparation of samples for SDS gel 
SS – Starting sample; FT – Flow through; CW – Column wash; E1–5 – Elute  1–5 
 
 
Following electrophoresis, in order to visualise the separate protein bands, the gel was 
stained with coomassie brilliant blue and destained in 20% methanol/10% acetic acid 
solution. The molecular mass of these protein bands can be approximated with 
reference to the protein ladder (molecular weight size marker). 
 
2.2.6.3 Western blotting 
 
Samples were run on SDS-PAGE gels (as described in 2.2.7.2) with coloured markers 
(Fisher Scientific, UK). The gel was placed on three sheets of wet 3 mm filter paper on 
the top leaf of the Western blotting cassette (Trans-Blot Electrophoretic Transfer Cell, 
BioRad). The gel was covered with a wet Protan Nitrocellulose membrane (Scheiler and 
Schuell, Dassel, Germany), ensuring no-air bubbles were present by rolling with a 
pastette. Three further sheets of filter paper were placed over the membrane and the 
cassette was closed. The cassette was placed in the tank such that the gel-side of the 
sandwich was facing the cathode, and the nitrocellulose membrane was facing the 
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anode. The tank was filled with 1X transfer buffer, connected to the power pack, 
placed in a polystyrene box containing ice and run for 1 h at 100 V, or until the 
prestained MW ladder had fully transferred to the blot. Following transfer, the 
nitrocellulose membrane was blocked for 1 h at room temperature with PBST/5% 
marvel milk protein/0.05% Tween-20.  The blocked membrane was incubated with 
anti-penta His HRP Conjugate (Qiagen; 1:1000 dilution), for 1 h at room temperature. 
The membrane was then washed 3 times for 5 minutes each in PBST, incubated with 
AEC developer for 5 minutes, and rinsed with dH20 to stop the reaction. 
 
2.2.7 Flow cytometry 
 
Flow cytometry technique was used to evaluate expression of TSHR and IGF-1R in 
transfected cell lines. BD Canto II flow cytometer (BD Bioscience), equipped with two 
laser channels was used. Data analysis was done by FlowJo software.   
 
2.2.7.1 Evaluation of IGF-1R expression in NWTB3 cells by flow 
cytometry 
 
The NWTB3 cells, mouse fibroblast cell line stably transfected to express human IGF-1R 
were kindly provided by Professor LeRoith. The transfected cells were reported to 
express 410,000 receptors per cell (Blakesley et al., 1995). IGF-1R expression on 
NWTB3 cells was examined by flow cytometry. NWTB3 cells were grown in T25 tissue 
culture flasks in DMEM medium. Flasks with confluent cells (70-90%) were prepared 
for flow cytometry as follows:  
Medium removed and cells washed with PBS twice before adding 2ml of cell 
dissociation medium (Sigma-Aldrich) to T25 flasks. Flasks incubated at 37˚C for 5-7 
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minutes until cells have detached. Afterwards, 8ml of complete medium added to each 
flask and resuspend cells. Cells transferred into a 15 mL falcon tube and counted 
before centrifugation at 1000 rpm for 5 min. Cell pellet resuspended in PBS containing 
1% BSA, 0.05% sodium azide to a concentration of 1 x 106 cells/ml and then 1ml of cells 
transferred to an FACS tube (BD Bioscience) through their cell strainer cap to avoid 
aggregation of cells and centrifuged at 1500 rpm for 5 min. The supernatant was 
removed and cells resuspended in 100 μl of primary antibody and incubated for 1 hour 
on ice. Primary antibodies were included 1H7 (Santa Cruz Biotechnology) as a positive 
control, IgG1 isotype or blank as a negative control, 17-69 and 24-57 IGF-1R 
monoclonal antibodies provided by Professor Kenneth Siddle (University of Cambridge, 
UK).    After 1 hour cells were washed twice in 1ml cold PBS +BSA +azide and then 
centrifuged at 1500rpm for 5min before adding 100 μl of secondary antibody. Cells 
with secondary antibody incubated on ice for 30 min. FACS tubes are ready to read by 
flow cytometer BD Canto II after three times washing as before and resuspended in 
300 µl of PBS, BSA, azide.   
 
2.2.7.2 Evaluation of TSHR expression in GPI9-5 cells by flow cytometry 
 
The GPI9-5 cells, CHO cell line stably transfected to express human TSHR A-subunit 
were kindly provided by Dr Phillip Watson (University of Sheffield, UK) (Metcalfe et al., 
2002).   TSHR A-subunit expression on GPI cells was examined by flow cytometry as 
describe above. Primary antibodies included 4C1 the gold standard mAb for evaluating 
TSHR expression by FACS for positive control and IgG2b for negative control. 
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2.2.8 Establishment of assays for IGF-1R Abs 
 
To our knowledge, there is no commercial kit available for detection of IGF-1R Abs. 
Herein, establishment of two assays including ELISA assay and competitive binding 




IGF-1R Ab ELISA established based on the protocol described by Yin and colleagues (Yin 
et al., 2011).   IGF1R extracellular domain (IGF1R ECD) was purchased from R&D 
Systems (UK). The source of receptor (102.9 kDa) is recombinant protein in murine 
myeloma cells. MaxiSorp (Nunc, Roskilde, Denmark) flat bottom ELISA plates were 
coated with 100 µl (30.6 ng/well) of IGF1R ECD suspended and diluted in PBS buffer at 
4°C for 12–16 hours. After washing three times with 250 µl of washing buffer (PBS 
0.05% Tween/ 2% BSA), coating step were blocked with incubation with 1% BSA in PBS-
Tween for 2 hours. Mouse serum (diluted 1:30 and 1:90 in washing solution), was 
incubated in antigen coated wells at room temperature for 1 h. After washing, 100 µl 
of alkaline phosphatase conjugated goat anti-mouse IgG Fc antibody (Sigma-Aldrich) in 
1:5000 dilution was added and incubated for 1 hour. After washing, substrate solution 
containing p-nitrophenylphosphate (pNPP) was added to each well for 40 min. 
Substrate conversion was measured at 405 nm using a Titertek Plus reader. 
2.2.8.2 Competitive binding assay 
 
Competitive binding assay were established based on the displacement of labelled-IGF-
1 by cold IGF-1 in the receptors, similar to that reported by Weightman and colleagues  
(Weightman et al., 1993).  However, there are some technical differences between 
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these two studies: (i) radioactive (125I) labelled IGF-1 has been replaced by acridinium 
ester labelled IGF-1 (called Lumi-IGF-1) and (ii) transfected cells (NWTB3) were used 
instead of human orbital fibroblasts as source of IGF-1R in the assay. Lumi-IGF-1 is 
kindly provided by Professor Lutz Schomburg and his colleagues (University of Berlin, 
Germany) (Minich et al., 2013). Luminescence activity of the stock tracer (Lumi-IGF-1) 
was at 108 RLU/μl.   For first instance, concentration of trace and number of cells were 
evaluated to optimise the assay. NWTB3 cells were grown as monolayer cell culture in 
96 well, 48 well and 24 well plates overnight in complete medium (DMEM 10% FCS). 
Next day, cells were washed with sterile PBS and different concentration of tracer and 
competitor (unlabelled IGF-1) were added and incubated for 6 hours at 4oC. Unlabelled 
IGF-1 at different concentration (10 fold dilution) used as competitor. Highest 
concentration of unlabelled IGF-1 was 10-7M which decreased to 10-10 M. Dilution 
worked out based on the 10-7M equal to 1μg/ml of IGF-1. Is’nt this in Appendix, please 
refer to it! Sterile PBS used as dilution buffer. Equal volume of tracer and competitor 
added to each monolayer cultured wells. Concentration of Lumi-IGF-1 is based on 
luminescence signalling (RLU/μl).  100 μl of mixture was added for 96 well plate and 
400 μl for 24 well plate. 
96 well plate were washed with PBS two times and directly read with luminometer 
(Berthold TriStar LB 941). Since the 24 and 48well plates were not suitable for direct 
reading in the luminometer, after the washing step in the binding assay, the monolayer 
cells were dissociated with cell dissociation medium and transferred to a fresh 96 well 
plate for counting of the luminescence signal. Percentage Binding of trace was 
calculated by dividing of counting from each well by count from no competitor times 
100.    
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2.2.9 Development of mAbs  
 
Non-secretor X63-Ag8.653 (X63) myeloma cell line (the fusion partner cell line) began 
expansion one week before fusion in complete RPMI-10/HEPES/pyruvate. Myeloma 
cells were checked under the microscope every day and transferred to fresh medium 
every alternate day.  By the day cell fusion was to be performed, total number of 1 × 
108 cells in two or three flasks (175 cm2) myeloma cells must be available. One day 
before fusion, myeloma cells were split into fresh complete RPMI-10/HEPES/pyruvate 
medium. Vigorous growth of myeloma cells is generally required for good fusion. 
Three days before fusion, animal was primed by i.v. injection of 2x106 NWTB3 cell as 
booster. At the day of fusion, boosted animal was sacrificed and spleen was harvested 
under sterile condition. Spleen was Transferred to a sterile 100-mm-diameter petri 
dish filled with 10 ml sterile complete serum-free RPMI. Spleen was teased into a 
single-cell suspension by squeezing with angled forceps and fine-tipped dissecting 
scissors. Debris was removed and cells were dispersed further by passage through a 
fine-mesh metal screen. Spleen cell suspension was transferred to a sterile 50-ml 
conical centrifuge tube and filled with sterile complete serum-free RPMI before 
spinning them down for 5 min at 1500 rpm (500 × g), room temperature. Red blood 
cells (RBC) were lysed by resuspending pellet in 5 ml ammonium chloride solution for 5 
min at room temperature. 45 ml sterile complete serum-free RPMI was added and 
centrifuge as in earlier step condition. Cell pellet was resuspended in 50 ml sterile 
complete serum-free RPMI and centrifuged once again. 
While spleen cells were being washed, separately myeloma cells were harvested by 
transferring the cells to 50-ml conical centrifuge tubes. Myeloma cells were 
centrifuged for 5 min at 1500 rpm (500 × g), room temperature. Myeloma cells were 
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resuspended in RPMI and all cells were pooled into one 50-ml conical centrifuge tube. 
Myeloma cells were washed three times at the same condition explained earlier. 
Separately, the spleen and myeloma cells were resuspended in 10 ml complete serum-
free RPMI. On basis of cell counts by using a haemocytometer, the amount of pre-
warm complete RPMI-20/HEPES/pyruvate needed to plate cells at about 4 × 106 total 
cells/ml was calculated. Myeloma and spleen cells were mixed at a 1:1 ratio in a 50 ml 
conical centrifuge tube. The tube was filled with complete serum-free RPMI and then 
cell mixture was centrifuged at 500 × g, room temperature for 5 min. The cell fusion 
was performed at 37°C by adding 1 ml pre-warmed 50% PEG to the mixed-cell pellet 
drop-by-drop over 1 min. Stirring the cells with the pipet tip after each drop was 
carefully done. By using a clean pipet, 1 ml prewarmed complete serum-free RPMI was 
added to the cell mixture drop-by-drop over 1 min, with stirring after each drop. An 
additional 1 ml of prewarmed complete serum-free RPMI was repeated once. Finally, 
with a 10-ml pipet, 7 ml prewarmed complete serum-free RPMI was added drop-by-
drop over 2 to 3 min. Fused cells were centrifuged at 500 × g, room temperature for 5 
min and the supernatant was discarded before adding 50 ml prewarmed complete 
RPMI-20/HEPES/pyruvate. Gently, 10 ml of cell suspension aspirated with a 10 ml 
pipet. 2 drops (100 to 125 μl) of suspension was added to each well of a 96-well flat-
bottom plate and plates incubated overnight in a humidified 37°C, 5% CO2 incubator. 
After one day of incubation, wells were checked under an inverted microscope. If 
seeded with the appropriate number of cells, there should be a nearly confluent 
monolayer of highly viable cells on the bottom and obvious clumps of cells. 
Subsequently hybridomas were selected in RPMI-20 supplemented with hypoxanthine 
(15 µg/ml), aminopterin (0.2 µg/m1) and thymidine (5 µg/ml) (HAT) or hypoxanthine 
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(15 µg/ml) and aminopterin (0.2 µg/ml) (HT). 2 drops complete RPMI-
20/HEPES/pyruvate/HAT/10% Doma Drive was added to each well with a 10 ml pipet. 
Plates were placed in humidified 37°C, 5% CO2 incubator again. On days 4, 5, 7, 9, and 
11, half the volume of each well was aspirated and fed the cells by adding 2 drops 
complete RPMI-20/HEPES/pyruvate/HAT/10% Doma Drive from a 10 ml pipet to each 
well. On day 14, feeding protocol repeated, except use complete RPMI-
20/HEPES/pyruvate/HT to feed cells and to return to 37°C, 5% CO2 incubator. On day 
15 and subsequently, wells were fed as noted using complete RPMI-
20/HEPES/pyruvate without HAT or HT. The hybridomas then were ready for screening 
when most of the wells containing growing cells demonstrate 10% to 25% confluence 
and when those with denser populations turn yellow within 2 days after feeding. 
 
2.2.10 Histology  
 
Histology is the microscopic study of a normal structure of body tissues. Study in tissue 
structure is almost impossible as very small size of cells and lack of refractive contrast 
between them unless using a certain method to stain a very thin layer of tissue. Thus, 
histology is set of complex techniques from excised of tissue to study it under 
microscope including tissue preservation (fixation), embedding, cutting and staining. 
As soon as tissue is excised, it begins to degenerate due to cell necrosis.  
To prevent this process tissue must be preserved either chemically (formaldehyde 
solution) or physically (snap frizzing). Tissue fixation also protects cells and tissue 
constituents from the subsequent processes. After fixation, tissue is ready to be 
embedded either in paraffin or OCT cryostat sectioning medium depend on the 
fixation method. Paraffin embedding is long process (from 12 hours to few days) that 
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facilitates penetration of melted paraffin into the fixed tissue to prepare it for cutting 
section. A very thin slice (normally between 4-6 μm) of tissue can be cut using 
microtome. Finally, to facilitate differentiation in the refractive indices of certain cell 
elements a particular staining is required. Haematoxylin-eosin is undoubtedly the most 
common staining method in histological laboratories to study tissues structure. 
However, there are more than hundreds staining method and techniques to study in 
more depths and specificity.  
Structure always follows function and histology is therefore a tool for determining the 
normal function and pathology of different tissues and organs. Particular changes in 
the microscopic structure of the tissues may reveal a certain disease. The study of 
these changes is known as histopathology. Obviously, it is essential to know the normal 
structure for an understanding of pathology. Thus in this project, study of tissue from 
healthy animal has been first performed to gain a sound knowledge in principles of 
histology techniques and normal structure of tissues which are in our interest. 
 
2.2.10.1 Mouse thyroid histology  
 
Initially, histology of mouse tissue was examined on tissue from normal mouse donors 
and then moved to immunised mice tissues. Mouse thyroid tissues were ﬁxed in 10% 
buffered formalin, embedded in parafﬁn, and sectioned for haematoxylin and eosin 
(H&E) staining. Haematoxylin and eosin stain is the standard stain for almost all tissue.  
It gives a visible look at the nucleus of the cells and their present state of activity in 
addition to abnormal growth, inflammation or fibrosis.  The haematoxylin and eosin 
stain uses two separate dyes, one staining the nucleus and the other staining the 
cytoplasm and connective tissue.  Haematoxylin is a dark purple dye that will stain the 
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chromatin (nuclear material) within the nucleus, leaving it a deep purplish-blue colour. 
Eosin is an orange-pink to red dye that stains the cytoplasmic material including 
connective tissue and collagen.  The normal thyroid gland was sectioned serially at 4 
μm, with discarding next ten serial step sections. Sections which have been flowed on 
the warm water, transferred on the normal glass slides. Slides have been left at room 
temperature for 5 to 10 minutes to dry out and putted in the automated staining 
machine for normal H&E. 
 
2.2.10.2 Establishment of histology technique for orbital tissue  
 
Initially, normal mouse extraocular muscles were accessed by transcranial dissection 
method provided by Dr Swaraj Bose (UC Irvine, USA). The entire orbital bony tissue 
comprising the orbital bones with the eyeball, extraocular muscles, and the optic nerve 
was carefully separated from the mouse and ﬁxed in buffered 10% formalin. From this 
stage to remove bony structure of orbital tissue, two different methods have been set 
up, decalcification and dissection. In decalcification method which is routine method in 
histopathology lab, after 24 h, the orbital bony tissue was placed in 10% decalciﬁcation 
solution for 3-5 days with change the solution daily basis and checking the remain free 
calcium ion un the solution. In the dissection method by using fine forceps and scissors 
bones have been removed from the orbital tissues under the dissection microscope. 
The most important part of retrobulbar histopathology is tissue embedding. We were 
advised by Dr Anja Eckstein (Germany) to use optical nerve as a reference point 
(Johnson et al., 2013), so it was important that the orientation of the orbit for 
embedding was correctly positioned to have this reference point in the middle of the 
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section.  Thereafter, the orbital tissue was embedded in the same orientation in 
parafﬁn block, serial and step sections as described above were performed starting 
from the lateral side (optic nerve side). Three serial sections were collected after every 
ten sections and subjected separately to H&E and masson’s trichrome (MTC) staining. 
At least three to ﬁve sections (after ten-step sections discarded) were examined. All 
sections have been studied by consultant pathologist (Dr Diaz-Cano, King’s College 
Hospital, London, UK) and also examined by independent colleague (Mrs. Gina-Eva 
Goertz, Essen, Germany with large experience on orbital histology) in double–blinded 
fashion to determine the differences between mice immunised with hTSHR A-subunit 
and control mice in terms of inflammation, adipogenesis, and fibrosis. For double-
blinded examination each slide has been scored based on the histopathological 
parameter including lymphocytic infiltration into orbital tissue, expansion of adipose 
tissue and fibrosis. At the end of double-blinded evaluation, the mice codes were 
revealed and data was assembled. MRI acquisition protocol 
 
In vivo MRI was performed under complete supervision of Dr. Po-Wa So on immune 
(n=8) and age-matched control mice (n=3) on a horizontal bore 7T MRI scanner 
(Agilent Technologies Inc, USA). Anaesthesia was induced and maintained in mice by 
inhalation of a 1-2% isoflurane-oxygen mix throughout imaging. The mouse head was 
located within a 25mm internal diameter quadrature MRI volume coil (PulseTeq Ltd, 
UK). T2-weighted MR images were acquired using a fast-spin-echo (FSE) sequence with 
repetition time (TR), 4s; effective echo time (TE), 60; echo train length of 8, RARE 
factor of 16; field of view (FOV) 26mm x 26 mm; matrix size 256 x 192 (100 μm in-
 121  
 
plane resolution) and 4 averages. Twenty-four contiguous coronal 0.61mm thick slices 
including the eyes and much of the brain were collected (Fig 2.2).  
 
Fig 2.2 A series of contiguous coronal T2w MRI 
A series of Twenty-four contiguous coronal T2-weighted MR images, from the 
front of the head towards the back of the head (A through to X). 
 
The MRI data were then used as scout images for MRI of the right eye at an oblique 
angle, comparable to that for histology. The position of the imaging slices to image the 
eye specifically with respect to the head is shown in Fig 2.3.  
 
 
Fig 2.3 A series of contiguous T2w MRI with axial slices guide. 
A series of contiguous T2-weighted MR images, from the front of the head 
towards the back of the head (A through to P), was used as scout images to 
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guide positioning of imaging slices (shown in blue) for the right eye to visualise 
the orbital muscles.   
 
Twenty-four contiguous 0.4mm thick, 94 μm in-plane resolution, MR images were 
collected from the surface of the eye towards the back of the eye (perpendicular to the 
long axis of the eye, similar to the orientation for histological processing), using a FSE 
sequence with TR, 1400; effective TE, 7.84; FOV, 12mm x 12mm; matrix size, 128 x128 
(94 μm in-plane resolution) and 24 averages (Fig 2.4). Respiration and temperature 
was monitored throughout MRI, with body temperature maintained at 37oC using 




Fig 2.4 A series of contiguous axial T2w MRI. 
A series of Twenty-four contiguous axial T2-weighted MR images, from the 
surface of the eye towards the back of the eye perpendicular to the long axis of 
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2.2.11 Quantification  
 
In this thesis, in order to get a better comparison between different conditions, 
quantification analysis has been done in three parts; infiltration of CD3+ T cell into 
orbital tissue, enlargement of orbital tissue by MRI, and size of eyeball by MRI. The 
method has been used for each of these quantification analysis is described below.     
Quantification analysis of infiltrated CD3+ T cells into orbital tissue for each group of 
immunisation was performed by “cell counter” plug-in of ImageJ (NIH) software. The 
analysis simply performed by uploading 5 different fields (100x magnification) of each 
immunohistochemistry section to the software where the size and colour of CD3+ T 
cells were already defined. For each mouse, mean of infiltrated cells per region of 
interest (ROI) were calculated and presented as CD3+ T cell infiltration index.  
In the axial MR images hypertrophy of extraorbital muscles were readily apparent. To 
confirm hypertrophy of extraorbital muscles we have used  computer based software, 
ImageJ (NIH). ImageJ allowed us to draw a “free hand line” around the muscles and 
then it automatically measured the marked area. The calculated area was then 
multiplied by the thickness of the slice (0.4 mm) to measure the muscle volume at that 
particular area. The same process was repeated for all MR slices where extraorbital 
muscles present. Eventually, the calculated muscle volumes were summed up to 
calculate the extraorbital volume throughout the orbit.      
Finally, the size of eyeball in MR images was quantified in order to assure observed 
proptosis in immune mice is not due to larger size of eyeball. In coronal view of MR 
images in five immune mice and three age-matched controls, diameter of eyeball was 
calculated by ImageJ software. The results are presented in Section 4.3.1.  
  








Development and Characterisation of a  
Preclinical Mouse Model of GO 
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3. Development and characterisation of a preclinical mouse 




As already outlined in the section 1.8, a number of experimental models of Graves’ 
disease in mice and hamster have been developed since the first model described by 
Shimojo and colleagues (Shimojo et al., 1996). This was followed by an outbred mouse 
model immunised with naked hTSHR plasmid (Costagliola et al., 2000). Collectively, 
earlier studies from our laboratory and other groups showed both the Shimojo model 
and naked plasmid model suffer from two main issues; low disease incidence and poor 
disease severity (low activity of TSAbs) (Rao et al., 2003, Seetharamaiah, 2003). The 
development of the experimental model using adenovirus for gene delivery coding for 
human TSHR (hTSHR) by Nagayama and colleagues (Nagayama et al., 2002) and in 
particular the idea of using hTSHR A-subunit instead of full length (Chen et al., 2003) 
has led to a model most widely used for Graves’ disease that has been successfully 
replicated (Gilbert et al., 2006, Land et al., 2006, Mizutori et al., 2006, Wu et al., 2011, 
Ye et al., 2012, Wiesweg et al., 2013) . From hereon, the adenovirus hTSHR A-subunit 
will be referred to hTSHR A-subunit-Ad. Importantly, despite the advantages of this 
experimental model, the model has two major drawbacks; (i) the majority of immune 
response is directed toward the highly antigenic adenovirus capsid antigens, which 
therefore limits the immunisation to maximum two or three injections (ii) the induced 
TSAbs decline rapidly after the last immunisation (McLachlan et al., 2012, McLachlan 
and Rapoport, 2014). Whilst the adenovirus model has been the most popular model 
for Graves’ diseases, careful analysis of the orbital tissue have shown that it does not 
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led to orbitopathy (Nagayama et al., 2002, Gilbert and Banga, 2006, Wiesweg et al., 
2013, Johnson et al., 2013). Along similar lines, a few reported animal models of GO in 
last two decades (Many et al., 1999, Costagliola et al., 2000) have also proved difficult 
to reproduce (Baker et al., 2005). 
In the course of experimental Graves’ disease model in Professor Banga’s laboratory, 
the group recently modified the animal model described by Kaneda and colleagues 
(Kaneda et al., 2007), by immunising hTSHR plasmid in vivo electroporation using 
calliper electrodes (Zhao et al., 2011). It was shown that this model maintains the 
longevity of induced antibody response to TSHR. Strikingly, orbital fibrosis was 
detected in some of animals undergoing experimental hyperthyroidism. This was the 
first sign that orbital manifestation could be induced in animals immunised by hTSHR 
in-vivo electroporation (Zhao et al., 2011).  
Upon observing orbital fibrosis in animals immunised by hTSHR A-subunit plasmid in 
vivo electroporation (Zhao et al., 2011), my PhD project was based upon modifications 
to the Zhao et al procedure to develop an improved mouse model of GO with features 
of orbital inflammation and adipogenesis.  
Earlier studies using hTSHR A-subunit-Ad as immunogen by McLachlan and colleagues 
showed that alteration of the antigenic dose resulted in change of the spectrum of 
anti-TSHR antibodies from TSAbs to TSBAbs (Chen et al., 2004). Therefore, we 
hypothesised that changing the antigenic dose of TSHR A-subunit plasmid prior to in 
vivo electroporation may result in altering the spectrum of induced anti-TSHR antibody 
and T cell responses to the hTSHR (Chen et al., 2004, Cemazar et al., 2006).  
In their early attempts to alter the antigenic dose of plasmid electroporation, in 
preliminary studies, Dr Zhao and Professor Banga altered the injection protocol over a 
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larger area as part of the immunisation evaluation. They tried to achieve this by 
injecting the 50 μl plasmid as separate injections of 5x10 µl in different, but close by 
sites over the shaved quadriceps leg muscle spread over an area of approximate 7 mm 
diameter of leg muscle area (to ensure muscle was covered by the 7 mm calliper plate 
electrode during electroporation). However, this technique was deemed technically 
difficult for large number of animal immunisations in terms of accuracy and 
reproducibility of the injections and not taken further (Zhao and Banga, unpublished 
data). Therefore, the working hypothesis was based on injection of 50µl plasmid over 
the wider surface area instead of a small area limited by the single injection protocol 
described by Zhao and colleagues (Zhao et al., 2011). For my project, the method to 
alter the delivery of the plasmid in an attempt to change the antigenic dose was to 
either inject the plasmid slowly as the needle was penetrated into the muscle or 
alternatively, releasing the plasmid gently from the syringe as the needle was 
withdrawn from the muscle. Small trial experiment showed that the later technique 
was easier to manipulate on the leg muscle of the anaesthetised mouse and thus was 
selected as the method of choice for injections in all the studies reported for the GO 
model.  
To summarise, my modified protocol for the delivery of hTSHR A-subunit plasmid 
involved a deeper injection of the plasmid over a larger muscle area, on the basis that 
this may lead to greater transfection efficiency after in vivo electroporation, resulting 
in alteration of antigenic stimulus. In contrast to the previous findings (Zhao et al., 
2011), modification of plasmid delivery in this manner resulted in marked different 
outcome in the immune response and consequent thyroid function, as well as the 
resultant orbital pathology. These studies are described in this Chapter.  
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3.2 Aims  
 
The objectives of this Chapter deal with induction of experimental Graves’ disease with 
concomitant complications of experimental Graves’ orbitopathy. 
 Set up an experimental mouse model for Graves’ orbitopathy following 
modified immunisation protocol. 
 Evaluation of initiation and progression of any changes to the orbital tissue by 
histological analysis.  
 Characterisation of immunological and biochemical (thyroid function) changes 
in the experimental GO model. 
 Determination of long term consequences of modified immunisation protocol 
in experimental GO model e.g. longevity of anti-TSHR response, maintenance 
of hyperthyroidism.   
 
  




In the following subsection of this Chapter, the results of evaluation for onset of 
Graves’ disease and concurrent orbital manifestations in a total number of 22 immune 
mice will be described. The animals were immunised in three separate cohorts:  
(i) Group 1 immunisation; evaluation of experimental GO model following modification 
of immunisation (8 immune mice sacrificed 6 weeks after end of immunisation),  
(ii) Group 2 immunisation; longitudinal studies on TSHR antibodies (8 immune mice 
sacrificed 9 weeks after end of immunisation)   
(iii) Group 3 immunisation; characterisation of long-term immunity to hTSHR (6 
immune mice sacrificed 15 weeks after end of immunisation).   
Control animals immunised with β-gal and IGF-1Rα plasmids were also described in 
each cohort. 
Finally, a separate cohort of mice, Group 4 immunisation, was immunised with hTSHR 
A-subunit plasmid in vivo electroporation to especially study IGF-1R antibodies which 
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3.3.1 Evaluation of experimental GO model after modification of 
immunisation 
 
Eight mice were challenged with hTSHR A-subunit plasmid by the modified protocol. 
Animals were weighed weekly during the course of immunisation until six weeks after 
end of immunisation. Animals similarly immunised with pTRiEx1.1 neo-IGF-1Rα (n=3) 
and pTRiEx1.1 neo-β-Gal plasmids (n=3) were used as the control group (Appendix 1). 
None of the control mice led to any visible changes in their health or to any histological 
manifestations in thyroid and orbital tissue. Immune animals and controls were 
sacrificed six weeks after end of immunisation. The two exceptions were one immune 
mouse that was selected for hybridoma fusion at four weeks after end of 
immunisation as well as another immune animal that showed severe signs of sickness 
at five weeks after end of immunisation.  
Thyroid glands were studied by histological analysis. Retrobulbar tissue of immune 
animals and controls was examined to evaluate sign of Graves’ orbitopathy which was 
include H&E staining on extraorbital muscles in first instance and then 
immunohistochemistry for CD3+ T cell and F4/80+ macrophages. Two animals showed 
chemosis, which was confirmed by histological studies on tissue form eyelid. Thyroid 
hormone level was measured to confirm histological finding of thyroid gland. 
Therefore, to understand effect of TSHR antibodies in changes of thyroid histology and 
physiology, thyrotropin blocking inhibition immunoglobulin assay was performed. 
Presence of different TSHR antibodies subtypes was also determined. All findings are 
described in detail in the following subsections.  
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3.3.1.1 Changes in weight of immune animals during course of 
immunisation 
 
The weight of the animals during the course of immunisation was monitored at weekly 
intervals. Usually, autoimmune hyperthyroidism results in significant weight loss, 
whereas weight gain is generally an indicator of hypothyroidism.  As mentioned earlier, 
eight mice were challenged with hTSHR A-subunit plasmid and six mice were similarly 
immunised with control pTRiEx1.1 neo-IGF-1Rα (n=3) and pTRiEx1.1 neo-β-Gal 
plasmids (n=3) were weighed weekly during the course of immunisation until six weeks 
after end of immunisation (sacrifice point). Analysis of the animals’ weight 
demonstrated significant weight gain in immune animals that were immunised with 
hTSHR A-subunit in vivo electroporation in comparison with controls. The mice weight 
presented at two time points, one week before last injection where there is no 
significant differences between immune mice and controls, and four weeks after end 
of immunisation that demonstrated a significant weight gain in immune mice (Fig 3.5). 
The result was unexpected since the weight gain suggested hypothyroid status in the 
immune animals.  The ongoing weight gain by the animals during the course of the 
experimental study   was the first exciting indication that the modified immunisation 
protocol may be resulting in a different manifestation of clinical presentation of the 
disease.   
  




















Fig 3.5 Immune mice weight monitoring 
Significant weight gain in Group 1 mice during the course of immunisation with 
pTRiEx1.1 hTSHR A-subunit plasmid (   ) (labeled hTSHR) compared to combined 
groups of IGF-1Rα and β-Gal that labelled as control (  ). 
 
 
3.3.1.2 Histological study of thyroid gland  
 
We next evaluated the thyroid glands of the immune mice in the group, which by 
weight analysis had been suspected for hypothyroid status. Examination of thyroid 
glands by hematoxylin-eosin (H&E) staining showed typical pattern of hypothyroidism 
in seven immune mice. Hypothyroid thyroid glands were characterised by thinning 
epithelial cells as well as disappearance of follicular membrane in some cases. The H&E 
staining (100x magnification) of each immune animal are presented to demonstrate 
hypothyroid gland features as described above (Fig 3.6 A-G). Interestingly, one thyroid 
gland presented with hyperthyroid features (Fig 3.6 H). Hyperthyroid gland 
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characterised by hypertrophy and hypercellularity of the follicular epithelial cells 
without any signs of thyroid inflammation.  
Thyroid glands excised from control animals including both IGF-1Rα and β-Gal mice 
showed normal features of mice thyroid. The normal thyroid tissue appears as closely 
packed follicles consisting of a single layer of thyroid follicular cells surrounding a 
lumen (Fig 3.7).  
 
Fig 3.6 Thyroid histological studies in immune mice of Group 1 
Thyroid histological studies on n=8 mice immunised with hTSHR A-subunit in 
vivo electroporation and sacrificed 6 weeks after end of immunisation. All 
sections are at 100x magnification (A-G) pathological feature of 
hypothyroidism, characterised by thinning epithelial cells and in some instances 
the follicular membrane was almost not visible (H) pathological feature of 
hyperthyroidism, characterised by hypertrophy and hypercellularity of the 
follicular epithelial cells without any signs of thyroid inflammation. 
 
 134  
 
 
Fig 3.7 Thyroid histological studies in control mice of Group 1 
Thyroid histological studies in control mice. All sections are at 100x 
magnification (A-C) n=3 thyroid glands from mice immunised with pTRiEx1.1 
IGF-1Rα with normal features and (D-F) thyroid gland from mice immunised 
with pTRiEx1.1 neo-β-Gal plasmids (n=3) with normal features. The normal 
thyroid characterised with closely packed follicles consisting of a single layer of 
thyroid follicular cells surrounding a lumen.  
3.3.1.3 Studies into retrobulbar histopathology  
 
Establishing the technique of orbital histopathology was an essential component of the 
project. In contrast to the earlier project in Professor Banga’s laboratory (Zhao et al., 
2011), on this occasion we determined to set up a reference point , such as the optic 
nerve in the middle of the section, in the orbital histology as described in the recent 
study by Professor Eckstein (Wiesweg et al., 2013).  Although histology processing and 
studying of mouse orbital tissue is difficult and not straightforward, as part of this 
project, all these procedure have been set up properly.  Optic nerve has been selected 
as a land mark to study extra-orbital muscles and retrobulbar connective tissue 
(Johnson et al., 2013, Wiesweg et al., 2013) (Fig 3.8). Two different methods were tried 
to separate extraorbital muscles from bones and rigid structures. Tissue decalcification 
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was executed as the recommended method from previous project (Zhao et al., 2011).  
However, the results indicated that excision of the bone by dissection had higher 
quality and with less artefact. Fig 3.8 represents histology of orbital tissue from a 
normal mouse showing optic nerve, extraorbital muscles and harderian gland. 
Variability in normal histology of orbital tissue was mostly seen in size of adipose tissue 
around optic nerve. However, this was not comparable with what we reported as 
expansion of adipose tissue in our immune mice.     
 
Fig 3.8 Histology of orbital tissue from a normal mouse 
(A) Orbital tissue including optic nerve (ON), extraorbital muscles and harderian 
gland (HA), 40x. (B) Higher magnification of normal mouse orbital tissue 
focusing on optic nerve and extraorbital muscles (100x).  
Subsequently, orbital samples of immunised mice were studied by using optic nerve as 
a reference point. Animals immunised with hTSHR A-subunit plasmid showed orbital 
pathology, with asymmetric bilateral disease. Two subtypes of orbital pathology were 
recognised: (i) interstitial inflammatory infiltrate into extra-ocular muscle, extending 
into the muscle tissue and isolating individual fibres. Importantly, one animal with 
severe sickness showed a large inflammatory infiltrate around the optic nerve, 
revealing dense perineural inflammatory infiltrate, along with intense intermuscular 
lymphocytic infiltrate dissecting the orbital muscle fibre bundles. (ii) the orbital 
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pathology developed by another animal with extensive adipogenesis, characterised by 
expansion of retrobulbar adipose tissue and widely separating the orbital muscle fibre 
bundles. By immunohistochemistry, the inflammatory cells were identified as CD3+ T 
cells and F4/80+ macrophages; the infiltrate was uniformly negative for B cells using 
anti-mouse B220 mAb.  
The interstitial inflammatory infiltrate into extraocular muscle was clearly 
demonstrated by histological analysis in six immune animals. The H&E staining from 
each immune animal represented to show retrobulbar tissue inflammation, animals 
indicated by their codes (Fig 3.9 A-D, G,H). Importantly, one animal (sacrificed early 
due to severe sickness) showed a large inflammatory infiltrate around the optic nerve, 
revealing dense perineural inflammatory infiltrate, along with intense intermuscular 
lymphocytic infiltrate dissecting the orbital muscle fibre bundles (Fig 3.9 E). One animal 
showed extensive adipogenesis, characterised by expansion of retrobulbar adipose 
tissue and widely separating the orbital muscle fibre bundles (Fig 3.9 F). In all 
presented H&E sections, optic nerve (ON) has been marked to facilitate histological 
analysis. Examination of the orbital tissues by H&E demonstrated that control mice 
had normal appearance of retrobulbar tissue. All histological slides were also examined 
by independent colleague (method was explained in section 2.2.11.2) to provide an 
assurance of the authentic differences between mice immunised with hTSHR A-subunit 
and control mice in terms of inflammation, adipogenesis, and fibrosis (Table 3.2). The 
data from independent examination of histological slides showed less than 10% (3 out 
of 34) variability between double-blind reported histological manifestations and 
expected results based on the immunisation plasmid in all three groups of 
immunisation (Appendix 1).  







Immunisation Plasmid Double-blind examination 






1 59/0 pTriEx-TSHR A-subunit Inflammation of EOM 
2 59/L pTriEx-TSHR A-subunit Inflammation of EOM 
3 59/R pTriEx-TSHR A-subunit Inflammation of EOM 
4 59/2 pTriEx-TSHR A-subunit Inflammation of EOM 
5 60/0 pTriEx-TSHR A-subunit Intense infiltration 
6 60/L pTriEx-TSHR A-subunit Adipose expansion 
7 60/R pTriEx-TSHR A-subunit Inflammation of EOM 









9 61/0 pTriEx-IGF-1Rα normal 
10 61/L pTriEx-IGF-1Rα normal 
11 61/R pTriEx-IGF-1Rα normal 
12 62/0 pTriEx-β-Gal normal 
13 62/L pTriEx-β-Gal normal 








15 63/0 pTriEx-TSHR A-subunit Inflammation of EOM 
16 63/L pTriEx-TSHR A-subunit Inflammation of EOM 
17 63/R pTriEx-TSHR A-subunit Inflammation of EOM 
18 63/2 pTriEx-TSHR A-subunit Inflammation of EOM 
19 64/0 pTriEx-TSHR A-subunit Inflammation of EOM 
20 64/L pTriEx-TSHR A-subunit adipose expansion 
21 64/R pTriEx-TSHR A-subunit normal* 






23 57/0 pTriEx-TSHR A-subunit Fibrosis/EOM inflammation 
24 
57/L pTriEx-TSHR A-subunit EOM inflammation (no 
fibrosis*) 
25 57/R pTriEx-TSHR A-subunit adipose expansion 
26 58/0 pTriEx-TSHR A-subunit Fibrosis/ EOM inflammation 
27 58/L pTriEx-TSHR A-subunit Fibrosis/ EOM inflammation 









29 56/0 pTriEx-IGF-1Rα normal 
30 56/L pTriEx-IGF-1Rα normal 
31 56/R pTriEx-IGF-1Rα normal 
32 55/0 pTriEx-β-Gal normal 
33 55/L pTriEx-β-Gal normal 
34 55/R pTriEx-β-Gal normal 
 
Table 3.2 Double-blinded examination of orbital histology  
The histological manifestations presented in the last column of this table are based on 
the double-blinded examination of all immune mice from three groups of 
immunisations. The histological manifestation is highlighted in red with * if there was 
differences from what was expected.  




Fig 3.9 H&E stained section of retrobulbar tissue from immune mice of Group 
1 
H&E stained section of retrobulbar tissue from individual mice immunised with 
hTSHR A-subunit plasmid. All histological slides are at 100x magnification. (A) 
59/0, (B) 59/L, (C) 59/R, (D) 59/2,  (G) 60/R, (H) 60/2 are shown extraorbital 
muscles changes including infiltration of inflammatory cells clear from 
increasing cellularity in muscle tissue. (E) 60/0, intense infiltrations of 
inflammatory cells around the optic nerve along with intense intermuscular 
lymphocytic infiltrate are clear. (F) 60/L Expansion of adipose tissue in 
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3.3.1.4 Histopathological studies by immunohistochemistry into 
retrobulbar tissue  
 
Subsequently, orbital tissue was used for specific histological studies by 
immunohistochemistry (IHC). Immunohistochemistry studies revealed that the 
majority of infiltrated inflammatory cells in extraorbital muscles were CD3+ T cells. The 
number of infiltrated cells in the orbital tissue varied in different mice. Control mice 
immunised with β-Gal did not show any infiltrated CD3+ T cells in orbital tissue. In 
addition, F4/80+ macrophages were detectable in orbital tissue from animals 
immunised with hTSHR A-subunit plasmid in vivo electroporation significantly more 
than in orbital tissue from control mice. The infiltrate was uniformly negative for B 
cells using anti-mouse B220 mAb.   
Herein below, a representative histopathological section of orbital tissue from each 
immune mice are illustrated to show more detail of two different subtypes of 
infiltrated inflammatory cells in  mice undergoing experimental GO that were 
examined six weeks after end of immunisation. For clearer demonstration, different 
magnifications of H&E staining of retrobulbar tissues in immune mice were presented 
alongside with the next section of immunohistochemistry staining.  
Intense interstitial inflammatory cells infiltration is clearly shown by H&E in mouse 
60/0 (Fig 3.9 A-C), where immunohistochemistry staining confirmed the majority of 
them are CD3+ T cells (Fig 3.9 D-F). Moreover, higher magnifications of H&E staining of 
mouse 60/L clearly demonstrates the adipose expansion that widely separating the 
orbital muscle fibre bundles (Fig 3.0 G-I). Furthermore, immunohistochemistry analysis 
in other immune animals that showed retrobulbar inflammation by H&E (Fig 3.10 A, 
D), revealed infiltration of CD3+ T cells (3.10 B and E) and F4/80+ macrophages (Fig 3.10 
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C and F) into extra-ocular muscle (marked by arrowhead). Quantification analysis in 
number of lymphocytic infiltrated cells in extraorbital mucsels was performed for all 
immune animals (Fig 3.12), the two mice with intense infiltration mostly around the 
optic nerve were delibrately excluded. The quantification data confirmed significant 
differences in number of infiltrated CD3+ T cells between hTSHR immunised mice and 
controls. The number of cells was analysed by ImageJ software on double-blinded 
fashion.      
  




Fig 3.10 H&E and IHC studies in orbital tissue from mice 60/0 and 60/L 
Histopathological study by H&E and IHC in orbital tissue from two mice immunised 
with hTSHR-A subunit plasmid [60/0 (panel A-F) and 60/L (panel G-I)]. (A) H&E staining 
of orbital tissue (100x) showing massive inflammatory infiltrate surrounding optic 
nerve and extraorbital muscles. (B) higher magnification of panel A (400x) to show 
intense infiltration around optic nerve.  (C) higher magnification of panel A (200x) to 
show massive infiltration dissecting the orbital muscle fibre bundles. (D)  IHC in serial 
section of panel A to identify CD3+ T cells showing massive CD3+ T cells (stained in 
brown using DAB as chromogen) infiltrating around the optic nerve and into the orbital 
muscle tissue (100x). (E) higher magnification of panel D (200). (F) higher magnification 
of panel D (200). (G) H&E staining of orbital tissue (100x) showing expansion of 
adipose tissue in retrobulbar fat. (H) higher magnification (200x) to show adipose 
tissue widely separating the orbital muscle fibre bundles. (I) higher magnification of 
panel H to demonstrate two different type of fat (white adipose tissue and brown 
adipose tissue are distinguishable by morphology). 
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Fig 3.11 H&E and IHC studies in orbital tissue from mice 59/0 and 59/L 
Histopathological study by H&E and IHC in orbital tissue from a mouse 
immunised with hTSHR-A subunit plasmid (59/0 and 59/L) sacrificed 6 weeks 
after end of immunisation. (A) H&E staining of orbital tissue (59/0) (100x) 
showing hypertrophy of extraorbital muscles and  interstitial inflammatory 
infiltrate. (B)  IHC to identify CD3+ T cells (arrowhead) showing CD3+ T cells 
(stained in brown using DAB as chromogen) infiltrating into the orbital muscle 
tissue (200x). (C) IHC to identify F4/80+ macrophages (arrowhead) showing 
macrophages infiltrating into the orbital muscle tissue (200x). (D) H&E staining 
of orbital tissue from a mouse immunised with hTSHR-A subunit plasmid (59/L) 
to show hypertrophy and dissecting the orbital muscle fibre bundles (200x). (E)  
IHC to identify CD3+ T cells (arrowhead) showing CD3+ T cells (stained in brown 
using DAB as chromogen) infiltrating into the orbital muscle tissue (200x). (F) 
IHC to identify F4/80+ macrophages (arrowhead) showing macrophages 
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Fig 3.12 Quantification of number of infiltrated CD3+ T cells into retrobulbar 
tissue. 
TSHR Groups 1,2, and 3 are outlined in Appendix 1. Note: two mice showing 
intensive infiltration of CD3+ T cells around the optic nerve (one from Group 1 
and one from Group 3) were excluded. 
The graph shows significant increase in number of lymphocytic infiltrated cells 
in all mice immunised with hTSHR A-subunit plasmid in three different groups 
comparing with control mice immunised with βGal and IGF-1R plasmid. The 
horizental dotted line represent meant+3SD of βGal mice.  
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3.3.1.5 Histopathological studies of chemosis  
 
Graves’ orbitopathy is characterised by orbital muscle inflammation and adipogenesis, 
resulting in expansion of the extraorbital tissue and proptosis. The extension of 
inflammation to eyelids and conjunctiva leads to swelling, redness and oedema which 
is called chemosis  (Dickinson, 2010a).  
From eight mice that were challenged with hTSHR A-subunit plasmid in vivo 
electroporation, two animals showed extraorbital changes with typical signs of acute 
orbital congestion, chemosis. Professor Miles Stanford (Consultant ophthalmologist) 
diagnosed the onset of chemosis in the immune mice. Interestingly, monitoring of 
chemosis over time in the animals showed one animal spontaneously to remit from 
the visual signs of chemosis after few days and the other animal remained congested 
over the period of two weeks of monitoring (Fig 3.13). Histological examination of the 
eyelid showed dilated and congested orbital blood vessels with typical features of 
vascular inflammatory reaction as well as infiltrating mast cells into the tissue (Fig 3.14 
A-C). 
  













Fig 3.13 Appearance of head region of 
hTSHR-A subunit plasmid immunised 













Fig 3.14 H&E stained section of eye lid tissue with chemosis 
(A) Eyelid tissue to show dilated and congested orbital blood vessels, the lens is 
labelled (40x). (B) Higher magnification (100x) to show congested blood vessels 
(arrowed). (C) Higher magnification (200x) to show mast cell infiltration into congested 
eyelid tissue (arrowed). 
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3.3.1.6 Evaluation of thyroid function   
 
 
Following the histopathological analysis of thyroid gland and retrobulbar tissue in 
experimental GO model, evaluation of thyroid function was proceeded to uncover the 
alteration thyroid status. Total T4 measurements in mice undergoing experimental 
thyroid autoimmunity are commonly used for first assessment of endocrine status 
during the course of disease. However, mouse total T4 concentrations are  variable 
and also dependent on the strain (McLachlan et al., 2012), thus it is not the most 
reliable indicators of thyroid function, but are commonly measured in experimental 
models as an indicator of thyroid function (Nagayama et al., 2002, Chen et al., 2003, 
Gilbert et al., 2006). We first determined the range of serum total T4 in 13 normal 
female BALB/c mice.  Absolute values of serum total T4 in normal mice ranged 
between 115.5 and 142.7 nmol/L. Based on these results, statistical analysis indicated 
mean of population and standard deviation (SD) respectively were 126.1 and 9.113.  
Thus, the range of mean- 3SD (95 nmol/L) set as lower range and mean+3SD (156 
nmol/L) set as upper range for normal mice sera and any value out of this range would 
be recognised as abnormal.  
Total serum T4 was measured in the serum samples from immune mice sacrificed 6 
weeks after end of immunization (Fig 3.15). Two animals showed significant reduction 
in total T4, confirming hypothyroidism.  The remaining five immune mice showing 
trend towards lower T4 values which is in close correlating with the findings of 
hypothyroid glands by histology (Fig 3.6 A-G). The one animal with hyperthyroid 
histology showed significantly elevated levels of T4. Coupling thyroid histology and 
total T4 test results confirmed that thyroid status of this set of immune animals have 
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been truly hypothyroid. T4 values in mice similarly immunised with pTRiEx1.1 neo-IGF-
1Rα plasmid and pTRiEx1.1 neo-β-Gal plasmids in vivo electroporation showed not 




Fig 3.15 Evaluation of thyroid function by ELISA in mice sera of Group 1 
Evaluation of thyroid function by ELISA in mice sera obtained 6 weeks after end 
of immunisation. Results indicate significant general downward trend in T4 
level of mice immunised with hTSHR A-subunit plasmid (hTSHR) in comparison 
to non-immune control mice (NMS). There are two immune animals with 
statistically significant decrease T4 level and one with significant increase.  The 
T4 value for animals immunised with IGF-1Rα plasmid and with β-Gal plasmid 
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3.3.1.7 Evaluation of thyrotropin binding inhibition immunoglobulins 
activity (TBII)  
 
The hTSHR A-subunit plasmid in vivo electroporation immunisation in female BALB/c 
mice is recognised for robust antibody responses to TSHR, which persist for months 
after end of immunisation (Kaneda et al., 2007, Zhao et al., 2011). To evaluate immune 
response, thyrotropin binding inhibition immunoglobulin (TBII) level in immune 
animals was measured (Fig 3.16). As the TRAK kits are highly optimised for using 100µl 
serum sample in the assay, due to limiting quantity of mouse serum, the assay was 
modified to use 50 μL mouse serum mixed with 50µl human serum known to be 
negative for TBII activity.  
All immune serum samples showed more than 50% inhibition of 125I-TSH binding 
activity, with the majority of sera showing more than 70% inhibition. Basically, sacrifice 
sera from majority (7 out of 8) of immune mice could inhibit more than 70% of 
radiolabeled bTSH which scored as highly positive. Only one animal from this group of 
immunisation showed 50% inhibition of 125I-labeled bovine TSH which was still far 
more than suggested grey zone by the assay instruction (15%) and control samples (Fig 
3.16). This result showed that hTSHR A-subunit plasmid in vivo electroporation 
immunisation in this group of mice successfully maintain humoral immunity for six 
weeks after end of immunisation which is similar to the finding by former study in our 
laboratory (Zhao et al., 2011).  
 
  




Fig 3.16. TRAK assay in immune mice sera of Group 1 
Measurement of TSH binding inhibitory immunoglobulin activity in Group 1 
mice  by competition with 125I-labelled bTSH (TRAK assay). The ordinate refers 
to % inhibition of 125I-labelled bTSH binding. By the instruction of TRAK kit the 
area between 0-15% inhibition represents the ‘grey’ zone and values above this 
area generally scored positive. The control samples including mice sera that 
immunised with β-Gal plasmid (βGal) and IGF-1Rα plasmid (IGF1R) as well as 
normal human samples (NHS) were proved to be negative.   
 
3.3.1.8 Determination of TSHR stimulating and blocking Abs  
 
The antibodies to TSHR comprise three different types, thyroid stimulation antibodies 
(TSAbs), thyroid stimulation blocking antibodies (TSBAbs) and neutral antibodies (Rees 
Smith et al., 1988). TSAbs mimic the actions of TSH and initiate the TSHR signalling 
cascade leading to hyperthyroidism. In contrast, TSBAbs inhibit the stimulation of TSHR 
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by TSH leading to decrease thyroid hormone secretion (Rees Smith et al., 1988, Jaume 
et al., 1997).  TSHR blocking antibodies binding site is not exactly similar to stimulating 
Abs (Sanders et al., 2007, Sanders et al., 2011, Morshed et al., 2012), however, TSBAbs 
inhibit the binding of TSH to receptor which then leads to hypothyroidism.  On the 
other hand, neutral TSHR antibodies neither block TSH binding site nor induce cAMP 
generation. Thus, determination of anti-TSHR antibody subtypes was necessary.  
To examine subtypes of antibodies to TSHR, there are few different bioassay methods 
(Lytton and Kahaly, 2010). In this study, cell based cAMP endpoint assay was 
performed to measure TSAbs and TSBAbs in mice sera. The JP09 cells, CHO (Chinese 
Hamster Ovary) cell line stably transfected to express full length human TSHR (Perret 
et al., 1990) provides a powerful response when stimulates with TSH or thyroid 
stimulating antibodies. The strength and concentration of TSHR stimulating antibodies 
is directly correlated to production of cAMP from JP09 cells. Examination of TSBAbs in 
mice sera requires an extra step, incubation of cells with sub saturation dose of bovine 
TSH (bTSH).  
The first bioassay experiment was performed to evaluate suboptimal dose of bTSH. 
The bTSH dose response (concentration from 0.005 to 1.6 mU/ml) was demonstrated 
that 0.2 mU/ml bTSH can be used as sub-optimal dose for subsequent studies (Fig 
3.17). In all experiments, Forskolin and KSAb1 mAb (100, 10, 1 and 0.1 µg/ml) were 
used as the positive controls and IgG2b (100 and 10 µg/ml) as the negative control. 
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Fig 3.17 The bovine TSH dose response in cAMP bioassay 
Different concentration from 0.005 to 1.6 mU/ml was tested. Based on the 
results of this experiment the concentration of  bTSH at 0.2 mU/ml was used as 
sub-optimal dose for subsequent studies. The experiment has performed twice 
in different days to assess reproducibility of assay which shows very close 
outcome (less than 5% difference throughout). The inset shows the results of 
different concentration (0.1-100µg/ml) of TSHR mAb (KSAb1), which has been 
done twice. The bar represents standard deviation.  
 
3.3.2 Longitudinal studies on TSHR antibodies during the course of 
disease 
 
To evaluate TSHR antibodies, longitudinal study was performed in a new cohort of 
eight female BALB/c mice. Animals were challenged with 50µl plasmid (1mg/ml) TSHR 
A-subunit plasmid into each biceps femoris muscle with in vivo electroporation.  This 
new group served to evaluate the reproducibility of the model and also serum was 
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analysed from weekly serial bleeds for longitudinal studies. Extra attention was paid to 
retain consistency in each injection of plasmid using modified protocol. Animals were 
sacrificed nine weeks after end of immunisation. In addition, in week seven after end 
of immunisation, some immune animals underwent MRI (see Chapter 4). Serum T4 
measurements showed significantly depressed hormone levels in this new cohort of 
animals. The reduction in serum total T4 and hence hypothyroid status in immune 
animals was replicated. High levels of anti-TSHR antibodies were present at point of 
sacrifice. TSHR antibodies comprised predominantly of TSBAbs, which evolved early 
during the immune response and persisted for several weeks. Histological analysis of 
thyroid glands showed majority of mice with hypothyroid glands. In addition, 
histological analysis of the orbital tissue in this group showed the same pattern of 
orbital pathology as described for the six weeks after end of immunisation group, 
comprising predominantly of interstitial inflammatory infiltrate into extraorbital 
muscle.  Importantly, disease heterogeneity was apparent by histological analysis of 
the orbital tissue. Two animals showed visible chemosis, confirmed by dilated blood 
vessels with accompanying oedema. 
 
 
3.3.2.1 Histological study of thyroid gland   
 
Animals were sacrificed nine weeks after end of immunisation. Interestingly, similar to 
the former group of immune mice, Group 1 immunisation (sacrificed six weeks after 
end of immunisation), histological studies in this cohort of animals predominantly 
showed hypothyroid features in thyroid gland (Fig 3.20 A-F). Thyroid gland from two 
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mice in this group showed hyperthyroidism (Fig 3.20 G, H). Importantly, histological 
analysis of thyroid gland in this cohort of immune animals compare to the former 
group proved reproducibility of animal model with hypothyroidism in mice immunised 
with hTSHR A-subunit.  
 
Fig 3.20 Thyroid histological studies in immune mice of Group 2 
Thyroid histological studies on n=8 mice immunised with hTSHR A-subunit in 
vivo electroporation and sacrifice 9 weeks after end of immunisation. All 
sections are at 100x magnification (A-F) pathological feature of hypothyroidism 
(G, H) pathological feature of hyperthyroidism.   
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3.3.2.2 Studies into retrobulbar histopathology  
 
Animals immunised with hTSHR A-subunit plasmid showed histological signs of orbital 
pathology. Histological analysis of the orbital tissue in this group showed the same 
pattern of orbital pathology as described for the former group of immune mice. Seven 
out of eight immune animals showed interstitial inflammatory infiltrate into 
extraocular muscle, extending into the muscle tissue (Fig 3.21 A-D, F-H). In addition, 
one animal showed extensive adipogenesis, characterised by expansion of retrobulbar 
adipose tissue and widely separating the orbital muscle fibre bundles (Fig 3.21 E). 
 
 
Fig 3.21 H&E stained section of retrobulbar tissue from immune mice of 
Group 2 
H&E stained section of retrobulbar tissue from individual mice immunised with 
hTSHR A-subunit plasmid. All slides are at 100x magnification. (A) 63/0, (B) 
63/L, (C) 63/R, (D) 63/2, (E) 64/0, (F) 64/L, (G) 64/R, (H) 64/2.  
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3.3.2.3 Histopathological studies of chemosis  
 
From eight mice that were challenged with hTSHR A-subunit plasmid by the modified 
protocol two animals showed extraorbital changes with typical signs of acute orbital 
congestion, chemosis (Fig 3.22 A, B). Histological analysis of the animals confirmed 
dilated blood vessels with accompanying oedema (Fig. 3.23 A, B). Interestingly, mast 
cells were readily recognised by morphology. (Fig. 3.23 C). 
 
Fig 3.22 Appearance of head region of two immune mice with chemosis 
Appearance of head region of two mice immunised with TSHR A-subunit 






Fig 3.23 H&E stained section of eyelid with chemosis 
H&E stained section of eyelid congested tissue from mouse head shown in (Fig 
3.27 A) to show (A) dilated and congested orbital blood vessels (arrowed) 
(100x), and (B) highlighting oedema (arrowed) (100x) and  (C) mast cells 
infiltration (arrowed) (400x).  
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3.3.2.4 Evaluation of thyroid function  
 
To confirm histological analysis of thyroid gland from immune animals, thyroid 
function was evaluated in serum obtained 9 weeks after end of immunisation (Fig 
3.24). Similarly to the former cohort of immune mice, results from total T4 test also 
showed a hypothyroid status;. Three animals showed significant depressed values of 
total T4, with one animal very close to the lower border of normal range for T4 values, 
correlating with the findings of hypothyroid glands by histology (Fig 3.20 A-D). Two 
animals with hyperthyroid histopathology (Fig 3.18 G, H) showed significantly elevated 
levels of T4. 
 
 
Fig 3.24 Evaluation of thyroid function by ELISA in immune mice sera of Group 
2 
Evaluation of thyroid function by ELISA in mice sera obtained 9 weeks after end 
of immunisation. Results indicate general downward trend in T4 level of mice 
immunised with TSHR A-subunit plasmid (TSHR) in comparison to non-immune 
control mice (NMS). It also shows that 2 immune animals with significant 
increase T4 level while 3 other immune mice are significantly depressed.    
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3.3.2.5 Longitudinal studies into TSHR Abs  
 
We performed longitudinal studies to evaluate TSHR antibodies. Serum was analysed 
from weekly serial bleeds. All animals were sacrificed nine weeks after end of 
immunisation. At the sacrifice point high levels of anti-TSHR antibodies were present, 
and comprised predominantly of TSBAbs, which evolved early during the immune 
response and persisted for several weeks (Fig 3.25). Basically, six out of eight immune 
mice were highly positive for TSBAbs throughout all points of bleeding (one week 
before last injection to six weeks after end of immunisation). The TSBAbs level in other 
two animals did not show significant increase, although it was weak positive in some 
points.  
The longitudinal study revealed that the TSAbs level in majority of immune mice did 
not increase during the course of immunisation (Fig 3.26). There was only one animal 
showed very high level of TSAbs which gradually decline by time. It is in contrary with 
results provided by adoptive transfer of TSHR autoantibody where the majority of 
TSHR antibody were TSAbs at the beginning point and turn to the TSBAbs after 22 
























Fig 3.25 Longitudinal analysis of TSBAbs  
Longitudinal analysis of TSHR antibodies induced after TSHR A-subunit plasmid-
in vivo electroporation in individual eight immune mice in Group 2 
immunisation. Serum samples were collected for TSHR antibody analysis on a 
weekly basis. The ordinate shows week when serum sample collected, with the 
first sample collected one week before the end of immunization (labelled -1), 
with all subsequent bleeds collected weekly until 6 weeks end of immunization. 
Measurement of blocking TSBAbs as % inhibition of TSH mediated stimulation 
(abscicca). Six animals were highly positive for TSBAbs, which evolved early 
during the immune response and persisted for several weeks.  
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Fig 3.26 Longitudinal analysis of TSAbs 
Longitudinal analysis of TSHR antibodies induced after TSHR A-subunit plasmid-
in vivo electroporation in individual eight immune mice in Group 2 
immunisation. Serum samples were collected for TSHR antibody analysis on a 
weekly basis. The ordinate shows week when serum sample collected, with the 
first sample collected one week before the end of immunization (labelled -1), 
with all subsequent bleeds collected weekly until 6 weeks end of immunization. 
Measurement of TSAbs shown as cAMP responses (pmols/ml) of serum sample 
bleeds (abscicca). Note the one animal positive for TSAbs, which gradually 
decline with time.  
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3.3.3 Characterisation of long-term immunity to hTSHR  
 
The hTSHR A-subunit plasmid in vivo electroporation model in female BALB/c mice is 
recognised for robust antibody responses to TSHR, which persist for months after end 
of immunisation (Kaneda et al., 2007). To study long-term effect of modified 
immunisation in ongoing immune animals, a group of six animals were immunised, 
Group 3 immunisation. Histopathology of thyroid and retrobulbar tissues as well as 
hormone and antibody levels examined 15 weeks after end of immunisation. In 
addition to six animal immunised with pTRiEx1.1 neo-hTSHR A-subunit plasmid in vivo 
electroporation, control animals immunised with pTRiEx1.1 neo-IGF-1Rα (n=3) and 
pTRiEx1.1 neo-β-Gal plasmids (n=3) were also  examined 15 weeks after end of 
immunisation (Appendix 1). Antibodies to TSHR that persisted for 15 weeks, 
demonstrated 4 out of the 6 animals with strong TSBAb antibodies with weak TSAbs.  
H&E examination of orbital tissue was characterised by orbital muscle fibrosis, which 
by Masson’s Trichrome staining exhibited extensive deposition of glycosaminoglycans 
with pericellular fibrosis in retrobulbar tissue. Thyroid gland histology from five out of 
the six animals showed hypothyroid status. 
 
3.3.3.1 Studies into retrobulbar histopathology  
 
Orbital tissue of immune animals and controls were examined by histological analysis. 
H&E stained sections of immune animals demonstrated inflammation in retrobulbar 
tissue. Inflammed retrobulbar tissue in immune mice was characterised by 
inflammatory cells infiltration into the extraorbital muscles that were confirmed by 
immunohistochemistry. A representative figure of H&E stained section of orbital tissue 
from immunised mice with pTriEx-hTSHR A-subunit plasmid are shown in Fig 3.30 A-I. 
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Interestingly, one immune mouse demonstrated intense lymphocytic infiltration in 
retrobulbar tissue particularly around the optic nerve (Fig 3.31 A-C). Moreover, 
another immune mouse showed excessive adipogenesis (Fig 3.31 D-F). In addition, 
fibrosis in orbital muscles by Masson’s Trichrome staining exhibited extensive 
deposition of glycosaminoglycans with pericellular fibrosis in retrobulbar tissue (Fig 
3.32 A-F).
 
Fig 3.32  Masson’s Trichrome staining in mice from Group 3  
Masson’s Trichrome staining to detect fibrosis in the retrobulbar tissue of mice 
were immunised with pTriEx-hTSHR.  
 
 
3.3.3.2 Evaluation of thyroid function  
 
Thyroid hormone level (total T4) was investigated in sera collected from immune mice 
sacrificed at 15 weeks after end of immunisation (Fig 3.31). Results from total T4 test 
proved thyroid histopathology. Interestingly, in this cohort of immunisation there was 
not any elevated T4 level as it expected from thyroid histology. Two mice showed 
significant depressed values of total T4, with remaining four mice showing a trend 
towards lower T4 values, correlating with the findings of hypothyroid glands by 
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histology (Fig 3.26 A-G). T4 values in mice similarly immunised with pTRiEx1.1 neo-IGF-
1Rα plasmid and pTRiEx1.1 neo-β-Gal plasmids in vivo electroporation showed not 
significant changes from normal mice sera.
 
 
Fig 3.33 Evaluation of thyroid function by ELISA in mice sera from Group 3 
Evaluation of thyroid function by ELISA in mice sera obtained 15 weeks after 
end of immunisation. Results indicate general downward trend in T4 level of 
mice immunised with TSHR A-subunit plasmid (TSHR) in comparison to non-
immune control mice (NMS). It also shows that 2 immune mice with 








In the studies described in this Chapter, a total number of 22 mice were evaluated in 
depth for onset of Graves’ disease and concurrent orbital manifestations following the 
modified immunisation protocol with hTSHR A-subunit plasmid in vivo electroporation, 
together with 12 control mice immunised with pTRiEx1.1 neo-IGF-1Rα (n=6) and 
pTRiEx1.1 neo-β-Gal plasmids (n=6). In addition, following the publication of the latter 
data(Moshkelgosha et al., 2013), another cohort of mice (n=8) was immunised with 
hTSHR A-subunit plasmid in vivo electroporation to especially study IGF-1R antibodies 
which will be discussed later in Chapter 5 (Appendix 1).  
This study was initiated based upon the earlier study from our laboratory which 
showed that hTSHR A-subunit plasmid in vivo electroporation led to the onset of 
Graves’ hyperthyroid disease (disease incidence of 66%) accompanied in some animals 
with fibrosis in orbital tissue (Zhao et al., 2011). Having successfully obtained 
experimental Graves’ disease with the new model accompanied by signs of orbital 
disease, the objective of my project was to modify the immunisation procedures in an 
attempt to induce experimental disease accompanied by bona fide GO. Earlier, 
preliminary studies from our laboratory to modify the immunisation procedure by 
reducing the concentration of hTSHR A-subunit plasmid from 50µg to 25µg led to a 
dramatic reduction in disease incidence to 12.5% (Zhao and Banga, Unpublished data). 
In other preliminary experiments to modify the delivery of the plasmid injection, we 
attempted giving the injection of 50µl plasmid in five closely, but separate areas of the 
leg muscle to increase the surface area of the injection site prior to the 
electroporation. However, we found that 5x10µl injections in a small localised area 
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was technically difficult to replicate and too demanding. In order to pursue with 
alteration of the antigenic dose of hTSHR A-subunit plasmid, we aimed to ‘spread’ 50 
μg of plasmid over wider area of muscle. This was achieved during the injection 
procedure by slow withdrawal of the needle as the plasmid was injected, resulting in a 
‘wider spread’ of the plasmid in the leg muscle. For reproducibility, this method was 
performed with great care and was remarkably successful in inducing the onset of 
orbital pathology in the model.  
In comparison with study reported by Dr Zhao and colleges (Zhao et al., 2011), the 
modification of plasmid delivery resulted in marked different outcome in the immune 
response and consequent thyroid function, as well as the resultant of orbital 
pathology.  The comparison  between  previous study in our laboratory (Zhao et al., 
2011) and Group 1 of immunisation in this study, is reasonably legitimate as the 
immune animals in both the different studies were evaluated  at six weeks after end of 
immunisation. Surprisingly, however the outcome of thyroid function following the 
two immunisations procedures was dramatically different. Hyperthyroidism was 
induced in 8 out of 12 immune animals (66%) in the Zhao et al study, compared to 1 
out of 8 immune animals (12.5%) in Group 1 in this study. Moreover, the modified 
protocol induced dramatic remodelling of the orbital tissue. The different pathological, 
immunological and thyroid function outcomes in the Zhao et al study and the model 
described herein are not due to a change in the commercial supplier of the mice 
(Harlan Laboratories, UK) nor in the rodent chow diet with an iodine content of 
1.2mg/Kg (Zhao et al., 2011). In addition, the animal unit housing conventional clean 
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rooms for the mice in the Zhao study and the unit housing the animals in this study 
was unchanged.  
Thus, we conclude that the modification in the plasmid immunisation resulted in a 
dramatic different outcome in the immune response to TSHR (Chen et al., 2004) with 
resultant orbital pathology. Interestingly, a recent study in an experimental optic 
neuritis inflammation which is one of the first complications of multiple sclerosis (MS) 
clearly emphasised that alteration in antigenic dose led to different outcome of the 
disease conditions (Soares et al., 2013). Soares and colleagues showed that injection of 
either 100 µg or 300 µg of a peptide immunoge (MOG35–55) in complete Freund's 
adjuvant, resulted in a different immune response during the course of disease 
development and also different forms of evolution of optic neuritis. In our study, 
although we have not altered the immunogenic dose, the modification of 
immunisation has changed the immune response as well as orbital pathology 
(Moshkelgosha et al., 2013). 
For the GO model developed in this thesis, the contribution of environmental 
pathogens to the onset of orbital disease is not known, since an independent group of 
animals has not been evaluated under specific pathogen free (SPF) conditions. 
Infection is an important environmental factor for development of Graves’ disease, 
particularly with the bacterium Yersinia enterocolitica (Bech et al., 1974, Lidman et al., 
1974, Shenkman and Bottone, 1976). Our animal unit is tested quarterly for a wide 
range of pathogens, with no new or opportunistic infections reported. It would be in 
particular interest to compare the histopathological results of immune mice 
maintained in SPF or conventional clean rooms to address this issue. Interestingly, the 
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adenovirus model demonstrates no major difference in the development of 
experimental Graves’ disease when the animals were housed under SPF conditions 
(Nagayama et al., 2002, Chen et al., 2003, Ye et al., 2011, Wu et al., 2011, Ye et al., 
2012) compared to animals housed in conventional clean conditions (Gilbert et al., 
2006, Johnson et al., 2013). 
The results of this Chapter clearly demonstrate the hypothyroid status in the immune 
animals. Hypothyroidism status has been confirmed by histological analysis of thyroid 
gland, total T4 level in the immune mice sera and significant weight gain. Examination 
of thyroid glands of GO experimental model by H&E staining shows typical pattern of 
hypothyroidism, with features including of thinning epithelial cells. In addition to 
histological analysis of thyroid gland, significant weight gain in immune mice during 
course of disease suggests the under activity of thyroid gland i.e. hypothyroidism. 
Furthermore, total T4 level in immune mice sera demonstrates significant downward 
trend in comparison to controls. The gold standard assay for determining thyroid 
status in the experimental model of Graves’ disease is measurement of mouse TSH 
(mTSH). A number of highly sensitive assays have been described for assessing serum 
mTSH level (Carayanniotis et al., 1995, Pohlenz et al., 1999, Zhu et al., 1999, Shibusawa 
et al., 2000, Schneider et al., 2001, Li and Carayanniotis, 2007). However, as the 
hypothyroid status has been shown by a variety of different regimes including thyroid 
histology, reduction in weight and total T4 level, the majority of animals in this study 
are hypothyroid; although, mTSH has not been evaluated.  We have considered using 
available commercial assays for measuring mTSH. All the available commercial kits are 
based on ELISA and have drawbacks such as requiring large serum volume (100µl) and 
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also suffer from a wide range of coefficient variation (CV). Moreover, the commercial 
assays use mTSH concentration measured as units of activity to quantify the 
concentration of mTSH in the assays. Although, we contacted company 
representatives to tackle these technical issues, we decided not to spend more time, 
effort, and valuable resources in measuring mTSH concentrations using these 
commercial kits.     
3.5 Summary  
 
To summarise the overall pathological findings in this study, 22 immune animals have 
been studied in depth following the modified immunisation protocol with hTSHR A-
subunit plasmid in vivo electroporation. All animals show asymmetrical bilateral orbital 
pathology, comprising of inflammation of extraorbital muscle. Importantly, disease 
heterogeneity was apparent in some immune mice showing discreet orbital pathology, 
with two animals showing a large inflammatory infiltrate around the optic nerve and 
three animals with extensive adipogenesis accompanied by expansion of retrobulbar 
adipose tissue. Fibrosis in the retrobulbar tissue was apparent towards the end stage 
of disease when immune animals left for long time. Three animals showed signs of 
chemosis. None of the 12 animals immunized with control plasmids show any orbital 
pathology or disease. Orbital pathology of all 22 immune mice is summarised in 













Neuroradiological analysis in experimental GO model   
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4. Neuroradiological analysis in experimental GO model 
4.1 Introduction  
 
Graves’ orbitopathy usually affects both the eyes symmetrically. However, in 15% of 
patients, it is asymmetric bilateral or unilateral (Muller-Forell and Kahaly, 2012). The 
clinical manifestation in most of GO patients are readily diagnosed by obvious lid 
retraction combined with proptosis and most likely with Graves’ disease history 
(Dickinson, 2010b). But, for accurate diagnosis in patients with asymmetric bilateral or 
unilateral protrusion or suspected optic neuropathy, orbital imaging is necessary (Fig 
4.1). Also, prior to decompression surgery, neuroradiological imaging is required to 
assess pathology (Pitz, 2010).  
 
 
Fig 4.1 Axial T1w MRI of a GO patient 
Axial T1w MRI showing unilateral orbital proptosis in the course of Graves’ 
disease. The distance, taken perpendicular to the connecting line gives a 
quantitative value for protrusion. The picture is adapted from Muller-Forell and 
Kahaly, 2012 . 
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There are different  imaging methods in neuroradiological clinics to study orbital 
manifestation of GO patients including orbital ultrasound and echography scanning, 
magnetic resonance (MR) imaging, computed tomography (CT) and positron emission 
tomography-computed tomography (PET/CT) (Kahaly, 1996, Muller-Forell et al., 1999, 
Kahaly, 2001, Aydin et al., 2003, Kahaly, 2004, Muller-Forell and Kahaly, 2012, Garcia-
Rojas et al., 2013).  
 
4.1.1 Clinical neuroradiological methods 
 
4.1.1.1 Magnetic resonance imaging  
 
Magnetic resonance imaging (MRI) has the unique ability to provide cross-sectional 
images of the interior of the body. Particularly, MR images give an excellent contrast to 
study soft-tissues. The principle of magnetic resonance phenomenon is the magnetic 
properties of atomic nuclei particularly those with an odd number of protons. Thus, 
each atom of the simplest and most abundant element in the body, hydrogen, behaves 
as a small magnetic dipole (Fig 4.2 panel 1). In the presence of static magnetic field, all 
hydrogen atoms align in and tumble around the direction of the magnetic field which is 
called precession (Fig 4.2 panel 2-4). By applying an external radio frequency current 
at the precession frequency, the hydrogen nuclei can be flipped (90o) in the magnetic 
field which is called excitation (Fig 4.2 panel 5).  After termination electromagnetic 
field, the spin of the hydrogen nuclei returns to its prior state (relaxation) by emitting 
electromagnetic waves (Fig 4.2 panel 6) (Westbrook and Kaut Roth, 1998). The radio 
frequency of emission waves can be monitored to generate an image based on the 
brightness of signals (Wichmann, 2002).   
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As the emitting electromagnetic waves are measures during the time of relaxation, it is 
important to know how long it takes that most of the protons back to their 
thermodynamic equilibrium.  The relaxation time that needs to be given to the 
“longitudinal” magnetic protons to mostly recover (63%) after being flipped is called 
the T1 relaxation. In addition to T1 relaxation, T2 relaxation time represents the given 
time to decay the measuring magnetic resonance signal.  
 
 
Fig 4.2 Basic concepts of MR imaging.  
Adapted from Westbrook and Kaut Roth, 1998.  
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Generally, MR images are based on the type of relaxation and concentration of water 
in the biological tissues. So, if the MR images acquire with the setup of T1 relaxation it 
will be called T1-weighted (T1w) and it will be T2-weighted (T2w) when using T2 
relaxation. High concentration of water (hydrogen) in the tissue cause to generate 
bright pixel (high signal) in the image with T2w characterisation, but low signal in T1w 
(Wichmann, 2002) as clearly shown in Fig 4.3. 
 
 
Fig 4.3 The differences between T1w and T2w in MRI of orbital tissue 
(a) Coronal T1w MRI of patient with Graves’ disease with asymmetry of the 
muscle involvement (b) Corresponding T2w fat suppressed, with bright signal of 
acute inflammation in the extraorbital muscles of left eye. The picture was 
adapted from Muller-Forell and Kahaly, 2012 . 
 
The standard neuroradiological protocols for imaging of orbital tissue are; (i) T1w 
image of the transverse, coronal sections, (ii) T2w (fat suppression) image of the 
transverse, coronal and parasagittal section. The most informative MRI scan for GO 
patients is acquired with 3 mm thickness slice of coronal view (perpendicular to the 
axis of the optic nerve) in combination with axial view as  shown in Fig 4.4 (Muller-
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Forell and Kahaly, 2012). This combination of MRI scans will reveal hypertrophy of 




Fig 4.4 The standard protocol of neuroradiology for GO patients  
(a) Axial T2w MR of a GO patient with hypertrophy of extraorbital muscles. (b) 




4.1.1.2 Computed tomography  
 
Computed tomography (CT) is the first and still most routinely used modern imaging 
technique that provides high accuracy in anatomical imaging. The distinctly different X-
ray absorption allows distinguishes between various biological tissues by measuring 
their different densities. The rotating X-ray-tube and detector system in the helical 
technique provides continuous radiation that results in faster scan acquisition and 
higher resolution (Ohnesorge et al., 1999). Apparently, the main concern in CT is the 
radiation burden, particularly for orbital scan as the lens is the most sensitive organ for 
radiation exposure (Maclennan, 1995, Maclennan and Hadley, 1995). Generally, in 
comparison to MR imaging, the CT examination of the orbit is less expensive, less time 
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consuming and higher availability with relatively comparable image quality. For GO 
patients, the standard protocol is quite similar to MRI acquisition protocol including 
axial and coronal view. The axial intersection provides the image parallel to the optic 
nerve and the coronal view acquire image of perpendicular to the axis of the optic 




Fig 4.5 The CT scan of orbital region from a patient with GO 
(a) Axial view of the orbital region showing bilateral enlargement of the 
extraorbital muscles and orbital protrusion. (b) Corresponding coronal view. 
The picture was adapted from Muller-Forell and Kahaly, 2012 . 
 
4.1.1.3 Orbital ultrasound and octreotide scanning 
 
The ultrasound examination of orbits in GO patients is far less informative in terms of 
disease activity and precise anatomical structure in comparison to earlier mentioned 
techniques. The beneficiary advantages are fast speed, low costs and lack of radiation 
(Prummel et al., 1993, Benning et al., 1994). The other disadvantage of ultrasound 
examination of extraorbital muscle volume in GO patients is that it is highly 
investigator dependent (Kahaly, 2001, Kahaly, 2004). Thus, this technique is not a 
recommended method for clinical investigation of GO in presence of CT or MRI.  
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The other semi objective and fairly sensitive technique that has been used for 
measurement of extraorbital muscle volume in GO patients is octreoscan (Kahaly et al., 
1995a, Kahaly et al., 1995b, Kahaly et al., 1998, Krassas and Kahaly, 1999, Gerding et 
al., 1999). The positive results of octreoscan are reliable and patient should be treated 
while negative results will not reveal much information about the disease. The 
disadvantages of octreoscan are the high cost per image and its radiation burden; 
although, it is less than CT (Forster et al., 2000).  
 
4.1.2 Preclinical imaging studies 
 
A reliable method to study soft tissue in the experimental model is in vivo imaging. MRI 
is a non-invasive imaging modality which provides highly accurate qualitative and 
quantitative images of the anatomical structures. The recent technical advances in 
small animal MRI instruments made it a popular modality in preclinical research. The 
two main advantages that MR imaging provides to preclinical research are (i) in vivo 
studies on live animal repeated at different time points (non invasive longitudinal 
analysis) and (ii) high resolution images of soft tissue. As the imaging subject in the 
preclinical MRI is much smaller than the clinical MRI, factors affecting resolution are 
intensified to achieve a high quality MR image. Factors affecting resolution include 
receiver coil size, magnetic field strength and most importantly image acquisition time. 
In most of the preclinical MRI centres, the magnetic field is 7.0 T instead of 1.5 or 3.0 T 
in clinical scanner. Furthermore, animals for MRI scans are anesthetised which allows 
acquiring images with much longer acquisition time in comparison with clinical MRI 
protocol. In the small animal MRI, the term "magnetic resonance histology" (MRH) 
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(Johnson et al., 1993), describes the specific image resolution by MRI, which is 
comparable to the resolution achievable by histological methods, less than 100 µm. 
The technology and hardware design for MRH were described over two decades ago 
(Budinger and Lauterbur, 1984, Chance, 1989, Johnson et al., 1993). The typical 
preclinical MRI scans are acquired to determine the volume or surface area of a 
specific tissue in murine experimental model. The optimal tissue contrast can be 
provided by selecting the specific imaging sequence and other parameters. Acquired 
MRI data are then analysed to measure signal intensities to calculate surface areas or 
volumes.  
 
4.1.3 Anatomy of mouse orbit and differences with human orbital 
structure  
 
To analyse the anatomical changes by MRI and to be able to interpret the MR images 
results based on the MRI in GO patients, it is necessary to precisely know the anatomy 
of orbital structure in mice and the differences with human orbits. Thus as part of 
background, anatomy of mouse orbit is described here.  
The orbital contents are protected  in orbital cavity by eight bones in mice; maxilla, 
lacrimal, zygomatic, frontal, temporal, sphenoid, ethmoid and palatine (Smith, 2002). 
The depth of the mouse orbit, including the eye, is approximately 5 mm (Paterson and 
Kaiserman-Abramof, 1981). In rodents, in addition to six extraorbital muscles including 
four rectus muscles; superior, inferior, medial and lateral and two oblique muscles; 
superior oblique muscle and inferior oblique muscle that can be found in all mammals, 
there is a retractor bulbi muscle that surrounds the optic nerve (Pachter et al., 1976). 
The oblique muscles lie outside the ring formed by the rectus muscles. Another 
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important anatomical difference in orbital region between mice and human is the 
presence of the harderian gland in rodents.  In mice, the extraorbital muscles are 
surrounded by the harderian gland which occupy much of the space in the orbital 
cavity (Paterson and Kaiserman-Abramof, 1981). The gland has a horseshoe shape with 
the concave surface closely in contact with the superior aspect of the globe. The 
Harderian gland has a pinkish-grey colour (Cohn, 1955). The anatomy of harderian 
gland has well-defined, but its function has remained obscure. It is found exclusively in 
animals with a nictitating membrane, to which its excretory duct is attached. Harderian 
secretions are thought to lubricate the nictitating membrane and may also be 
important in maintaining the tear film (Cohn, 1955).   
4.1.4 Preclinical MRI in experimental GO model  
 
In this chapter, we describe the development of MRI scanning method in orbital region 
of the experimental GO model. In addition, it will be discussed the importance of MRI 
data in future translational research. Immune animals undergoing orbitopathy have 
been examined by MRI which provided an undoubted evidence to study macroscopic 
view of orbital manifestations in live animals. For the imaging studies, animals were 
selected from the group of immunisation of longitudinal studies (sacrificed 9 weeks 
after end of immunisation). The histopathological studies of these animals were 
already described in Chapter 3.  
Briefly, in 7 weeks after end of immunisation, immune animals (n = 5) examined by in 
vivo MRI to assess pathological changes in orbital region. Furthermore, age matched 
normal female BALB/c mice (n=3) were imaged as control. For each mouse, 
anaesthesia was induced and maintained by inhalation of a 1-2% isoflurane-oxygen 
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mix throughout imaging. Two distinct orientations have been chosen to acquire MR 
images, coronal and axial. For coronal view, T2w MR images were acquired with 100 
μm in-plane resolution. The MRI data were then used as scout images for MRI of the 
right eye at an oblique angle, axial view. For axial view, 94 μm in-plane resolution MR 
images were collected from the surface of the eye towards the back of the eye 
(perpendicular to the long axis of the eye, similar to the orientation for histological 
processing). The data from MR imager then analysed to work out pathological 
differences between immune animals and age matched controls. All animals were then 
humanely destroyed at 9 weeks after end of immunisation (Moshkelgosha et al., 
2013). Interestingly, Kuriyan and colleagues showed a similar analytical method for 
studying retrobulbar tissue changes in GO patients with MRI/CT (Kuriyan et al., 2013). 
By using this method they could distinguish two subtypes of GO in human patients (will 
be discussed later in this chapter).  
  




The main purpose of this Chapter was to investigate the feasibility of using preclinical 
MRI as non invasive technique, alternative to histopathology. The objectives of this 
Chapter deal with quantitative and qualitative imaging of the orbital morphology in the 
GO experimental model developed in female BALB/c mice immunised with hTSHR A-
subunit plasmid in vivo electroporation, including: 
 Development of high resolution MRI scanning method in orbital tissue in the 
experimental GO model  
 Quantitative analysis of MRI of orbital tissue from the experimental GO model.  
 Correlation of orbital histology with MRI in the experimental GO model 
 Correlation of MRI of the experimental GO model with clinical 








To our knowledge, this is the first time that a neuroradiological analysis by small 
animal MRI method was conducted in extraorbital muscles. So, we had to characterise 
different parameters including imaging orientation. Based on the imaging orientation 
protocol for orbital MRI in clinical neuroradiology (Muller-Forell and Kahaly, 2012) and 
with consultations from Dr Neil Deasy (clinical neuroradiologist, King’s College Hospital 
NHS Foundation Trust, London), we decided to perform coronal view and axial view.          
 
4.3.1 Coronal view, to identify proptosis of the eye in the GO model  
 
The coronal in vivo MRI was performed in mice immunised with hTSHR A subunit in 
vivo electroporation (n = 5) and age matched control mice (n = 3).  T2w MRI images 
were acquired of the eyes and frontal region of the brain in anesthetised animals (Fig 
2.2). Importantly, coronal MR images of the mouse head readily identified unilateral 
proptosis in two of five immune mice (Fig 4.6, 4.7), proptosis in the later immune 
animal was less pronounced, compared with the control mouse (Fig 4.8). Unilateral 
protrusion had been apparent on visual inspection of the immune animals but was 
readily confirmed by in vivo MRI. In addition, an extra quantification analysis has been 
performed to make sure what we reported here as proptosis is authentic and not due 
differences in the size of orbital globe (Fig 4.9).   
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Fig 4.6 Contiguous coronal view T2w MRI of mouse 64/R with orbital 
protrusion 
Contiguous coronal view T2-weighted MR images (imaging slice thickness of 
0.61mm) of the head of an immune mouse 64/R are shown from A to H. Clear 
proptosis of the right eye compared to the left eye is observed even from the 
front of the eye through to the back of the eye (from image C through to E). 
The right eye clearly protrudes from the outline of the mouse head (highlighted 
by a white arrow) as defined by the high signal intensity of subcutaneous 
adipose tissue compared to the left eye which does not exhibit proptosis. 
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Fig 4.7 Contiguous coronal view T2w MRI of mouse 64/L with orbital 
protrusion 
Contiguous coronal view T2-weighted MR images (imaging slice thickness of 
0.61mm) of the head of an immune mouse 64/L are shown from A to F. Less 
pronounce proptosis than mouse 64/R (Fig 4.6) of the right eye compared to 
the left eye is observed through to the back of the eye (from image B through 
to D). The right eye clearly protrudes from the outline of the mouse head 
(highlighted by a white arrow).  
 
  




Fig 4.8 Contiguous coronal view T2w MRI of control mice  
Contiguous coronal view T2-weighted MR images of the head region of three 
age-matched controls (AM1-AM3), AM1 is shown in A to F, AM2 in G to L and 
AM3 in M to S. It is clear that none of the age-matched controls show 
protrusion in either left or right eyes. The lack of eye protrusion in age-matched 
controls was defined by orbital location based on the surface of the head 
region. The head outline is defined by the high-signal intensity of subcutaneous 
fat.  
 
Fig 4.9  Diameter of eyeball in immune and age matched control mice 
Quantitative analysis confirmed that proptosis that has been reported is not 
due to differences between the sizes of eyeball.    
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4.3.2 Quantification of extraorbital muscle hypertrophy  
 
It was clear from MR images of axial view that there was a difference in the size of 
extraorbital muscles in immune animals compare to age matched controls. The 
optimal method to evaluate the differences in extraorbital muscles was to measure 
orbital muscle volumes from the MR images. Recently Dr Feldon and colleagues 
suggested a quantitative method to measure enlargement extraorbital muscles in GO 
patients (Kuriyan et al., 2013).  Based on their method, a ratio of the total extraorbital 
muscles area to orbit area (EMA:OA) was calculated. Technically, the superior rectus 
and the levator palpebrae superioris were measured together due to the closeness of 
these muscles (Kuriyan et al., 2013). However, in our study, we were unable to use the 
exact method to show enlargement of specific muscles due to limitations of MRI 
resolution in preclinical setting. Thus, the quantification of -orbital region confirmed 
significant enlargement of retrobulbar tissue in immune animals (Fig 4.11-4.15) 
compared with the age-matched controls (Fig 4.16-4.18). For this purpose, ImageJ 
(NIH) was used to measurement of the volume of the orbital muscle of the right eye. 
The results of quantification of extraorbital volume are presented in Fig 4.19. 
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Fig 4.19 Quantification of MRI showing hypertrophy in the retrobulbar tissue   
Enlargement of the retrobulbar tissue shown as EOM volume in mm3 (abscissa) 
in the immune mice compared with age matched control mice. The 





4.3.3 Alignment of MRI results with histological studies 
 
The high resolution MR imaging of orbital region in preclinical model of Graves’ 
orbitopathy clearly showed quantifiable enlargement of the retrobulbar tissue. As 
there was no literature reference for MR images analysis in extraorbital muscles in 
mice and due to the limitations of MRI resolution in preclinical setting, we aligned the 
MRI results with histological analysis of orbital region to get a better interpretation of 
the MRI data. For this reason, we purposely acquired axial MR images along the optic 
nerve exactly as the subsequent histological analysis of the same eye, following 
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alignment of MRI with histology is to confirm hypertrophy of extraorbital muscles that 
has been readily apparent in MRI by another method.  
As it was clear from MRI analysis of retrobulbar tissue, the enlargement mostly 
involved superior area of muscles (in the concave region of harderian gland). 
Interestingly, histological analysis of extraorbital muscles in mice undergoing 
experimental GO exhibited the hypertrophy of same muscles, rectus superior and 
oblique superior (Fig 4.20) compared to age-matched controls (Fig 4.21). For precise 
analysis, extraorbital muscles volume has been measured in the histological slides. To 
quantify extraorbital muscles volume, the same method, image analysis by ImagJ, was 
recruited which had been used for analyses of MR images. The quantification of 
extraorbital muscles volume in histological analysis from experimental GO mice 
demonstrated an increase trend compared to age-matched control mice (Fig 4.22 A). 
Strikingly, the quantification analysis has been revealed a significant hypertrophy in 
experimental GO mice when superior muscles were analysed specifically (Fig 4.22 B).  
It is important to aware of the differences between the absolute value for muscle 
volume in MRI and histology. As it already described in the method of quantification, 
the measurement of volume is based on the mathematical algorithm of roundup 
measurement which apparently consist of quantisation error. The more slices that 
were measured the lower quantisation error. Thus, the extraorbital muscle volume is 
more realistic in the histological analysis in comparison with MRI. It would be 
suggested reducing thickness of slices (increasing number of slices) in MRI to obtain 
more precise quantification. However, the challenge for reducing thickness of slices is 
the time of acquiring image would be increased.  
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Fig 4.20 Alignment of MR images with histology of extraorbital muscles in 
mice undergoing GO 
All MR images (left column) are contiguous axial view T2-weighted, 
perpendicular to the long axis of the eye. Harderian gland (HA) and optic nerve 
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(ON) marked in images. Extraorbital muscles (EOM), structures are clearly 
obvious from histological slide of the same area aligned with MRI (right 
column). A, B mouse code 63/2, C, D mouse code 64/0, E, F mouse code 64/L, 
G, H mouse code 64/R, A, B mouse code 64/2, I, J mouse code 63/2.  
 
 
Fig 4.21 Alignment of MRI with histology of extraorbital muscles in control mice  
All MR images (left column) are contiguous axial view T2-weighted, perpendicular to 
the long axis of the eye. Harderian gland (HA) and optic nerve (ON) marked in images. 
Extraorbital muscles (EOM), structures are clearly obvious from histological slide of the 
same area aligned with MRI (right column). A, B mouse code AM1, C, D mouse code 
AM2, E, F mouse code AM3. 
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Fig 4.22 Quantification of hypertrophy in the extraorbital muscles by 
histology 
 (A) Shows the upward trend in the EOM volume in mm3 (abscissa) in the 
immune mice compared with age-matched control mice. (B) Shows the 
significant hypertrophy in superior muscles in the immune mice compared with 
age-matched control mice (presented as volume in mm3). Dotted line presents 
the mean value of superior muscle volume in control mice added with three 
times of standard deviation.   
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4.4 Discussion  
 
In this Chapter, we have described the neuroradiological analysis by high resolution 
MRI in orbital region of preclinical GO model. A total number of 5 immune mice 
following the modified immunisation protocol with hTSHR A-subunit plasmid in vivo 
electroporation were evaluated by in vivo MRI for orbital morphology. The in vivo 
small animal MRI provided an undoubted evidence to study macroscopic view of 
orbital changes in live animals. In addition to 5 immune animals from the cohort of 
immunisation for longitudinal studies (sacrificed 9 weeks after end of immunisation), 3 
age-matched female BALB/c mice were selected as controls. The analysis of MRI data 
described in this chapter and advantages of the established imaging method will be 
discussed below. 
The studies on orbital pathology were initiated by careful literature review to find a 
standard protocol for acquiring MR images in orbital region. Although, number of 
studies recently reported using MRI technique in the experimental murine model of 
retinal development (Lindsey et al., 2007, Chen et al., 2008a, Muir and Duong, 2011, 
Chen et al., 2011, Wang et al., 2012)  and optic nerve crash (Xu et al., 2008, Sun et al., 
2011, Zhang et al., 2011, Talla et al., 2013) with particular interest in contrast agents 
(Lin et al., 2014), there were no reports dealing with preclinical extraorbital muscles of 
orbital region. We therefore had to set up the MRI technique based on the imaging 
orientation protocol for orbital MRI in clinical neuroradiology (Muller-Forell and 
Kahaly, 2012). For this reason we developed collaboration with Dr Neil Deasy (clinical 
neuroradiologist, King’s College Hospital NHS Trust, London).  From his consultations, 
we set up the MRI protocol described by two different image acquisition of head 
region with distinct orientations exactly as the clinical MRI protocol for GO patients.  
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Based on the clinical MRI method, two distinct orientations of coronal and axial view 
have been acquired. For coronal view, T2w MR images were acquired with 100 μm in-
plane resolution. The MRI data were then used as scout images for MRI of the right 
eye at an oblique angle, axial view. For axial view, 94 μm in-plane resolution MR 
images were collected from the surface of the eye towards the back of the eye 
(perpendicular to the long axis of the eye, similar to the orientation for histological 
processing). 
Although in clinical neuroradiology, orbital imaging is often applied for diagnosis in 
patients with GO (Muller-Forell and Kahaly, 2012), It has been postulated that 
differences in the orbital bone structure between humans and rodents (Smith, 2002) 
may not allow manifestation of eyeball protrusion in the orbital region of mice 
(Wiersinga, 2011). Despite this difference in orbital anatomy, we showed by high-
resolution in vivo MRI, clear enlargement retrobulbar tissues and unilateral proptosis 
in some animals (Moshkelgosha et al., 2013). The coronal view of MR images clearly 
confirmed bilateral proptosis in 2 immune animals. Moreover, the quantitative analysis 
showed significant increase of extraorbital muscle volume in immune animals compare 
with age-matched controls. Interestingly, alignment of histological slides of 
extraorbital muscles with MR images confirmed the hypertrophy in orbital muscles.  
Furthermore, neuroradiological studies in GO patients reported a common feature of 
considerable differences in the involvement of orbital muscles (Majos et al., 2007, 
Chen et al., 2012, Politi et al., 2014). To specifically classify the subtype of orbital tissue 
involvement in GO patients, a ratio of the total extraorbital muscles area to orbit area 
(EMA:OA) is calculated (Kuriyan et al., 2013). When this index for GO patients is within 
the controls mean ± two SD, they are classified as type I patients (Kuriyan et al., 2013) 
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which is associated predominantly with fat compartment enlargement (El-Kaissi et al., 
2004). Patients with an EMA:OA ratio greater than the control mean ± 2 SD are 
classified as type II patients who are predominantly associated with extraorbital 
muscles enlargement. In this preclinical model we were unable to use the same index 
to classified immune mice due to the limitations in resolution of preclinical MRI 
setting. However, we could use the histological sections to integrate with MR images in 
order to specify involvement of orbital tissue. Interestingly, the alignment of 
histological sections with MRI revealed that the enlargement of orbital tissue is mostly 
associated with extraorbital muscles rather than fat expansion, i.e. type II. Of particular 
interest, the alignment of histology with MRI in preclinical model of GO demonstrated 
the higher rate of involvement in superior muscles. Thus, this is another advantage of 
the experimental GO model to recapitulate the clinical features in GO patients. The 
quantification of histological slides was demonstrated a most significant muscles 
hypertrophy in superior muscles rather that other extraorbital muscles. Higher 
magnification of histology analysis showed that the hypertrophy in muscles is due to 
inflammation and accumulation of fibrotic myofibroblast. However, to address the 
question why superior muscles are involved the hypertrophy more than other muscles, 
further molecular investigations are needed.   
The significance of results presented in this Chapter will suggest setting up the 
preclinical MRI acquisition protocol for orbital region with larger number of animals. In 
addition, despite a high resolution image provided in this Chapter, it would be advised 
to acquire MRI with higher resolution by increasing acquisition time. Higher resolution 
MRI of orbital region will allow a better segregation of extraorbital muscles from 
surrounding tissue. The higher resolution imaging seems to be necessary in case of 
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using MRI as a method for longitudinal and therapeutic studies. As clearly shown by 
alignment of histology and MRI, the resolution of MRI in this chapter was not enough 
to distinguish adipose expansion in an individual mouse (64/L). The other way of 
improving the resolution in MRI is to add the contrast agents in order to increase 
brightness in tissue of interest. The role of contrast agents in increasing the resolution 
of different tissue has been very well studied (Hao et al., 2012, Talla et al., 2013, Cheng 
et al., 2013, Telgmann et al., 2013, Politi et al., 2014).  Furthermore, the clinical 
evaluation of inflammatory activity is routinely studied by MRI (Politi et al., 2014). The 
clinical MRI acquisition method by T2w is able to show oedema in extraorbital muscles 
in order to investigate inflammation activity.  In addition, a contrast agent, gadolinium, 
with T1w image acquisition is also suggested to distinguish between “active” and 
“inactive” inflammation in orbital muscles by quantifying signal intensity ratios (Politi 
et al., 2014). The different methods of MRI acquisition need to be validated by 
comparing the MRI results with the clinical activity score of experimental GO model.    
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4.5 Summary  
 
In summary, in vivo MRI data of 5 immune animals undergoing orbitopathy following 
the immunisation with hTSHR A-subunit plasmid and 3 age-matched female BALB/c 
mice have been studied by the established method of small animal MRI.  The coronal 
view of MR images clearly confirmed bilateral proptosis in 2 immune animals. The 
quantitative analysis showed significant increase of extraorbital muscle volume in 
immune animals compared with age-matched controls.  The MRI results are concluded 
























 AM1  Normal -  Normal  Normal 
 AM2  Normal -  Normal  Normal 





































Table 4.1 summary of in vivo MRI analysis of all 5 mice immunised with hTSHR A-
subunit plasmid undergoing experimental Graves’ orbitopathy and 3 age matched 
(AM) controls.   
EOM: inflammation in extraorbital muscles based on the histological studies 
§= positive by assessment for chemosis. 
* + = unilateral proptosis; ++ = pronounced unilateral proptosis; Normal = no 
detectable protrusion, 
 







The enigma of antibodies induced to IGF-1R following 
immunisation with TSHR A-subunit plasmid   
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5. The enigma of antibodies induced to IGF-1R following 




The  investigation of a ‘long acting thyroid stimulator’ (LATS) in the serum of patients 
with Graves’ disease (Adams, 1958, McKenzie, 1958) following an observation of 
abnormal responses (Adams and Purves, 1956a) to an assay established to detect TSH 
stimulating activity (Adams and Purves, 1956b), represented a milestone for studies 
into the aetiology of the disease. Subsequent studies demonstrated that biologically 
active LATS resides in the gamma-globulin fraction of plasma (McKenzie, 1962). This 
finding was further developed by Kriss and colleagues who showed that LATS was an 
immunoglobulin G and therefore suggested the autoimmune basis for Graves’ disease 
[(Kriss et al., 1964), reviewed in (Weetman, 2003)].  Further studies on autoimmunity 
in Graves’ disease led to the identification of TSHR as the target autoantigen (Manley 
et al., 1974, Smith and Hall, 1974, Mehdi and Nussey, 1975). With the close association 
of Graves’ orbitopathy and Graves’ disease, the notion has been held that TSHR was 
also the target autoantigen in GO (Kriss et al., 1967, Rotella et al., 1986).  
In the last two decades, however, different eye muscle and orbital connective tissue 
antigens have been implicated in GO pathogenesis. In particular, the flavoprotein 
subunit of succinate dehydrogenase, also known as 64 kDa antigen, a fragment of the 
FOX-P1 transcription factor G2s, orbital fibroblast membrane antigen collagen XIII, and 
calcium binding protein calsequestrin have all been implicated as autoantigens 
(Bernard et al., 1991, Wall et al., 1993, Mizokami et al., 2004, Gopinath et al., 2006, de 
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Haan et al., 2010, Wescombe et al., 2010, Lahooti et al., 2010, Wall and Lahooti, 2011, 
McCorquodale et al., 2012). Furthermore, extensive proliferation in the orbital tissue 
of patients undergoing orbitopathy has suggested that an excess of growth factors is 
responsible for the inordinate orbital tissue expansion. Among other growth factors, 
there is much evidence for insulin-like growth factor-1 (known as somatomedin C in 
the 1980s), to be implicated in the pathogenesis of Graves’ orbitopathy. IGF-1 
influences several aspects of immunity, including B and T cell development (Smith, 
2010a).  
More recently, platelet-derived growth factor (PDGF) has also been implicated as 
another putative growth factor in GO pathogenesis (van Steensel et al., 2009, van 
Steensel et al., 2010). PDGF is important in normal wound healing, and increased levels 
or activity of PDGF have been shown to be involved in pulmonary, liver, dermal, and 
cardiac fibrosis, in which it primarily acts as a mitogen for fibroblasts with a 
myofibroblast phenotype (Andrae et al., 2008). The laboratory of Professor Dik showed 
that both isoforms of PDGF, PDGF-AB and especially PDGF-BB, are produced by 
monocytes, macrophages and mast cells within the orbital tissue of GO patients (van 
Steensel et al., 2012). They also provided evidence for a potential role of PDGF-BB in 
increasing production of inflammatory mediators (e.g. CCL2, IL-6, and IL-8) and 
hyaluronan secretion, as well as proliferation of orbital fibroblasts (van Steensel et al., 
2010). PDGF thus stimulates several key pathogenic pathways in GO and represents an 
attractive therapeutic target for the treatment of GO (van Steensel et al., 2009, van 
Steensel et al., 2011, Virakul et al., 2014).  
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5.1.1 IGF-1R and Abs to IGF-1R  
 
The role of IGF-1 in GO was first reported from a case study in 1986 (Hansson et al., 
1986).  Hansson and colleagues demonstrated that the concentration of somatomedin 
C (IGF-1) in the retrobulbar biopsy specimens of GO patients were significantly 
increased in comparison to controls, and in comparison with other tissues from the 
same GO patients (Hansson et al., 1986). Subsequently, the same group reported a 
specific role for IGF-1 in orbital tissue pathology by showing that other closely related 
growth factors such as insulin and IGF-II were minimally involved in the disease 
process (Hansson, 1989). However, examination of thyroid glands from patients with 
Graves’ disease showed no apparent changes in IGF-1 concentration compared with 
normal thyroid tissue (Minuto et al., 1989). Other in vitro findings from Professor 
Ingbar’s laboratory revealed a close functional association between IGF-1 and TSH in 
cell proliferation of the rat clonal thyroid epithelial cell line, FRTL-5 (Tramontano et al., 
1986, Tramontano et al., 1987, Tramontano et al., 1988a, Tramontano et al., 1988b). 
They demonstrated that IGF-1 promoted FRTL-5 cell proliferation and enhanced the 
effect of TSH on DNA synthesis (Tramontano et al., 1986) (see section 1.4.3 for more 
details). Subsequently, substantial overlap between TSHR and IGF-1R downstream 
signalling was reported. Both receptors extensively utilise the Akt/FRAP/mTOR/P70s6k 
pathway (Cass and Meinkoth, 1998).  
Meanwhile, a potential role of anti-IGF-1R Abs in the pathogenesis of Graves’ disease 
was proposed by Kohn and colleagues (Kohn et al., 1986). Their studies indicated that 
immunoglobulins from patients with Graves’ disease not only increased collagen 
synthesis in human fibroblasts (Rotella et al., 1986), but also immunoprecipitated the 
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tyrosine kinase domain of IGF-1R (Kohn et al., 1986). Following these findings, 
Professor Kendall-Taylor’s laboratory demonstrated the presence of IGF-1R Abs in sera 
of Graves’ patients with and without overt orbital manifestation (Weightman et al., 
1993). Initially, Weightman and colleagues confirmed the expression of high affinity 
IGF-1 binding sites in orbital fibroblast (Fig 5.1 A). Although this binding site has not 
been confirmed to be a part of the IGF-1R, its dissociation constant is similar to that 
previously reported for IGF-1R (Rosenfeld and Dollar, 1982, Jonas and Harrison, 1985, 
Tollefsen et al., 1987). Subsequently, they showed that immunoglobulins from Graves’ 
patients but not control individuals can displace radiolabeled IGF-1 in human orbital 
fibroblasts obtained during surgery for squint, from two normal donors (Weightman et 
al., 1993). Purified IgGs from 12 out of 23 patients with Graves' disease significantly 
inhibited binding of labelled-IGF-1 to orbital fibroblasts, regardless of the clinical 
activity of the disease (Fig 5.1 B). Notably, one serum sample exhibited >50% inhibition 
in binding of the tracer (circled in red in Fig 5.1 B). Their data is shown below to 









Fig 5.1 Displacement of labelled IGF-1 by purified IgG from GO patients. 
Adapted from Weightman et al. 1993. 
The data from this study showed displacement of labelled-IGF-1 with purified 
IgG from individual patients with Graves’ disease. (A) Competitive displacement 
of 125I-IGF-1 binding to the monolayer culture of orbital fibroblasts by 
unlabelled IGF-1. (B) Distribution and comparison of 125I-IGF-1 binding to orbital 
fibroblast monolayer after incubation with IgG prepared from normal (n = 13) 
or Graves' disease (n = 23) sera. The point circled in red in the Graves’ IgG 
column has been highlighted by me in the figure to show the one serum sample 
with >50% inhibition of IGF-1 binding.  
 
A decade after Weightman and colleagues had shown displacement of labelled-IGF-1 
by purified IgG from Graves’ patients, Professor Smith’s laboratory reported that 
Graves’ IgGs were able to stimulate the secretion of IL-16 and RANTES in human orbital 
fibroblasts (Pritchard et al., 2002). Interestingly, a blocking mAb to IGF-1R (1H7 mAb) 
inhibited the IL-16 and RANTES response, suggesting that IGF-1R may be implicated in 
the inflammatory response of the orbital fibroblasts (Pritchard et al., 2002, Pritchard et 
al., 2003). Therefore, the data provides experimental evidence that Graves’ IgGs exert 
their effects on the orbital fibroblast at least in part through the IGF-1R pathway.  
Pritchard and colleagues also demonstrated that immunoglobulins isolated from 
patients with Graves’ disease displaced labelled IGF-1 (Pritchard et al., 2003). 
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However, it is important to emphasise that Pritchard and colleagues did not evaluate 
inhibition of binding of labelled IGF-1 by serum from individual patients, but instead 
used pooled serum samples. They postulated that a subset of Graves’ IgG contains Abs 
that stimulate the IGF-1R [(Pritchard et al., 2002, Pritchard et al., 2003) reviewed in 
(Smith et al., 2012)]. Their data is shown below in Fig 5.2 A and 5.2 B.  
Apart from the studies that illustrate the significant increase in concentration and 
immunoreactivity of IGF-1R Abs in GO patients, there is increasing in vitro evidence 
suggesting that the IGF-1R signalling pathway may operate in conjunction with the 
TSHR pathway in the pathophysiology of orbitopathy. A recent immunoprecipitation 
study, in combination with confocal microscopy, confirmed a close physical association 
between TSHR and IGF-1R (Tsui et al., 2008). It was suggested that the two receptors 
co-localise on orbital fibroblast plasma membranes, possibly forming a functional 
complex receptor (Tsui et al., 2008). In related receptor systems, crosstalk between 
IGF-1R and other receptors such as epidermal growth factor receptor (van der Veeken 
et al., 2009) and lysophosphatidic acid  (LPA) receptor (Luttrell et al., 1995) has been 
demonstrated, potentially supporting a similar cross talk between IGF-1R and TSHR. In 
addition, evidence revealed a substantial overlap between TSHR and IGF-1R signalling 
pathway including the Akt/FRAP/mTOR/p70s6k pathway (Cass and Meinkoth, 1998, 
Park et al., 2000a, Park et al., 2000b, Park et al., 2005). IGF-1R-mediated signalling has 
a wide spectrum of functions in tissue growth and development, and may participate 
in the pathogenesis of several metabolic, neoplastic, and immunologic diseases 
(Bateman and McNeill, 2006, Kurmasheva and Houghton, 2006, Walenkamp and Wit, 
2006). This mechanism can most likely be explained by the indirect association of two 
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receptors via downstream signalling molecules in orbital fibroblasts (Smith et al., 2008, 




Fig 5.2 Displacement of labelled IGF-1. Adapted from Pritchard et al., 2003 
with permission from Prof T. J. Smith 
(A) 125I-IGF-1 binding displacement with increasing concentrations of unlabelled 
IGF-1, Des(1–3), GD-IgG, and control IgG (named  N-IgG). (B) The effects of IL-
1β, IGF-1, and GD-IgG, without or with 1H7 mAb on T cell chemotactic activity 
showing that IGF-1 as well as GD-IgG can enhance  T cell chemotactic activity 
which can be inhibited by 1H7 mAb. 
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Furthermore, studies on hyaluronan secretion from orbital fibroblasts has shed light on 
the functional interaction between TSHR and IGF-1R pathways.  Notably, there is 
evidence that pathological activation of TSHR signalling, stimulation with TSHR mAbs 
or constitutive activation of TSHR by mutation can lead to increased production of the 
hyaluronan from preadipocyte fibroblasts (Zhang et al., 2009). Professor Smith’s 
laboratory determined that IgG isolated from patients with Graves’ disease (GD-IgG), 
but not recombinant human TSH, enhanced hyaluronan synthesis in undifferentiated 
orbital fibroblast (Smith and Hoa, 2004). Consequently, they confirmed that this 
response was mediated through IGF-1R, as the blocking IGF-1R mAb, 1H7 mAb, 
inhibited hyaluronan synthesis (Smith and Hoa, 2004). In contrast, Professor 
Wiersinga’s group reported that neither GD-IgG nor recombinant human TSH could 
enhance hyaluronan synthesis in undifferentiated orbital fibroblast (van Zeijl et al., 
2010). However, they subsequently confirmed the increase of hyaluronan production 
in response to GD-IgG, but not recombinant human TSHR, by using differentiated 
orbital fibroblasts (van Zeijl et al., 2011). More recently, Kumar and colleagues 
reported an increase in production of hyaluronan in response to bovine TSH as well as 
human stimulatory TSHR mAb (M22) in undifferentiated orbital fibroblasts from GO 
patients (Kumar et al., 2012). Regardless of differences between these studies 
(discussed in more detail in Chapter 1), the latter study also showed that blocking mAb 
to IGF-1R (1H7 mAb) inhibited hyaluronan synthesis (Kumar et al., 2012). Thus, 
functional studies in orbital fibroblasts suggest a close relationship at a functional level 
between TSHR and IGF-1R.  
Supportive evidence for the role of IGF-1R pathway in the pathogenesis of Graves’ 
orbitopathy has been recently revealed by an important molecular study from Dr Ezra 
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and colleagues (Ezra et al., 2012). In essence, they have applied gene expression 
profiling on archived histological samples of orbital fat from active, but untreated GO 
patients. The results of this study showed that in addition to Wnt signalling 
components, IGF-1R and its ligand, as well as downstream transcriptional regulators 
such as SGK (PDK/Akt signalling), score highly in a hit map of differentially expressed 
genes detected by microarray. These results were then confirmed by qRT-PCR (Ezra et 
al., 2012). Despite the limitation of rare availability of active GO orbital fat specimens, 
this study identified significant changes in IGF-1R molecular signalling systems in the 
orbital tissue. However, other groups using similar approach for studying orbital tissue 
of GO patients did not show significant changes in the components of IGF-1R pathway 
(Kumar et al., 2005, Lantz et al., 2005, Chen et al., 2008b, Planck et al., 2011). 
Differences in disease severity between patients, as well as a history of treatment with 
steroids and radiotherapy, may explain the differences between the results of the 
latest study of Ezra and colleagues (Ezra et al., 2012) compared with earlier studies 
(Kumar et al., 2005, Lantz et al., 2005, Chen et al., 2008b, Planck et al., 2011).  The 
careful selection of specimens by Dr Ezra and colleagues may have been crucial for the 
demonstration of a role for the IGF-1R pathway in their study (Ezra et al., 2012). 
Whilst all the above studies indicate a pathophysiological role for IGF-1R Ab in 
differentiation of orbital fibroblast, it has been extremely difficult to measure IGF-1R 
Ab in GO patients. Attempts to measure anti-IGF-1R Abs in patients’ sera have been 
reported recently by two independent groups.  In Professor Schomburg’s laboratory, 
although they could specifically measure IGF-1R Ab in isolated IgG from human sera, 
there were no obvious differences between GO patients and controls (Minich et al., 
2013). They have shown that there was no clear association between IGF-1R Ab levels 
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and the activity of GO when using a luminescent immunoprecipitation assay with 
human embryonic kidney cells stably transfected with IGF-1R (Minich et al., 2013). 
Professor Wiersinga’s laboratory determined IGF-1R stimulating activity by using IGF-
1R kinase receptor activation assay. The results indicated that in a subset of patients 
with GO, IgGs may have IGF-1R stimulating activities after taking TBII activity and age 
into account (Varewijck et al., 2013). They divided GO patients into two groups based 
on the TBII activity and demonstrated where TBII was above mean +1 SD, IGF-1R 
stimulating activity was positively correlated with age. In a subgroup of patients who 
had IGF-1R stimulating activity above mean -1 SD, depletion of IgGs significantly 
decreased IGF-1R stimulating activity (Varewijck et al., 2013).  
An Editorial by Professor Smith accompanying the two articles (Smith, 2013) addressed 
the potential issues that may be responsible for the contradictory results between 
these two reports, as well as the earlier studies of Weightman et al and Pritchard et al 
(Weightman et al., 1993, Pritchard et al., 2003). The Editorial commented that both of 
these studies underestimated the complexities of IGF-1 binding proteins (IGFBPs) to 
influence binding of IGF-1 to IGF-1R. Six family members of IGFBPs have been 
identified with different cellular functions (Firth and Baxter, 2002). IGFBP2, for 
example, is able to modulate the actions of IGF-1 on IGF-1R and can influence post-
IGF-1R signalling (Shen et al., 2012).  The unavailability of IGFBPS in transfected cell 
lines may be responsible for inhibition in binding IGF-1 to its receptor. Therefore, it 
was suggested that the use of a transfected cell line (Minich et al., 2013, Varewijck et 
al., 2013)  instead of human fibroblasts as used in earlier studies (Weightman et al., 
1993, Pritchard et al., 2003)  may be responsible for the disparate results (Smith, 
2013).  
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Recently, our laboratory developed an experimental model of Graves’ disease which 
also showed histological signs of fibrosis in the orbital tissue,  based on hTSHR A-
subunit plasmid in vivo electroporation (Zhao et al., 2011). It was shown that this 
model maintains longevity of induced antibody response to TSHR with accompanying 
hyperthyroidism in 8 out of 12 mice. A proportion of the animals immunised with 
hTSHR A-subunit plasmid were positive for IGF-1R Abs. To get an insight into potential 
mechanisms responsible for induction of IGF-1R Abs in mice immunised with hTSHR A-
subunit plasmid, three models were proposed that may explain this activity. The 
proposed models could help us to investigate the role of induced IGF-1R Abs in the 
pathogenesis of GO.    
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5.2 Aims  
 
The main purpose of this Chapter was to investigate the mechanisms of induction of 
anti-IGF-1R Abs in animals immunised with hTSHR A-subunit plasmid in vivo 
electroporation. I proposed to address this by the following aims: 
 
 Development and validation of different assays for measuring anti-IGF-1R Abs.  
 Evaluate the induction of anti-IGF-1R Abs in mice immunised with hTSHR A-
subunit plasmid in vivo electroporation. 
 Development of anti-IGF-1R Abs as mAbs from mice immunised with hTSHR A-
subunit plasmid in vivo electroporation. 
 Characterisation of the anti-IGF-1R mAbs to investigate their role in 








5.3.1 Development and validation of assays for IGF-1R Abs  
 
There are no commercial kits available to measure mouse or human IGF-1R Abs. In this 
project, detection of IGF-1R Abs by a reproducible and rapid assay was crucially 
important. As mentioned earlier, in my supervisor’s laboratory, a radioligand binding 
assay to measure anti-IGF-1R Abs had been developed (Zhao et al., 2011). To measure 
anti-IGF-1R Abs in mice, Zhao and colleagues used a radioligand-binding assay with 
antigen generated using an in vitro transcription and translation system (TnT, 
Promega) (Tree et al., 2000, Zhao et al., 2011) to produce radioactive 35S-methionine-
IGF-1Rα subunit. Mouse serum samples were incubated with radiolabeled IGF-1R in 
the immunoprecipitation buffer and immune complexes captured on protein G-
Sepharose. The presence of IGF-1R Abs in serum leads to increase in the radioactive 
count. Although the coupled TnT assay has been widely used for generating 
radiolabelled antigens for measuring autoantibody binding to islet cell antigens such as 
glutamic acid decarboxylase (GAD) and IA-2 in type 1 diabetes (Bonifacio et al., 2010), 
it has not been used for measuring IGF-1R Abs.  
Although Zhao and colleagues had used coupled TnT assay for measurement IGF-1R 
Abs in mice sera and published their results, I wanted to expand on evaluating 
different assay designs to select an assay that was reproducible and rapid and hence 
suitable for hybridoma screening. So, for my studies dealing with anti-IGF1R Abs in the 
mouse model, my first objective was to develop and validate other assays for anti-IGF-
1R Abs.  
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5.3.1.1 Flow cytometry 
 
NWTB3 cells, being a mouse fibroblast cell line (NIH/3T3) stably transfected to express 
human IGF-1R was provided by Professor LeRoith (Blakesley et al., 1995). The 
transfected cells were reported to express 410,000 receptors per cell (Blakesley et al., 
1995).  Initially, NWTB3 cells were evaluated on IGF-1R expression with IGF-1R mAb, 
1H7 mAb (1µg/ml) (BioLegend, UK). Gating strategy was evaluated based on 75-80% of 
50,000 counted cells (called P1) as shown in Fig 5.3 A. NWTB3 cells were positive for 
IGF-1R expression with >77% highly positive cells in the population, compared to less 
than 1% in isotype matched, IgG1 control mAb (Fig 5.3 B, C). Different concentrations 
of 1H7 mAb were tested and data analysed by determination of the mean fluorescence 
intensity (MFI), (Fig 5.3 C-F). Using anti-IGF-1R mAbs, the intra-assay coefficient of 
variation (CV), (precision within the assay) was determined to be 10%. Inter-assay CV 
(precision between assays) was calculated using the same anti-IGF-1R mAb, measured 
in three consecutive runs and determined to be <25%. The calculations of inter-assay 
and intra-assay CV for the flow cytometry assay are described in Appendix 2.  
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Fig 5.3 Flow cytometry in NWTB3 cells with 1H7 mAb 
 (A) Gating strategy. SSC-A: side scatter, FSC-A: forward scatter. (B) 
Fluorescence intensity histogram of negative control, isotype matched, IgG1 (1 
μg). Fluorescence intensity histogram (blue histogram vs red as negative 
control) of (C) 1μg 1H7 mAb which showed 77% cell positive. (D) 0.3μg 1H7 
mAb showed 70% cell positive. (E) 0.1μg 1H7 mAb showed 55% cell positive.  
(F) Mean florescent intensity of binding to different concentration of 1H7 mAb 
to NWTB3 cells. The experiment has been performed three times with 
comparable results. The bar represents standard deviation.  1μg of 1H7 mAb 
demonstrated 8000 MFI while the same concentration of isotype matched mAb 
resulted in <500 MFI. 
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In addition to the aforementioned flow cytometry study by indirect (sandwich) 
staining, another experiment evaluated IGF-1R expression in NWTB3 cells by direct 
staining using PE labelled 1H7 mAb (BD Biosciences) by flow cytometry. The 
percentage of positivity in stained cells ( 75% vs 83%) and fluorescent intensity (13100 
vs 15900) for indirect and direct staining respectively, clearly showed that direct 
staining presents comparable results to the indirect 1H7 mAb (Fig 5.4 A-C). Indirect 
staining methods are generally considered to be more sensitive and superior to direct 
staining methods due to ‘amplification’ of the signal in the former (Hay et al., 2001). 
Thus, the fact that direct and indirect staining for IGF-1R expression in NWTB3 cells 
was comparable, further support the high levels of expression of IGF-1R in the 
transfected cells. 
To further investigate the flow cytometry analysis in NWTB3 cells, we tested a new set 
of IGF-1R mAbs.  Professor Kenneth Siddle (University of Cambridge, UK) kindly 
provided four anti-IGF-1R mAbs directed to different determinants of IGF-1R (Soos et 
al., 1992). The mAbs termed 24-31 mAb, 24-60 mAb, 17-69 mAb and 24-57 mAb were 
supplied as freeze dried ascites  (Table 5.1). The freeze dried ascites was gently 
resuspended in sterile water and purified by protein G column chromatography and 
tested by flow cytometry on NWTB3 cells. Data are shown in Fig 5.4 D-H. 
Determination of signal intensity by flow cytometry of IGF-1R mAb to different 
determinants resulted in wide range of MFI and positive staining for NWTB3 cells.  At a 
concentration of 1 μg of 24-31 mAb showed 7% positive cells (Fig 5.4 D), 24-60 mAb 
showed 25% positive cells (Fig 5.4 E), 24-57 mAb showed 60% positive cells (Fig 5.4 F), 
and 17-69 mAb showed 30% positive cells (Fig 5.4 G). The mean fluorescence intensity 
of each experimental condition is concluded in Fig 5.4 panel H.  Among the IGF-1R 
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mAbs, the highest MFI value belonged to 24-57 mAb. On the other hand, 24-31 mAb 
did not show significant difference from isotype match control. The variation in the 
results of the other mAbs is likely due to the differences in the specific epitope 
determinants exposed on native IGF-1R on the plasma cell membrane of NWTB3 cells. 
These anti-IGF-1R mAbs were not evaluated for binding by flow cytometry by Soos and 
colleagues, thus it is not possible to correlate the flow cytometry binding data 
described herein to the epitope binding patterns (Table 5.1) reported in their 
publication (Soos et al., 1992). However, it is well known from TSHR mAb analysis that 
the variation in mAbs determinants leads to differences in positivity of flow cytometry 
(Patibandla et al., 1997, Shepherd et al., 1999, Mizutori et al., 2009). For example, 
compared to other mAbs, 2C11 mAb and 4C1 mAb to TSHR are considered gold 
standard Abs for flow cytometry since their determinants appear to be most easily 
accessible on the native receptor.   
anti-IGF-1R mAb isotype epitope blocking 
activity 
24-31 IgG1 283-440 or 586-908 0 
24-60 IgG2a 184-283 ++ 
24-57 IgG1 440-586 ++ 
17-69 IgG1 440-586 + 
 
 
Table 5.1 Specification of anti-IGF-1R mAbs received from Professor Siddle’s 
laboratory  
 Anti-IGF-1R mAb codes are derived from the nomenclature used by Soos et al, 
1992. Blocking activity classified based on the inhibition of 125I-IGF-1binding to 
receptor; ‘0’ = 20% inhibition, ‘+’ = 35-60% inhibition and ‘++’ > 80% inhibition. 
 





Fig 5.4 Flow cytometry in NWTB3 cells with different anti-IGF-1R mAbs 
IGF-1R mAbs include PE-1H7 for direct staining and four other mAbs directed to 
different determinants of the receptor (A) Gating strategy. SSC-A: side scatter, 
FSC-A: forward scatter. For panels B to G; Fluorescence intensity histogram 
(blue histogram vs red as negative control) of (B) 1H7 mAb (1 μg, indirect 
staining) showed 75% positive cells (it is comparable with 77% positive cells in 
the different experiment presented in Fig 5.3) , (C) PE-1H7 mAb (direct staining) 
indicated 82% positive cells (D) 24-31 mAb (1 μg) showed 7% positive cells, (E) 
24-60 mAb (1 μg) showed 25% positive cells, (F) 24-57 mAb (1 μg) showed 60% 
positive cells, (G) 17-69 mAb (1 μg) showed 30% positive cells. (H) Mean 
fluorescent intensity of binding different anti-IGF-1R mAbs to NWTB3 cells. The 
experiment has been performed two times with comparable results. The bar 
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5.3.1.2 Evaluation for constitutive expression of TSHR in NWTB3 cells  
 
Since I planned to use the stably transfected NWTB3 cells expressing hIGF-1R in flow 
cytometry to evaluate anti-IGF-1R Abs in mice immunised with hTSHR A-subunit 
plasmid, it was important to first determine that the NWTB3 cells did not express 
TSHR.  The gold standard anti-TSHR mAb for evaluating TSHR expression by flow 
cytometry, 4C1 was used for these experiments. In addition, another mAb with agonist 
activity to the TSHR developed in our laboratory (KSAb1) was utilised (Gilbert et al., 
2006). Gating strategy for flow cytometry is shown in Fig 5.5 A. The flow cytometry 
results of NWTB3 cells clearly indicated that there is no binding site for the examined 
TSHR mAbs.  The mean fluorescence intensity of 1H7 mAb at highest concentration 
was above 7000. However, the MFI value for TSHR mAbs at same concentration were 
not more than 600, equal to the value for control mAb (Fig 5.5 B, C). 
In addition, expression of TSHR was examined in the GPI9-5 cells, which served as 
positive control, with 4C1 mAb used at the same concentrations (Fig5.6). GPI9-5 cells, 
CHO cell line stably transfected to express human TSHR A-subunit, were kindly 
provided by Dr Phillip Watson (Sheffield) (Metcalfe et al., 2002). Gating strategy for 
flow cytometry of GPI9-5 cells with isotype control (IgG2a) is shown in Fig 5.6 A. The 
flow cytometry results showed high level of TSHR expression by GPI9-5 cell. The 
highest concentration of 4C1 mAb exhibited 12,500 MFI with more than 77 percent of 
positive cells (Fig 5.6 B, C).  The flow cytometry results of NWTB3 cells clearly indicated 
that there is no binding site for the examined TSHR mAbs.  The mean fluorescence 
intensity of 1H7 mAb at highest concentration was above 7000. However, the MFI 
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value for TSHR mAbs at same concentration were not more than 600, equal to the 
value for control mAb (Fig 5.5 B, C). 
 
            
 Fig 5.5 Evaluation of TSHR expression in NWTB3 cells by flow cytometry 
Different concentrations of anti-TSHR mAbs (4C1 mAb and KSAb1) as well as 
anti-IGF-1R mAb, 1H7 mAb, on NWTB3 cells were tested. (A) Gating strategy. 
SSC-A: side scatter, FSC-A: forward scatter. (B) Fluorescence intensity histogram 
of different concentrations (1μg, 0.3μg, 0.1μg) of four different mAbs, 1H7 
mAb, KSAb1, 4C1 mAb and negative control IgG1. (C) Mean fluorescence 
intensity shows that NWTB3 cells do not express TSHR. Negative controls are 
buffer and IgG1.  
 
 
 216  
 
                           
Fig 5.6 Flow cytometry in GPI5-9 cells by anti-TSHR mAb  
(A) Gating strategy. SSC-A: side scatter, FSC-A: forward scatter. (B) 
Fluorescence intensity histogram of different concentrations (1μg, 0.3μg, 
0.1μg) of 4C1 mAb and negative control, IgG2a. (C) The data of mean 




5.3.1.3 Cell based competitive binding assay 
 
After successful establishment of the flow cytometry assay to measure IGF-1R Abs and 
verifying the expression of IGF-1R by NWTB3 cells, the competitive binding assay was 
designed. The competitive binding assay was set up based on the displacement of 
labelled-IGF-1 by cold IGF-1, similar to that reported by Weightman and colleagues 
(Weightman et al., 1993).  However, there are some technical differences between 
these two assays: (i) radioactive (125I) tracer has been replaced by chemiluminescence 
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ligand and (ii) transfected  (NWTB3) cells expressing hIGF1R were used instead of 
human fibroblasts in the assay. Lumi-IGF-1 was provided by Professor Lutz Schomburg 
(University of Berlin, Germany) (Minich et al., 2013). Luminescence activity of Lumi-
IGF-1 was at 108 RLU/μL.   Initially, concentration of tracer and number of cells were 
evaluated to optimise the assay. Briefly, monolayer cells were cultured in 96 well and 
24 well plates overnight, cells were washed and incubated for 6 hours at 4oC with 
different concentration of Lumi-IGF-1.  The concentration of Lumi-IGF-1 was between 
5x105 RLU/μl and 1x103 RLU/μl with five fold dilution. Fig 5.7 shows that Lumi-IGF-1 
was able to bind to IGF-1R expressed in NWTB3 cells.  Binding to receptors by Lumi-
IGF-1 in 24 well plate were four fold higher in comparison to the binding observed in 
96 well plate. It is most likely due to the larger number of the cells in the former plates. 
Thus, 24 well plate was selected for subsequent studies.  
 
Fig 5.7 Binding of Lumi-IGF-1 NWTB3 cells in dose dependent manner 
(A) 96 well plates with 20,000 NWTB3 monolayer cell cultures. (B) 24 well 
plates with 80,000 NWTB3 monolayer cell cultures. The results showed that 
binding of Lumi-IGF-1 to the receptor is 4 fold higher in 24 well plate compared 
to 96 well plate.  
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The next experiments examined the binding of Lumi-IGF-1 to NWTB3 cells in 24 well 
plates in competition with different concentrations of unlabelled IGF-1 to evaluate the 
sensitivity of assay. Monolayer of NWTB3 cells were cultured in 24 well plates 
overnight, cells were washed and incubated for 6 hours at 4oC with different 
concentrations of tracer (Lumi-IGF-1) and competitor (unlabelled IGF-1). Highest 
concentration of unlabelled IGF-1 was 10-7 M which decreased to 10-10 M with 10 fold 
dilution. Dilution worked out based on the 10-7 M equal to 1μg/ml of IGF-1 in sterile 
PBS (details of calculation are presented in Appendix 3).  
The competition binding results indicated that the concentration of 5x104 RLU/μl of 
Lumi-IGF-1 is the optimum condition for binding assay. From the results in Fig 5.8, it is 
obvious that the sensitivity of assay increased as the tracer concentration declined 
from 5x105 RLU/μl to 5x104 RLU/μl. However, decrease in tracer concentration from 
5x104 RLU/μl to 104 RLU/μl caused to reduction in the binding sensitivity. The optimum 
condition (24 well monolayer NWTB3 cells with 5x104 RLU/μl) provided the sensitivity 
of approximately 1.7 nM of IGF-1 (IC50 = 1.7nM) which was very close to the sensitivity 
demonstrated by competition assay in the study by Weightman et al (IC50 = 1nM) 
(Weightman et al., 1993) (Fig 5.9 A,B). The details of calculation to compare between 
two studies are presented in Appendix 4.  
 219  
 
                      
 
Fig 5.8 Competition curve of different concentrations of Lumi-IGF-1 
The competition curve with unlabelled (cold) IGF-1 (24 well plates). is shown in 
(A) Lumi-IGF-1 concentration is 5x105 RLU/μl, (B) Lumi-IGF-1 concentration is 
105 RLU/μl, (C) Lumi-IGF-1 concentration is 5x104 RLU/μl, (D) Lumi-IGF-1 
concentration is 104 RLU/μl. The red lines in each panel is represents the IC50.  
 
The next step was to verify the competition assay optimised for displacement with 
cold IGF-1, for its ability to function with anti-IGF1-R Abs in a dose dependent manner. 
In the studies reported by Weightman and colleagues, purified IgG from pooled sera of 
Graves’ patients were used for displacement 125I-IGF-1 (Weightman et al., 1993). As 
the sera of Graves’ patients were not available for our study, I decided to evaluate two 
IGF-1R mAbs directed to different determinants on the receptor. Purified 24-57 mAb 
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and 1H7 mAb, both characterised with strong blocking activity of binding IGF-1 to its 
receptor (Soos et al., 1992, Kusada et al., 2008), were examined for displacement of 
Lumi-IGF-1. Surprisingly, although, it was shown that Lumi-IGF-1 can be displaced by 
cold IGF-1 in a dose dependent manner with appropriate sensitivity, neither 1H7 mAb 
nor 24-57 mAb could displace Lumi-IGF-1 as effectively as cold IGF-1 (Fig 5.9 C, D). 
Hence, despite the fact that the competition assay were designed very carefully 
following the analysis of flow cytometry results, during the validation of assay, it was 
clear that measurement of anti-IGF-1R Abs in serum samples would be far beyond the 




ELISA for detection IGF-1R Ab was established based on the protocol described by Yin 
and colleagues (Yin et al., 2011). They were able to detect IGF-1R Abs in sera from 
patients treated with Dalotuzumab, an anti-IGF1R Abs, intended for cancer therapy. 
For this reason, recombinant human IGF-1R extracellular domain (rhIGF-1R ECD) was 
obtained from a commercial sourse (R&D Systems). The source of receptor (102.9 kDa) 
was recombinant protein produced in murine myeloma cells. The purified receptor 
showed a single polypeptide band in SDS PAGE gels but details of the purification 
procedure for recombinant IGF-1R was not provided by supplier (R&D Systems, UK).  
Initially, ELISA was examined by testing of 1H7 mAb at different doses (from 15 ng to 
500 ng) to verify the capability of ELISA in measuring the Ab in a dose dependent 
manner (Fig 5.10). The analysis of 1H7 mAb at different doses by ELISA clearly 
indicated the ability of this assay for measuring anti-IGF-1R Ab from 30 ng per well (Fig 
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5.10).  15 ng of 1H7 mAb did not show significant difference with blank. The significant 
difference started from 30 ng of 1H7 per well. For further evaluation the assay, serum 
samples of mice immunised with pTriEx-IGF-1Rα from the study by Dr. Zhao and 
colleagues (Zhao et al., 2011) were used to determine the inter-assay and intra-assay 
CV. The result of this experiment was used to analyse assay precision.  Assay precision 
was determined using antiserum containing high and moderate levels of Abs to IGF-1R. 
The intra-assay CV calculated by analysing of 8 antisera in duplicate which determined 
to be less than 3.2%. Inter-assay CV was calculated by using the same set of antisera, 
measured in five consecutive runs and determined to be less than 6.6% (Appendix 5).  
 
 
Fig 5.11 Re-examination of IGF-1R Abs by ELISA assay in serum samples in 
immune mice from study by Zhao and colleagues   
The data of mice immunised with hTSHR A-subunit plasmid (blue), pTriEx-IGF-
1Rα plasmid (green), and non-immunised mice sera (grey) presented by OD. 
E21/0, the mouse scored positive in the TnT assay, was significantly positive by 
ELISA too. Sera diluted 1:20. Numbering system is same as used in Zhao and 
colleagues. Different concentrations of 1H7 mAb (red) served as positive 
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control. NMS: normal mice sera. The dotted line shows mean of normal mice 
sera value plus 3 times of standard deviation (Mean+3 SD).  
 
Once the assay evaluation had been successfully conducted, as well as re-examination 
of serum samples from Zhao and colleagues study (Zhao et al., 2011) confirmed the 
positivity of their serum samples for IGF-1R Abs by  ELISA, I then initiated the 




Fig 5.12 Re-examination of IGF-1R Abs by flow cytometrey in serum samples 
in immune mice from study by Zhao and colleagues  
Different concentrations of 1H7 mAb (red) were tested as positive control. The 
data of mice immunised with hTSHR A-subunit plasmid (blue),  pTriEx-IGF-1Rα 
(green) and non-immunised mice sera (grey) presented by mean fluorescent 
intensity. Numbering system is same as used in Zhao and colleagues. Control 
IgG1 served as isotype matched (ISO, black).  
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5.3.2 Evaluation of IGF-1R Abs in mice immunised with TSHR A-
subunit using modified protocol  
 
Having successfully developed and validated ELISA for measuring IGF-1R Abs in the 
sera of immune animals allowed us to examine IGF-1R Abs in mice immunised with 
hTSHR A-subunit plasmid from my studies.  For better understanding, in this Chapter, 
the nomenclature of each group of immunised mice is changed to group number as 
outlined in Appendix 1.  Therefore, from hereon, the results of anti-IGF-1R Abs in mice 
sera immunised with hTSHR A-subunit plasmid will be referred to the Group starting 
from the Group 1 (cohort of mice sacrificed 6 week after end of immunisation), 
following by the Group 2 (cohort of longitudinal study, sacrificed 9 weeks after end of 
immunisation) and Group 3 (long term effect study, sacrificed 15 week after end of 
immunisation). In addition, a new group of mice were immunised especially for IGF-1R 
mAb development and sacrificed 6 week after end of immunisation, this group is 
referred to as Group 4 (Appendix 1). 
 
5.3.2.1 Studies into induction of IGF-1R Abs in Group 1 immunisation  
 
As described earlier, in the Group 1 immunisation, eight mice were challenged with 
hTSHR A-subunit plasmid. Animals similarly immunised with pTRiEx1.1 neo-IGF-1Rα 
(n=3) and pTRiEx1.1 neo-β-Gal plasmids (n=3) were used as the control group. During 
the course of immunisation, one animal was sacrificed due to severe sickness. Rest of 
immune animals and controls were sacrificed six weeks after end of immunisation. Abs 
to IGF-1R in this group of animals was tested four weeks after end of immunisation by 
ELISA (Fig 5.13). Assessment of Abs to IGF-1R by ELISA demonstrated that 7 out of 8 
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animals immunised with hTSHR A-subunit plasmid were positive for anti-IGF-1R Abs 
when tested at 1:20 dilution. However, the Abs levels to IGF-1R were lower in 
comparison with the serum samples from mice immunised with IGF-1Rα plasmid. 
Control animals (mice immunised with pTRiEx1.1 neo-β-Gal plasmids) scored negative 




Fig 5.13 Evaluation of IGF-1R Abs by ELISA in mice immunised with hTSHR A-
subunit plasmid of Group 1 
Group 1 immunisation with hTSHR A-subunit plasmid (labelled hTSHR), IGF-1R 
plasmid (labelled IGF-1R) and control β-Gal plasmid (labelled βGal). The dotted 
line indicates mean+3 SD based on control β-Gal plasmid-immunised mice. Two 
mice immunised with TSHR A-subunit plasmid, 59/R and 59/2 were used to 
develop mAbs are indicated (see section 5.1.3)   
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To confirm the results of Abs to IGF-1R by ELISA, mice sera were also tested by flow 
cytometry assay (Fig 5.14). As already mentioned, flow cytometry was not able to 
detect anti-IGF-1R Abs in every individual mice immunised with TSHR A-subunit, but 
the serum samples with the strongest positivity in ELISA, also scored positive by flow 
cytometry (Fig 5.14). In addition, all three positive control sera from mice immunised 
with IGF-1Rα plasmid showed significant increase in MFI value.  
 
 
Fig 5.14 Determination of IGF-1R Abs by flow cytometry in mice immunised 
with hTSHR A-subunit plasmid of Group 1 
Group 1 immunisation (labelled hTSHR, blue), IGF-1R plasmid (labelled IGF-1R, 
green) and control β-Gal plasmid (labelled βGal, gray). The dotted line indicates 
mean + 3 SD based on control β-Gal plasmid-immunised mice. 1H7 mAb (red) 
served as positive control. 
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To evaluate alteration of antibodies in the GO experimental model, longitudinal study 
was performed in the Group 2 immunisation with eight female BALB/c mice. Animals 
were bled every week from one week before the last injection until week 6 and serum 
samples were analysed from the serial bleeds for longitudinal studies. All animals were 
sacrificed nine weeks after end of immunisation. Histological studies and TSHR Ab 
levels were presented in Chapter 3 and proved that this cohort of animals 
recapitulated orbital manifestation of earlier group of immunisation. However, in 
contrast to the earlier cohort of immunisation, all of the eight mice immunised with 
hTSHR A-subunit plasmid scored negative at all the time points (expect one weakly 
positive) for anti-IGF-1R Abs by ELISA (Fig 5.15). A weekly analysis of IGF-1R Abs for 
individual animals presented from one week before end of immunisation (-1) to six 
weeks after end of immunisation.  
  







Fig 5.15 Longitudinal analysis of anti-IGF-1R antibodies by ELISA in immune 
mice of Group 2 
Serum samples were collected every week in individual mice for IGF-1R Ab 
analysis in Group 2 animals. The ordinate shows week when serum sample 
collected, with the first sample collected one week before the end of 
immunisation (labelled -1), with all subsequent bleeds collected weekly until 6 
weeks after end of immunisation. Measurement of IGF-1R Ab by ELISA, 
presented as OD. None of the immune animals were scored positive for IGF-1R 
Ab (except one weakly positive in week 1). 
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5.3.3 Development of mAbs to IGF-1R   
 
Development of mAbs in an experimental model can be challenging if the goal is to 
generate mAbs to an antigen (IGF-1R) that is a different protein from the immunogen 
(TSHR). Initially, I planned to conduct mock fusions to practice the hybridoma 
technique, while the animals dedicated for the mAb project were undergoing the long 
immunisation scheme. The mock fusions would allow me to gain expertise in the 
technique to maximise number of wells with hybridoma cell growth, before moving to 
develop hybridomas from hTSHR A-subunit immune mice also positive for anti-IGF-1R 
Abs. However, before beginning on the mock fusions, I was overtaken by the events 
since at the same time immune mice from Group 1 immunisation unexpectedly 
appeared to be ready for fusion, with strong positive signal for IGF-1R Abs (Fig 5.13, 
red ). Therefore, despite my lack of hybridoma technique, we decided to shelf the 
mock fusion plan and proceed ahead with hybridoma development from immune 
animals positive for IGF-1R Abs. Two fusions have been completed on mice immunised 
with pTriEx-TSHR A-subunit which were positive for IGF-1R Abs level in sera. The 
results of generation of hybridomas for IGF-1R mAbs in mice immunised with hTSHR A-
subunit are described below. 
 
5.3.3.1 First attempt on generation of hybridoma for mAbs to IGF-1R  
 
In Group 1 immunisation, serum bleed samples were evaluated for IGF-1R Abs by 
ELISA, four weeks after the end of immunisation. Based on the ELISA results, animal 
59/R was selected for the first fusion, results are shown in Fig 5.13 (two highest OD 
value including 59/R, highlighted with red triangle). All steps of fusion procedure were 
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followed by hybridoma protocol mentioned in Chapter 2. Briefly, three days before 
fusion, mouse was given 0.5 ml of NWTB3 cell (2x106 cells/mL) in saline by i.v. 
injection. On day of fusion, the animal sacrificed by CO2 inhalation and the spleen 
excised under aseptic conditions. Following hybridoma generation, the cells were 
plated into five 96 flat well plates in complete DMEM-20/HEPES/pyruvate/HAT/10% 
Doma Drive. Doma Drive (Immune systems, UK) is a concentrated feeder supplement 
containing a complex mixture of growth factors to enhance hybridoma growth and 
survival rates. Plates incubated overnight in a humidified 37°C, 5% CO2 subscript 
incubator. On days 4, 5, 7, 9, and 11, half the volume of each well replaced with fresh 
complete DMEM-20/HEPES/pyruvate/HAT/10% Doma Drive. On day 14, feeding 
protocol changed to replace HAT with HT medium (complete DMEM-
20/HEPES/pyruvate/HT). 
Total number of wells that showed growth of hybridoma was approximately 18%. All 
the wells tested for IGF-1R Ab by ELISA 3 times (3-5 days apart) and for TSHR Abs with 
TRAK kit. There was not any well showing positive signal either with ELISA (Table5.2) or 
TRAK (data not shown).  
 
 
Table 5.2 Results of first attempt to generate IGF-1R  
The anti-IGF-1R Abs in hybridoma supernatants were measured by ELISA (4 weeks 
after fusion). As positive control, 1H7 mAb was used a serial dilutions, starting from 
500ng (A1) to 100ng (E1) [shadowed in green]. Well numbers F1-E12 represent the 
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hybridoma culture supernatants. Well numbers F12-H12 represents the IgG1 
negative control [shadowed in yellow]. The ‘raw’ data of OD is shown. 
 
 
5.3.3.2 Second attempt on generation of hybridoma for mAbs to IGF-1R 
 
Five weeks after the last injection, in the Group 1 immunisation, one animal, 59/2 
which was positive for IGF-1R Abs suddenly showed signs of severe sickness. Thus, it 
was decided to sacrifice the animal immediately and use the spleen cells for 
hybridoma production, despite the fact that there was no opportunity to give the i.v. 
injection with NWTB3 cells. Moreover, the myeloma cells had not been split to achieve 
a ‘perfect’ log phase for fusions. The log phase growth condition of myeloma cells is 
critically important for the hybridoma technique. This immune mouse was thus 
sacrificed 5 weeks after last immunisation. All the fusion steps and feeding hybridoma 
was same as the protocol that already described for the first fusion. 
Total number of wells showed hybridoma growth increased to 26%. All the wells tested 
for IGF-1R Ab by ELISA 3 times (3-5 days apart) and for TSHR Abs with TRAK kit. There 
was not any well showing positive signal neither with ELISA nor TRAK assay. Table5.3 is 
shown the results of the final IGF-1R Ab measurement by ELISA in supernatant. Despite 
the fact that the hybridomas generated from this sick animal were all negative for anti-
IGF1R (or TSHR) Abs, the growth of hybridoma fusion was 26% (compared to 18% in 














Table 5.3 Results of second attempt to generate IGF-1R mAb  
The anti-IGF-1R Abs in hybridoma supernatants measured by ELISA 24 days after 
hybridoma fusion. The experiment has been conducted in two ELISA plates, P1 and 
P2. As positive control, 1H7 mAb was used a serial dilutions, starting from 500ng 
(A1) to 100ng (E1) in both plates [shadowed in green]. Well numbers F1-E12 in P1 
and F1-D6 in P2 are hybridoma supernatants from 2nd hybridoma fusion. Well 
numbers F12-H12 of P1 and F6-H6 of P2 are negative control [shadowed in yellow]. 
The ‘raw’ data of OD is shown. 
 
  




An earlier study from our laboratory showed that a proportion of hTSHR A-subunit 
plasmid immunised mice (3 out of 12) develop anti-IGF-1R Abs (Zhao et al., 2011). In 
the studies described in this Chapter, a total of 22 mice from three groups of animals 
immunised with hTSHR A-subunit plasmid were evaluated for induction of anti-IGF-1R 
Abs (Moshkelgosha et al., 2013). Another group of 8 animals were specially immunised 
as a separate group with hTSHR A-subunit plasmid for studies on generation of IGF-1R 
mAbs. Thus a total of 30 immune mice in four groups (Appendix 1) were evaluated for 
anti-IGF-1R Abs in this thesis. In addition, animals were also immunised with pTRiEx1.1 
neo-IGF-1Rα (n=6) for induction of polyclonal Abs to IGF-1R. These immune animals as 
reported in the study by Dr Zhao et al did not show any manifestations of orbital 
alteration and remained healthy throughout the course of the study. Control animals 
were injected with pTRiEx1.1 neo-β-Gal plasmids (n=6). In comparison with the study 
reported by Zhao and colleges (Zhao et al., 2011), we developed the  ELISA and flow 
cytometry assays to measure anti-IGF-1R Abs. Although, herein we have made a small 
modification of plasmid delivery as well as using different assay to measure IGF-1R 
Abs, the serum samples of mice from the Group 1 immunisation were positive for IGF-
1R Abs, 7 out of 8. The other groups of immune mice, Group 2 and Group 3 were all 
negative for anti-IGF-1R Abs. Importantly, in the longitudinal study, Group 2, where 
animals were bled weekly to study the development of the immune response to 
hTSHR, anti-IGF-1R Abs were also measured. All the weekly bleed samples from this 
group notably were negative for IGF-1R Abs. This indicates that the appearance of IGF-
1R Abs were neither restricted to 6 weeks after the end of immunisation, nor 
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disappeared following their appearance, when the immune animals were left for long 
term e.g. 9 weeks or 15 weeks after the end of immunisation. The possible reasons for 
the enigmatic results of this chapter in the development of IGF-1R Abs on GO 
pathogenesis will be discussed below.  
The important role of IGF-1R Abs in the pathogenesis of GO was indicated by their 
ability to promote release of  inflammatory cytokine and chemokine (Pritchard et al., 
2003) and secretion of hyaluronan (Smith and Hoa, 2004, Kumar et al., 2011) in 
primary cultures of human orbital fibroblasts. However, measurement of IGF-1R Abs in 
sera of GO patients was difficult and results were contradictory due to lack of gold 
standard assay (Weightman et al., 1993, Pritchard et al., 2003, Minich et al., 2013, 
Varewijck et al., 2013, Smith, 2013). Thus, for this project development of reproducible 
and rapid assay for measuring anti-IGF-1R Abs was important.  
The foremost method could be competitive displacement assay similar to that 
described independently by Weightman et al and Pritchard et al (Weightman et al., 
1993, Pritchard et al., 2003), where orbital fibroblasts were used as source of the 
receptor. However, human orbital fibroblasts were not available to us, as we were 
unable to source human tissue in our laboratory due to ethical issues. We therefore 
obtained an IGF-1R transfected cell line (NWTB3) from Professor LeRoith’s laboratory 
(New York, USA). Examination of NWTB3 cells by flow cytometry revealed high level of 
expression of IGF-1R, whilst TSHR was not expressed. The examination of TSHR 
expression by NWTB3 was important as we wish to measure IGF-1R Abs in the sera 
containing a mixture of TSHR Abs. Following the evaluation of IGF-1R expression in 
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NWTB3 cells, this cell line can be used for two assays, flow cytometry and competitive 
displacement assay.  
To set up competitive displacement assay, the ligand labelled with 125I or another 
tracer was required.  We acquired IGF-1 labelled with the luminescent tracer (called 
Lumi-IGF1) from Professor Schomburg (Minich et al., 2013). Using Lumi-IGF1 in 
competition assay on confluent cultures of NWTB3 cells in 24 well plates showed that 
1nM of unlabelled IGF-1 was able to inhibit 50% binding of Lumi-IGF-1. However, when 
anti-IGF-1R mAbs were evaluated for displacement of Lumi-IGF1 in the cellular binding 
assay, neither 1H7 nor 24-57 mAbs were able to compete with the tracer. Hence, the 
competitive binding assay was not further evaluated. Furthermore, flow cytometry 
were able to measure anti-IGF-1R mAbs. However, the assay was not sufficiently 
sensitive to distinguish IGF-1R Ab in sera of every individual immune mice and 
controls. The same issue of measuring polyclonal anti-sera by flow cytometry method 
was reported in detection of anti-TSHR Abs when using a TSHR transfected cell line 
(Harfst et al., 1992, Costagliola et al., 1994, Harfst et al., 1994, Patibandla et al., 1997, 
Jaume et al., 1997). This may be attributable to lower avidity or titre of Abs, or to the 
presence of Abs against many more epitopes (Harfst et al., 1994).  
At the same time, a non-cellular based assay for measuring IGF-1R Abs was published 
using rhIGF-1 as source of receptor (Yin et al., 2011). This assay was set up using a 
commercial source of rhIGF1R for ELISA. Once the ELISA was developed and validated 
with different concentrations of 1h7 mAb and IGF-1R immunised mice sera, the serum 
samples of mice immunised with hTSHR A-subunit plasmid in the Group 1 
immunisation was examined. The data showed the presence of anti-IGF-1 Abs in the 
sera of 7 out of 8 animals. Notably, the source of receptor in ELISA is hIGF-1R, which 
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may not be suitable for detection of Abs with specificity for mouse IGF-1R (mIGF-1R) 
which do not cross react with the human receptor. However, based on our knowledge, 
neither a transfected mouse IGF-1R (mIGF-1R) cell line nor purified recombinant mIGF-
1R protein was available. Thus, to faithfully evaluate IGF-1R Abs in mice immunised 
with hTSHR A-subunit plasmid, the next step should be the development of mIGF-1R 
stably transfected cell line.  
To confirm the presence of IGF-1R Abs in mice immunised with hTSHR A-subunit 
plasmid, development of mAbs was attempted in two separate experiments. However, 
these attempts were unsuccessful. My first attempt was unsuccessful most likely due 
to the lack of experience in the technique, as the percentage of the culture wells 
showing growth of hybridoma cells was relatively low (regardless of the enhancement 
in the second hybridoma fusion). The last attempt was made to generate anti-IGF-1R 
mAbs in Group 4 immunisation that was purposely immunised for this reason. Despite 
the improvement in the technical skills (90% of hybridoma wells showing growth, with 
three TSHR positive wells), I was not successful in developing IGF-1R mAbs due to poor 
IGF-1R Abs level in the sera.  
It is unclear why induction of IGF-1R Abs in 7 out of 8 mice that were immunised with 
hTSHR A-subunit in Group 1 was not subsequently repeated in any other groups of 
immunisation reported in this thesis (Appendix 1). This is unlikely to be due to 
differences in plasmid preparation or the immunisation procedure, since all immune 
mice of Group 2, Group 3, and Group 4 immunisations responded to successful 
induction of experimental GO when the orbital tissue was examined by histopathology. 
The BALB/c animals in the different experimental groups were all derived from the 
same commercial source (Harlan, UK) and housed in the same animal unit, with no 
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reported opportunistic infections, which may influence the development of the model. 
Until we understand how the anti-IGF-1R Abs arise in animals immunised with hTSHR 
A-subunit plasmid in vivo electroporation, it is difficult to explain the discrepant results 
in the different groups. It may simply be due to ‘stochastic event’ that the anti-IGF-1R 
Abs have not been induced and if so, then examination of additional groups of animals 
immunised with hTSHR A-subunit plasmid in vivo electroporation should clarify this 
possibility. These experiments are presently underway, where new groups of BALB/c 
mice have been set up for immunisation with hTSHR A-subunit plasmid in vivo 
electroporation in our laboratory in KCL and in another laboratory in Essen, Germany 
(See Chapter 6) in studies to replicate the model, where all immune animals will also 
be examined for anti-IGF-1R antibodies by ELISA and flow cytometry.  However, from 
the results that has been presented in this Chapter, it seems that IGF-1R is not an 
essential autoantibody in pathogenesis of GO. 
In spite of the fact that I was not able to measure IGF-1R Abs in all immune animals 
undergoing GO, it is very important to understand how such an Abs may induce in 
positive cases. The experimental model of Graves’ orbitopathy described in this thesis 
has revealed the critical role of TSHR as a primary target antigen in GO. However, 
evidence for substantial overlap between TSHR and IGF-1R signalling pathway 
including of the Akt/FRAP/mTOR/p70s6k pathway (Cass and Meinkoth, 1998, Park et 
al., 2000a, Park et al., 2000b, Park et al., 2005) suggested that IGF-1R and TSHR might 
participate together in the pathogenesis of GO. In addition to the in common signalling 
pathway of these two receptors, physical and functional interactions between IGF-1R 
and TSHR have been indicated (Tsui et al., 2008) that can explain induction of IGF-1R 
Abs in mice immunised with hTSHR A-subunit plasmid.  
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In summary, experimental model of GO described in this thesis has revealed the critical 
role of TSHR as a primary target antigen in the disease. Abs to TSHR were induced in all 
experimental animals, and some animals were also positive for anti-IGF-1R Abs in 
different assays developed in this thesis. However, the induction of anti-IGF-1R Abs 
was not reproducible in the groups of immune animals examined in this thesis, which 
made it difficult to generate mAbs. Additional studies are warranted to study the 
development of anti-IGF-1R Abs in animals immunised with TSHR A-subunit plasmid in 
vivo electroporation and these studies are presently underway, which will lead to a 
better understanding of how the anti-IGF-1R Abs develop and their role in the 
pathophysiology of GO.    
 
  





Chapter Six  
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6. General discussion and future experiments 
6.1 General discussion 
The thyroid autoimmune diseases, Graves’ disease and Hashimoto’s thyroiditis, are the 
most common autoimmune disease affecting humans with a prevalence of 
approximately 2% in Caucasians (Hollowell et al., 2002). It is well known that these 
diseases arise in genetically susceptible individuals in association with environmental 
factors (Tomer and Huber, 2009). Considerable progress has been made in determining 
the genes responsible for thyroid autoimmune disease. Moreover, the processes 
involved in the breakdown in tolerance to “self” thyroid antigens are gradually being 
revealed (McLachlan et al., 2012, McLachlan and Rapoport, 2014) . A fundamental 
understanding of many biological and immunological processes of thyroid 
autoimmunity has stemmed from experimental studies in animal models, particularly 
in rodents. These models have been elucidated at the cellular and molecular levels. 
There is presently no evidence that spontaneously arising Graves’ disease occurs in 
species other than humans, whereas autoimmune thyroiditis does occur 
spontaneously in a number of mammals and birds. Hashimoto’s thyroiditis, without 
immunisation, develops spontaneously in Biobreeding rats (Allen et al., 1986), NOD 
mice (Bernard et al., 1992) and NOD.H2h4 mice (only if given iodine in their drinking 
water), (Rasooly et al., 1996), obese strain (OS) chickens (Aichinger et al., 1984) and 
laboratory breeds of dogs (Tucker, 1962). It is striking that unlike the occurrence of 
thyroiditis in many nonhuman species, neither TSHR antibodies nor Graves’ 
hyperthyroidism develop spontaneously in animals. Recent investigations into the 
whether the species closely related to human evolution, the great apes develop 
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Graves’ like syndromes have also proved negative (McLachlan et al., 2011). However, 
in last two decades, a number of induced experimental models have been developed 
for Graves’ disease (Section 1.5). Despite the successful achievements in the 
development of experimental model of Graves’ disease, several other attempts for 
development of experimental GO model were either unsuccessful (Johnson et al., 
2013) or difficult to substantiate (Baker et al., 2005).  
The TSHR A-subunit plasmid immunisation in vivo electroporation method (Kaneda et 
al., 2007) was initially evaluated in our laboratory for induction of Graves’ disease and 
persistence of long term immunity to the TSHR (Zhao et al., 2011). At the same time, 
the model was studied further for development of signs of orbital manifestations 
(Zhao et al., 2011). This study showed that immunisation with hTSHR A-subunit 
plasmid in vivo electroporation led to the onset of Graves’ disease (disease incidence 
of 66%) which was accompanied with orbital tissue fibrosis in some animals (Zhao et 
al., 2011). Therefore, the objective of my project was to modify the immunisation 
procedures in order to induce the orbital pathology of GO such as inflammation and 
adipogenesis. There were few variables that could be modified, including examining 
different inbred mice strains, changing the dose of the immunogenic plasmid, and 
altering the immunisation/electroporation procedure. In this study, we decided to 
modify the immunisation protocol in order to enhance the plasmid delivery. The 
rationale for this was based upon the earlier studies from Dr McLachlan’s laboratory 
showing that changing the dose of adenovirus TSHR A-subunit delivery leads to 
alteration of disease outcome (Chen et al., 2004).  
 The plasmid was injected deeper into the leg muscle and was released while needle 
was gradually withdrawn. This resulted in spreading the plasmid over a larger muscle 
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area. We speculated that the modification in immunisation may lead to greater 
transfection efficiency which may lead to alteration of antigenic stimulus and outcome 
of the anti-TSHR response.  In comparison with an earlier study (Zhao et al., 2011), the 
differences in orbital pathology, immunological responses and thyroid function are not 
due to a change in the commercial supplier of the mice (Harlan Laboratories, UK) nor 
in the iodine content (1.2mg/Kg) of rodent chow diet. In addition, the animal unit 
housing, conventional clean room, for the mice was unchanged in two studies. Thus, it 
is concluded that the modification in the plasmid immunisation resulted in a dramatic 
different outcome. The significant differences consist of the orbital pathology, the 
immune response to TSHR (Chen et al., 2004, Soares et al., 2013), and thyroid function 
which will be discussed in more detail below.  
In this thesis, a total of 30 BALB/c female mice in four different groups were evaluated 
for the onset of Graves’ disease and concurrent orbital manifestations. The study into 
the GO experimental model revealed that all immune animals show orbital 
remodelling, manifest with orbital heterogeneity as found in patients with GO. The 
heterogeneity of orbital pathology in GO experimental model that recapitulate 
orbitopathy in patients was divided into two main subtypes. The orbital pathology in 
majority of immune animals was characterised by infiltration of interstitial 
inflammatory cells into extraocular muscle.  Concordantly, about 10% of immune mice 
showed expansion of retrobulbar adipose tissue and widely separating the orbital 
muscle fibre bundles. Importantly, two animals from different cohorts showed acute 
inflammation characterised by optic neuropathy with a large inflammatory infiltrate 
around the optic nerve as well as intense intermuscular lymphocytic infiltrate. 
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Strikingly, a rare orbital manifestation in GO patients, chemosis, was readily detectable 
in some animals. There was no correlation with subtype of GO pathology or onset of 
chemosis with thyroid status or presence and subtype of anti-TSHR (or IGF-1R) 
antibody in the model. In addition, 12 animals that served as controls, immunised with 
pTRiEx1.1 neo-IGF-1Rα (n=6) and pTRiEx1.1 neo-β-Gal plasmids (n=6). None of the 12 
animals immunised with control plasmids showed any orbital pathology or disease.  
Surprisingly, in the majority of immune animals, the thyroid function scored as 
hypothyroid status. Hypothyroidism status has been confirmed by histological analysis 
of the thyroid gland, total T4 level in the immune mice sera and significant weight gain. 
Examination of thyroid glands of GO experimental model by H&E staining showed a 
typical pattern of hypothyroidism, including thinning of the thyroid epithelial cells, a 
characteristic sign of underactivity of the gland. In addition to histological analysis of 
the thyroid gland, significant weight gain in immune mice during course of disease 
suggested the underactivity of thyroid gland i.e. hypothyroidism. Of particular interest, 
the thyroid gland did not show any sign of inflammation which is similar to the findings 
with the adenovirus model of Graves’ disease (Nagayama et al., 2002, Chen et al., 
2003, Gilbert et al., 2006, McLachlan and Rapoport, 2014).   Furthermore, serum total 
T4 levels in most of immune mice sera demonstrated significant downward trend in 
comparison to controls. To address the question why the immune animals develop 
hypothyroidism following the modified immunisation protocol, the TSHR Abs and their 
subtypes were evaluated. Measurement of anti-TSHR antibodies by radiobinding 
(TRAK) assay in immune mice sera clearly indicated that all 30 mice were highly 
positive for TSHR Abs with greater than 50% inhibition of radiolabelled TSH binding (in 
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TRAK assay). The subtypes of TSHR Abs were assessed by bioassay using JP09 cells and 
measurement of induced cAMP (Rao et al., 2003, Gilbert et al., 2006). The data showed 
that the subtype of induced anti-TSHR antibodies was dominated by blocking 
antibodies. However, few immune animals showed positivity for stimulating Abs.  
Importantly, irrespective of whether the anti-TSHR response was blocking or 
stimulating antibodies, the animals developed orbital complications, indicating that 
disease development was not solely dependent on the subtype of antibody. 
Further studies into the induction of anti-TSHR antibody subtypes by serial bleeding in 
longitudinal studies showed that the TSBAbs evolved early during immunisation and 
persisted for months. The longitudinal studies also indicate that the subtype of 
antibody spectrum to TSHR in the model is not prone to changing from stimulating to 
blocking antibodies or vice versa during the course of disease, as occasionally reported 
in patients (Takeda et al., 1988, Cho et al., 1989, Takasu et al., 1990, Kraiem et al., 
1992, Takasu and Matsushita, 2012, McLachlan and Rapoport, 2013). The remarkable 
difference between subtypes of TSHR Abs in this study (TSBAbs) and in the adenovirus 
model (TSAbs) (Nagayama et al., 2002, Dağdelen et al., 2009, Wiesweg et al., 2013) 
may contribute to the orbital pathological outcome in the two models. Concordantly, 
more recent findings from Nagayama’s laboratory in Graves’ disease animal model 
provided some supportive evidence. In the long-term studies of their adaptive transfer 
animal model, the recipient animals developed TSBAbs as well as some weak signs of 
orbital inflammation (Nakahara et al., 2012). Therefore, it was emphasised the critical 
role of TSBAbs in the onset of Graves’ orbitopathy.   However, our results described 
some animals with predominant stimulating TSHR Abs that developed orbital 
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pathology too. In addition, the clinical studies suggested that the concentrations of 
different subtypes of TSHR antibodies are dynamic values that may alter during 
therapeutic intervention such as radioiodine therapy (Takeda et al., 1988, Cho et al., 
1989, Takasu et al., 1990, Kraiem et al., 1992, Takasu and Matsushita, 2012) or normal 
physiological changes such as pregnancy (Hara et al., 1990, Zakarija et al., 1990, Kung 
and Jones, 1998, Lu et al., 2005). By dramatic changing in the mixed pool of TSAbs and 
TSBAbs, predominated subtype may alter the clinical presentation. Thus, switching of 
the anti-TSHR Abs from TSAbs to TSBAbs (Nakahara et al., 2012, McLachlan and 
Rapoport, 2013), or the dominant presence of TSBAbs during the course of 
autoimmunity as reported in this study, may be important contributory factors for the 
onset of GO. Apparently, the mechanism is not clear (McLachlan and Rapoport, 2013) 
and needs to be studied in more depth on GO experimental model. Regardless of the 
subtypes of TSHR Abs, the results of this study confirmed the pathological role of TSHR 
as primary autoantigen in Graves’ orbitopathy.  
Evidence supporting the TSHR as primary autoimmune target in Graves’ 
hyperthyroidism has been derived from early studies in Graves’ disease (Adams and 
Purves, 1956a, Kriss et al., 1964, Rapoport et al., 1998), however the role of TSHR in 
the pathogenesis of GO remained less clear and uncertain to this day  (Diana et al., 
2014, Wall, 2014). The demonstration by several clinical report and laboratory studies 
in the GO patients further connected the orbital and thyroidal manifestations. 
However, confirmatory in vivo data has not been provided until our report was 
published (Moshkelgosha et al., 2013). The results of this study have confirmed the 
substantial role of TSHR as primary target antigen in the in vivo model (Bahn, 2013). 
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The GO experimental model will allow further studies to investigate more detail of the 
role of TSHR and TSHR antibodies in GO diseases. It also provides an opportunity to 
study the role of other potential pathogenic antigens in the development of Graves’ 
orbitopathy such as IGF-1R. 
The enigmatic role of IGF-1R Abs in the pathogenesis of Graves’ orbitopathy was 
studied in the experimental GO model. In the earlier study from our laboratory, Dr. 
Zhao and colleagues showed that a small number of hTSHR A-subunit plasmid 
immunised mice (3 out of 12)  developed anti-IGF-1R Abs (Zhao et al., 2011).. Using 
other assays to measure anti-IGF-1R Abs, confirmed positivity of anti-IGF-1R Abs in the 
sera from mice that immunised with hTSHR A-subunit. In the Group 1 immunisation, 
n=7 immunised mice were evaluated by ELISA for anti-IGF-1R antibody and 6 out of 7 
were significantly positive. However, the other three groups of immunisation, none of 
the immune mice were significantly positive for anti-IGF-1R antibody. In the 
longitudinal study, where animals were bled weekly to study the development of the 
immune response to hTSHR, anti- IGF-1R antibodies were also measured. All the 
weekly bleed samples from this group notably were negative for IGF-1R antibodies. 
This indicates that the appearance of IGF-1R antibodies is not restricted to 6 weeks 
after the end of immunisation.  
Although, IGF-1R Abs did not appear in all immune animals, it is critical to investigate 
how such an antibody may induce and more importantly, what pathogenic role it may 
play in the onset of GO. Evidence for substantial overlap between TSHR and IGF-1R 
signalling pathway including of the Akt/FRAP/mTOR/p70s6k pathway (Cass and 
Meinkoth, 1998, Park et al., 2000a, Park et al., 2000b, Park et al., 2005) suggested that 
IGF-1R and TSHR might participate together in the pathogenesis of GO. To address the 
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potential role of IGF-1R as an autoantigen in GO, we immunised by electroporation a 
small number of animals with IGF-1Rα plasmid. Although these mice generated high 
levels of IGF-1R antibody, they developed no apparent pathology. Therefore, a 
conclusive method to study the nature of induction and potential pathogenesis of anti-
IGF-1R Abs in the mice that immunised with hTSHR A-subunit plasmid is to generate 
mAbs. In this study, several attempts to generate anti-IGF-1R mAbs from the mice 
immunised with hTSHR A-subunit were not successful. The unsuccessful attempt to 
generate such mAbs was not due to lack of experience or technical issues as the 
primary hybridoma cells with a positive signal for anti-TSHR mAbs were obtained. Since 
high affinity TSAbs generated from murine models of Graves’ disease have now been 
available for a number of years and been well characterised (Ando et al., 2002, Sanders 
et al., 2002, Costagliola et al., 2002, Gilbert et al., 2006), we decided not to take the 
primary hybridomas positive for TSHR antibodies further for cloning and long stability 
of antibody secretion to generate new TSAb mAbs to save on resources and my time. 
Thus, much more determined effort is clearly required to address the questions on the 
role of IGF-1R Abs in the pathogenesis of GO. 
Apart from biochemical, immunological and histological studies on the GO model, in a 
number of immune animals, the orbital manifestation was examined by MRI. Initially, 
it was not clear that using MRI would improve our understanding of orbital 
manifestation in the GO model particularly in proptosis. Because, it had been 
postulated that differences in the orbital bone structure between humans and rodents 
(Smith, 2002) may not allow the eyeball protrusion happening in the mice (Wiersinga, 
2011). Despite the differences in the orbital anatomy, we showed by high-resolution in 
vivo MRI the unilateral proptosis as well as clear hypertrophy of the orbital muscles in 
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some animals (Moshkelgosha et al., 2013). The coronal view of MR images clearly 
confirmed bilateral proptosis in two immune animals. Moreover, the quantitative 
analysis showed a significant increase of extraorbital muscle volume in immune 
animals compare with age-matched controls. The MRI method for examination of 
orbital manifestation in the GO model was set up based on the clinical 
neuroradiological methods. As there was not any scientific report in the literature 
dealing with MRI analysis of extraorbital muscles in the rodents, the MRI results 
needed confirmatory supports from different assay. Thus, to evaluate the MRI results 
on hypertrophy in extraorbital muscles, the quantitative analysis was performed in the 
corresponding area of histological slides. Interestingly, alignment of histological slides 
of extraorbital muscles with MR images confirmed the hypertrophy in orbital muscles. 
Therefore, the high resolution in vivo MRI method can be used for non invasive 
longitudinal studies into the GO model.  
In conclusion, the robust mouse model developed for Graves’ orbitopathy. The animal 
model described in this thesis recapitulates the orbital manifestation of GO patients 
including; orbital inflammation, infiltration of inflammatory cells, adipogenesis, 
chemosis, and proptosis. It is also a strong evidence for the primary pathogenesis 
factor of TSHR in GO. In addition, it is postulated the potential role of TSBAbs in 
pathogenesis of the disease.  Furthermore, the experimental GO model will allow 
investigators to invent new approaches to the study of GO. The most important 
advantage of the GO model is to facilitate the studies in the delineation of 
immunologic processes and molecular events early in GO development. Moreover, 
novel approaches to disease prevention and new therapies for established disease can 
now be studied in vivo.  




No single animal model recreates exactly the diverse elements of human disease, and 
each different model carries advantages and limitations and highlights particular 
aspects of the disease. So, it is important to emphasise limitations of this animal model 
and differences with human GO patients’ signs and symptoms. Some of the unique 
attributes of the mouse GO model that are different from the human disease are listed 
below.Spontaneous disease in human versus inducible in the mouse model 
The major difference between GO in human patients and the mouse model is related 
to the fact that disease occurs spontaneously in human patients and autoimmune 
response is toward the self antigen (hTSHR), while in the mouse model the disease is 
induced with the xenogeneic antigen (hTSHR as the antigen). It is presently unknown 
whether immunisation of mice with mTSHR plasmid in combination with 
electroporation is sufficient to break the immune tolerance in the mice, although it 
was already shown that the mTSHR adenovirus injection in mice was not successful 
(Nakahara et al., 2010). Studies for developing experimental GO model using mTSHR 
plasmid with electroporation are ongoing in our laboratory.      
 Absence of thyroid inflammation: 
Studied in thyroid tissue from GO patients demonstrated inflammation comprising of a 
lymphocytic infiltrate into the thyroid tissue. There is also evidence on forming focal 
germinal centre in thyroid tissue of Graves’ disease and GO patients. However, precise 
assessment of thyroid tissue from immune mice in this thesis did not show sign of 
inflammation of lymphocytic inflammation in thyroid tissue. Despite this dissimilarity 
between human GO patients and GO animal model in terms of thyroid inflammation, it 
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is already shown that thyroid inflammation is lacking in other animal models for 
Graves’ disease such as the adenovirus model (Nagayama et al., 2002, Chen et al., 
2003, Gilbert et al., 2006). The simple explanation for this could be the difference 
between immunogenicity of the antigen in human and animal models. In human GO 
and Graves’ patients, the self-antigen immunogenic factor that causing the disease 
while in animal models it is immunisation against TSHR from different spices (hTSHR).  
 
 Hypothyroid status in most of experimental GO mice: 
Graves’ disease is defined mainly by autoimmune hyperthyroidism which accompanies 
most cases with orbital complications (Weetman, 2000, Bahn, 2010). However, there is 
also evidence on individual cases with autoimmune hypothyroidism due to dominance 
of blocking TSHR Ab (not HT hypothyroidism) with GO symptoms (McLachlan and 
Rapoport, 2013). In the GO model described in this thesis, the thyroid status of most 
immune animals was hypothyroid. Studies on subtypes of TSHR Abs confirmed 
hypothyroidism in the immune mice are due to the presence of anti-TSHR antibodies 
with strong TSBAb activity. However, the incidence of hypothyroidism in patients 
undergoing autoimmune hypothyroidism mediated by TSH blocking antibodies is less 
frequent. 
 Anatomical difference between orbital structure:  
One of the main factors causing GO symptoms includes proptosis, which is the result of 
limited space in the bony structure surrounding the orbital tissue. In mouse orbital 
region, the orbital contents are protected in orbital cavity by eight bones called 
maxilla, lacrimal, zygomatic, frontal, temporal, sphenoid, ethmoid and palaextraorbital 
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In addition, the orbital region in the mouse is surrounded by a unique gland called 
Harderian gland (Paterson and Kaiserman-Abramof, 1981). However, as the Harderian 
gland is ‘soft tissue’, it provides space for expansion of the orbital tissue during any 
inflammatory event .This anatomical difference between the mouse and the human 
orbital region has led Prof Wiersinga to postulate the impossibility of developing 
proptosis in mice (Wiersinga, 2011). However, my data in the mouse model in 
combination with high resolution, small animal MR imaging clearly show that proptosis 
does indeed occur in immune mice undergoing experimental GO, which was clearly 
visualised by MRI (Moshkelgosha et al., 2013).   
6.3  Proposed future studies 
 
The availability of a preclinical model for Graves’ orbitopathy that recapitulate orbital 
condition of GO patients will allow studies on a disorder that has proved immensely 
difficult to study in human patients. Progress in understanding the molecular basis of 
GO has been hindered in the past by the fact that the retrobulbar tissue that is 
available from decompression surgery is exceedingly small derived at the end stage of 
disease. Moreover, any clinical trial needs to be performed in multicentre trials to 
ensure the availability of adequate numbers of GO patients (for example, a trial 
utilizing Teprotumumab as an IGF-1R blocking strategy currently is underway, 
http://clinicaltrials.gov/show/NCT01868997). Thus, preclinical GO model is an ideal 
opportunity to study 1) natural history of the disease 2) molecular pathogenesis of GO 
and 3) therapeutic intervention by novel targeted biological therapies.   
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The priority has been to evaluate the reproducibility of the model in different 
laboratories. Professor Banga and I have made a start to reproduce the model by 
establishing the model in Professor Anja Eckstein’s group in the Department of 
Ophthalmology, University of Duisburg-Essen, Germany. The animal licence has 
recently been approved by the German authorities for establishing the new GO model 
in University of Duisburg-Essen. We have provided the hTSHR A-subunit pTriEx1.1 
plasmid and the control β-Gal plasmid to Professor Eckstein’s laboratory for the 
replication studies. Milligram quantities of the plasmids have been prepared in Essen 
laboratory, using exactly the same procedure. Female BALB/c mice will be obtained 
from the same commercial supplier in Germany (Harlan GmbH) as the supplier in KCL 
(Harlan, UK). We have made in depth investigations with the commercial suppliers to 
ensure that the BALB/c strains in KCL and Essen laboratories will be the same strain 
derived from the same original breeding pairs. Both the commercial sources supply the 
same strain, termed BALB/cOlaHsd.  
In addition, the immunisations in Essen laboratory will be synchronised with 
simultaneous immunisation run as positive controls in our laboratory in KCL. 
Moreover, for the London laboratory experiments, we aim to use both the plasmid 
preparations from the Essen laboratories, as well as the plasmid preparations of the 
London laboratories to run as positive controls, to ensure that differences in standard 
reagents (e.g. quality of distilled water) during the preparation of the plasmid does not 
influence the development of the model. The replication experiments in Duisburg-
Essen are planned to start with the first immunisations in October 2014. All the 
animals will be housed in clean room facilities in Duisburg-Essen, like the animals 
housed in the unit in KCL. Animal health screening reports for the animal units in KCL 
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and University of Duisburg-Essen for the past 12 months have been carefully studied 
and compared with microbiologists to ensure that the pathogens reported in the 
‘clean’ SPF facilities in the two units are not substantially different, which may 
potentially contribute to differences in the development of the GO model in different 
laboratories. The injection procedure combined with placing of the calliper electrodes 
requires considerable dexterity and skill. Hence, all the four immunisation in vivo 
electroporation steps every 3 weeks apart will be performed in the Essen laboratories 
by Professor Banga and myself to ensure that subtle differences in the precise injection 
and electroporation technique do not contribute influence the development of the GO 
model. With all the precautions we have taken, we are confident that we will 
successfully reproduce the GO model in the Essen laboratories. Overall, we aim to 
publish the results of the replication study to inform the scientific community of the 
transferability of the new GO model. 
The new preclinical model described in this thesis can be used to study natural history 
of the disease. Recently, studies into the progression of GO (Piantanida et al., 2013, 
Menconi et al., 2014) recapitulated our understanding of the natural history of Graves’ 
orbitopathy, known as Rundle’s curve (Rundle and Wilson, 1945, Rundle, 1957, 
Wiersinga, 1992, Perros and Kendall-Taylor, 1998). It is well known that GO signs and 
symptoms become worse rapidly during the initial phase, up to its peak of maximum 
severity and then be improved and finally reached a static plateau. However, the 
mechanism of resolving the orbital conditions in the majority of GO patients has not 
been revealed. Hence, further studies in preclinical GO model can demonstrate (i) 
whether experimental GO model follow the Rundle’s curve and importantly (ii) the 
mechanism of improvement in the orbital condition. The study into natural history of 
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the disease in the experimental GO model needs a large number of animals to 
investigate the disease condition longitudinally by histopathological method. 
Otherwise, the striking results of MRI imaging in this study can provide a non-invasive 
platform for the longitudinal study. However, as clearly shown by the alignment the 
results of histology and MRI, the resolution of MRI was not sufficient to distinguish 
adipose tissue expansion in the orbital tissue of an individual mouse. Thus, the 
preliminary study in order to improve the MRI resolution by adding contrast agents to 
increase brightness in tissue of interest is recommended.  
Furthermore, the in vivo molecular mechanism of GO pathogenesis is the novel area 
that can be driven by GO model. Apart from studies into targeted genes from GO 
patients (Yin et al., 2012), a recent technological advance, array technology, developed 
a high throughput screening of gene profiling. This technology has been recruited to 
investigate alterations of transcriptome in orbitopathy from patients’ sample (Planck 
et al., 2011, Ezra et al., 2012). The limitation in availability of patients’ tissue is a great 
preventive problem for further studies. Thus, experimental GO model can be an 
advantage to overcome the limitations in molecular investigation of pathogenesis of 
disease. A better understanding of the inflammatory cytokines and the molecular 
pathways regulating endothelial migration of inflammatory cells into the orbital tissue 
will lead to new knowledge on orbital inflammation and potentially identify novel 
targets for therapeutic intervention.  
In addition, the experimental GO model is a promising vehicle for translational studies 
of potential novel therapeutic agents and drug development. As mentioned earlier, 
apart from classical therapeutic strategies, there are two novel approaches for 
targeted biological therapy in GO (i) systemic dampening the immune response 
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dysregulation and (ii) antagonising excessive TSHR signalling. Rituximab (RTX), anti-
CD20 mAb, is a well studied example for the targeted therapy with modulation in 
immune response. Although, the significant effect of RTX in activity and severity of GO 
patients has been recently documented (Salvi et al., 2013), the first randomised clinical 
trial (RCT) of RTX in moderate-to-severe GO patients has failed to support the role of 
RTX as a therapeutic agent for treatment of GO (Stan et al., 2013). Furthermore, recent 
in vitro studies using either SMLs antagonists for TSHR signalling (van Zeijl et al., 2012, 
Turcu et al., 2013) or PI3K inhibitor (Zhang et al., 2014) resulted in some reduction of 
hyaluronan synthesis and adipogenesis. Recently, SMLs have also been evaluated in 
vivo (Neumann et al., 2014, Davies et al., 2014) in a non-autoimmune, but endocrine 
induced mouse model of hyperthyroidism (Hamidi et al., 2010). The experimental GO 
model described in this thesis will open a new avenue for translational studies of these 
novel therapeutic agents. These studies will no doubt facilitate the initiation of 
randomised clinical trials of novel agents in patients with GO.  
Finally, further studies in the putative role of IGF-1R in pathogenesis of GO by this 
animal model will improve our understanding of the molecular mechanisms of disease. 
As a future direction, a specific project dealing with the development an anti-IGF-1R 
mAbs induced in an individual mouse immunised with hTSHR A-subunit plasmid, would 
help to shed light on currently mysterious mechanism of action of this antigen in the 
pathophysiology of GO. 
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Appendices 
Appendix 1 Summary of individual immune mice in 4 groups of 
immunisations 
  



























59/0 pTriEx-TSHR  hypo TSBAbs +ve EOM + + 
59/L pTriEx-TSHR  hypo TSBAbs -ve EOM + + 
59/R pTriEx-TSHR  hypo TSBAbs +ve EOM + + 
59/2 pTriEx-TSHR  hyper TSAbs +ve EOM + + 
60/0 pTriEx-TSHR   hypo TSAbs ND intense infiltration +++ + 
60/L pTriEx-TSHR  hypo TSBAbs +ve adipose expansion + + 
60/R pTriEx-TSHR  hypo TSBAbs +ve EOM + + 
60/2 pTriEx-TSHR  hypo TSBAbs +ve EOM + + 
61/0 pTriEx-IGF-1Rα normal None +ve normal - - 
61/L pTriEx-IGF-1Rα normal None +ve normal - - 
61/R pTriEx-IGF-1Rα normal None +ve normal - - 
62/0 pTriEx-β-Gal normal None -ve normal - - 
62/L pTriEx-β-Gal normal None -ve normal - - 








63/0 pTriEx-TSHR  hypo TSBAbs -ve EOM + + 
63/L pTriEx-TSHR  hyper TSBAbs -ve EOM + + 
63/R pTriEx-TSHR  hypo TSBAbs -ve EOM + + 
63/2 pTriEx-TSHR  hyper TSBAbs -ve EOM + + 
64/0 pTriEx-TSHR  hypo TSBAbs -ve EOM + + 
64/L pTriEx-TSHR  hypo TSBAbs -ve adipose expansion + + 
64/R pTriEx-TSHR  hypo TSAbs -ve EOM + + 








57/0 pTriEx-TSHR  hypo TSBAbs -ve Fibrosis/EOM + + 
57/L pTriEx-TSHR  hypo TSAbs -ve Fibrosis/EOM + + 
57/R pTriEx-TSHR  hypo TSBAbs -ve adipose expansion + + 
58/0 pTriEx-TSHR  hypo TSBAbs -ve Fibrosis/EOM + + 
58/L pTriEx-TSHR  normal TSAbs -ve Fibrosis/EOM + + 
58/R pTriEx-TSHR  hypo TSBAbs -ve intense infiltration +++ + 
56/0 pTriEx-IGF-1Rα normal None +ve normal - - 
56/L pTriEx-IGF-1Rα normal None +ve normal - - 
56/R pTriEx-IGF-1Rα normal None +ve normal - - 
55/0 pTriEx-β-Gal normal None -ve normal - - 
55/L pTriEx-β-Gal normal None -ve normal - - 





65/0 pTriEx-TSHR  hypo ND -ve EOM + + 
65/L pTriEx-TSHR  normal ND -ve EOM + + 
65/R pTriEx-TSHR  hypo ND -ve EOM + + 
65/2 pTriEx-TSHR  normal ND -ve EOM + + 
66/0 pTriEx-TSHR  hypo ND -ve EOM + + 
66/L pTriEx-TSHR  hypo ND -ve EOM + + 
66/R pTriEx-TSHR  hypo ND -ve EOM + + 
66/2 pTriEx-TSHR  hypo ND -ve EOM + + 
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Appendix 2 Flow cytometry intra-assay and inter-assay CV 
 
  
 Samples Intra-assay CV  
Test 1 
Intra-assay CV  
Test 2 
Intra-assay CV  
Test 3 
Interassay CV 



























 Total 7.58 8.78 7.69  
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Appendix 3 Calculations for competition assay; displacement of LUMI-
IGF-1 with unlabelled IGF-1 
 
The plan was to make IGF-1 at ‘double‘ the concentration and then mix with an equal 
volume of LUMI-IGF-1 at ‘double’ the concentration to achieve the final working 
concentrations of IGF-1 at 10-6M and LUMI-IGF-1 at 5x105 RLU/µl. 
 
LUMI-IGF-1 
Stock   108 RLU/µl 
Required 106 RLU/µl (double working dilution) 
So do 1:100 dilution of LUMI-IGF-1 at 108 RLU/µl in PBS/1% BSA to achieve 106 RLU/µl 
 
IGF-1 (Molecular weight 7649 Daltons) 
7649 g/L  1 M   
7.7 g/L   1 mM  10-3 M 
7.7  mg/L  1 µM  10-6 M 
7.7 µg/L  1 nM  10-9 M 
7.7  ng/ml  1 nM  10-9 M 
 
To make calculations easier, instead of working with 7.7 µg/ml, we decided to work 
with 
10 µg/ml (10mg/L). 
 
Stock solution of IGF-1 = 10 mg/ml or 1 mg/ml aliquots 
Do 1:10 dilution of IGF-1 at 1 mg/ml in PBS/1% BSA to achieve 0.1 mg/ml = 100 µg/ml 
[a] 
Take [a] and do 1:5 dilution in PBS/1% BSA to achieve 20 µg/ml = 2x10-6M [b] 
Take [b] and do 10 fold dilutions to achieve 2x10-7–2x10-11M 
 
Finally, add equal volumes of LUMI-IGF-1 and IGF-1 to achieve: LUMI-IGF-1 at 5x105 
RLU/µl and IGF-1  at 10XM (where X is -11 to -6)    
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Appendix 4 Calculations for comparison of competition assay in this 
















Weightman et al, 1993 
Cold IGF-1 cocentration: 
          
         Log[IGF] (nM) 
                              
            
-3 -2 -1 0 1 2 
IGF (nM) 0.00
1 
0.01 0.1 1 10 100 
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assay CV  
Test 1 
Intra-
assay CV  
Test 2 
Intra-
assay CV  
Test 3 
Intra-
assay CV  
Test 4 
Intra-









































6.13 4.22 3.84 4.53 4.96 6.02 
5 E9/0 
 



















































































































4.40 3.79 5.21 3.67 
 
2.58 5.69 
 Total 2.08 2.60 3.19 2.24 2.82  
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Appendix 6 Cutting Edge publication accompanied with “News and Views” 
 
  
 301  
 
  
 302  
 
Appendix 7 Abstract of oral presentation at 37th ETA conference 2013, 
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Appendix 8 Young Investigator Award certificate, 37th ETA conference 2013, 
Lieden, The Netherlands  
 
http://www.eta2013.org/_downloads/Prize-Winners-2013.pdf 
 
 
